<!DOCTYPE html>
<html lang="ja">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025年度INC問題</title>
    <style>
        :root {
            --primary-color: #0056b3;
            --light-gray: #dcedc8;
            /* A slightly darker complementary green */
            --dark-gray: #333;
            --menu-background: #2c3e50;
            --site-bg-color: #e8f5e9;
            /* A slightly darker green */
        }

        html {
            scroll-behavior: smooth;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
            margin: 0;
            background-color: var(--site-bg-color);
            color: var(--dark-gray);
        }

        body.menu-open {
            overflow: hidden;
        }

        /* --- Hamburger Menu --- */
        .menu-button {
            position: fixed;
            top: 15px;
            left: 15px;
            z-index: 1001;
            background: none;
            border: none;
            cursor: pointer;
            padding: 15px;
            /* 変更点: 10pxから15pxに変更し、ボタンのクリック範囲を拡大しました */
            background-color: rgba(255, 255, 255, 0.8);
            border-radius: 50%;
            box-shadow: 0 2px 5px rgba(0, 0, 0, 0.1);
        }

        .menu-button__icon,
        .menu-button__icon::before,
        .menu-button__icon::after {
            display: block;
            background-color: var(--dark-gray);
            position: absolute;
            height: 2px;
            width: 24px;
            transition: transform 400ms cubic-bezier(0.23, 1, 0.32, 1);
        }

        .menu-button__icon::before {
            content: '';
            margin-top: -8px;
        }

        .menu-button__icon::after {
            content: '';
            margin-top: 8px;
        }

        .menu-open .menu-button__icon {
            background: rgba(0, 0, 0, 0);
        }

        .menu-open .menu-button__icon::before {
            margin-top: 0px;
            transform: rotate(405deg);
        }

        .menu-open .menu-button__icon::after {
            margin-top: 0px;
            transform: rotate(-405deg);
        }

        .main-nav {
            position: fixed;
            top: 0;
            left: 0;
            height: 100%;
            width: 280px;
            z-index: 1000;
            background-color: var(--menu-background);
            transform: translateX(-100%);
            transition: transform 0.3s ease-in-out;
            display: flex;
            flex-direction: column;
        }

        .main-nav.is-open {
            transform: translateX(0);
        }

        .nav-options {
            padding: 15px 20px;
            background-color: rgba(0, 0, 0, 0.2);
            margin-top: 50px;
        }

        .nav-options label {
            color: white;
            display: flex;
            align-items: center;
            cursor: pointer;
        }

        .nav-options input {
            margin-right: 10px;
        }

        .nav-list {
            list-style: none;
            padding: 10px 0 20px 0;
            margin: 0;
            flex-grow: 1;
            overflow-y: auto;
        }

        .nav-list a {
            display: block;
            color: white;
            text-decoration: none;
            padding: 12px 20px;
            transition: background-color 0.2s;
        }

        .nav-list a:hover {
            background-color: var(--primary-color);
        }

        .submenu-wrapper {
            display: flex;
            align-items: center;
            justify-content: space-between;
        }

        .submenu-wrapper a {
            flex-grow: 1;
        }

        .submenu-toggle {
            background: none;
            border: none;
            color: #fff;
            cursor: pointer;
            padding: 12px 20px;
            font-size: 1em;
            transition: transform 0.2s;
        }

        .submenu-toggle[aria-expanded="true"] {
            transform: rotate(180deg);
        }

        .submenu-list {
            list-style: none;
            padding-left: 0;
            background-color: rgba(0, 0, 0, 0.3);
            display: none;
            /* Hidden by default */
        }

        .submenu-list.is-open {
            display: block;
        }

        .submenu-list a {
            padding-left: 40px;
            font-size: 0.9em;
        }


        /* --- Content Styling --- */
        .page-header {
            text-align: center;
            padding: 2em 1em;
            background-color: var(--light-gray);
        }

        .page-header__title {
            font-size: 2.2em;
            color: var(--primary-color);
            margin: 0;
        }

        main {
            padding: 1rem 2rem 2rem;
            max-width: 800px;
            margin: 0 auto;
        }

        main.fading-out {
            opacity: 0;
            /* フェードアウト中の状態 */
        }

        .content-section {
            display: none;
        }

        .content-section.is-active {
            display: block;
        }

        h2 {
            font-size: 1.8em;
            color: var(--primary-color);
            border-bottom: 1px solid #ddd;
            padding-bottom: 0.4em;
            margin-top: 1em;
        }

        h3 {
            font-size: 1.3em;
            font-weight: bold;
            margin-top: 2em;
            border-left: 5px solid var(--primary-color);
            padding-left: 0.8em;
        }

        p,
        li {
            line-height: 1.7;
            text-align: justify;
        }

        p {
            scroll-margin-top: 20px;
        }

        ul {
            list-style: none;
            padding-left: 1em;
        }

        li {
            margin-bottom: 0.5em;
        }

        .related-pages {
            font-size: 0.9em;
            padding: 10px;
            background-color: #fff;
            border-radius: 4px;
            margin-bottom: 1.5em;
            border-left: 3px solid var(--primary-color);
        }

        .related-pages a {
            text-decoration: none;
            font-weight: bold;
            color: var(--primary-color);
        }

        .related-pages a:hover {
            text-decoration: underline;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 1em;
            margin-bottom: 2em;
            font-size: 0.95em;
        }

        th,
        td {
            border: 1px solid #ccc;
            padding: 10px;
            text-align: left;
        }

        th {
            background-color: var(--light-gray);
        }

        td {
            background-color: #fff;
        }

        blockquote {
            border-left: 5px solid #ccc;
            padding-left: 1.5em;
            margin-left: 0;
            font-style: italic;
        }

        .document {
            border: 1px solid #ccc;
            background-color: #fafafa;
            padding: 1em 1.5em;
            margin-top: 1.5em;
            border-radius: 5px;
        }

        /* --- Back to Top Button --- */
        #back-to-top-btn {
            display: none;
            position: fixed;
            bottom: 25px;
            right: 25px;
            z-index: 99;
            border: none;
            background-color: var(--primary-color);
            color: white;
            cursor: pointer;
            width: 50px;
            height: 50px;
            border-radius: 50%;
            font-size: 24px;
            opacity: 0.7;
            transition: opacity 0.3s, transform 0.3s;
        }

        #back-to-top-btn:hover {
            opacity: 1;
            transform: scale(1.1);
        }

        /* コールアウトの共通スタイル */
        .callout {
            padding: 20px;
            margin: 20px 0;
            border-left: 5px solid #eee;
            border-radius: 5px;
        }

        .callout p {
            margin: 0;
            /* pタグのデフォルトマージンをリセット */
        }

        /* 種類ごとのスタイル */

        /* ノート (note) */
        .callout.note {
            background-color: #e7f3fe;
            border-left-color: #2196F3;
        }

        /* 警告 (warning) */
        .callout.warning {
            background-color: #fff4e5;
            border-left-color: #ff9800;
        }

        /* ヒント (tip) */
        .callout.tip {
            background-color: #e8f5e9;
            border-left-color: #4CAF50;
        }

        .lang-switcher {
            position: fixed;
            /* Keep it fixed on the screen */
            top: 20px;
            /* Distance from the top */
            right: 20px;
            /* Distance from the right */
            z-index: 1001;
            /* Make sure it's above other content */
            background-color: rgba(255, 255, 255, 0.8);
            padding: 5px 10px;
            border-radius: 15px;
            box-shadow: 0 1px 4px rgba(0, 0, 0, 0.1);
        }

        .lang-switcher button {
            background: none;
            border: none;
            cursor: pointer;
            font-size: 1em;
            font-weight: bold;
            color: #aaa;
            padding: 5px;
        }

        .lang-switcher button.active {
            color: var(--primary-color);
        }

        /* --- Language Visibility Control --- */
        .lang-en {
            display: none;
        }

        body.show-en .lang-en {
            display: inline;
            /* or block, depending on element */
        }

        body.show-en .lang-ja {
            display: none;
        }
    </style>
</head>

<body>

    <button class="menu-button" id="menu-toggle" aria-label="メニューを開く" aria-expanded="false">

        <span class="menu-button__icon"></span>

    </button>
    <div class="lang-switcher">
        <button id="lang-jp" class="active">JP</button> | <button id="lang-en">EN</button>
    </div>
    <nav class="main-nav" id="main-nav">
        <div class="nav-options">
            <label for="new-tab-checkbox">
                <input type="checkbox" id="new-tab-checkbox">
                <span class="lang-ja">新しいタブで開く</span>
                <span class="lang-en">Open in new tab</span>
            </label>
        </div>
        <ul class="nav-list">
            <li>
                <div class="submenu-wrapper">
                    <a href="#facts">
                        <span class="lang-ja">問題事実本文</span>
                        <span class="lang-en">Facts</span>
                    </a>
                    <button class="submenu-toggle" aria-expanded="false" aria-controls="facts-submenu">▼</button>
                </div>
                <ul class="submenu-list" id="facts-submenu">
                    <li><a href="#p-1">¶1</a></li>
                    <li><a href="#p-2">¶2</a></li>
                    <li><a href="#p-3">¶3</a></li>
                    <li><a href="#p-4">¶4</a></li>
                    <li><a href="#p-5">¶5</a></li>
                    <li><a href="#p-6">¶6</a></li>
                    <li><a href="#p-7">¶7</a></li>
                    <li><a href="#p-8">¶8</a></li>
                    <li><a href="#p-9">¶9</a></li>
                    <li><a href="#p-10">¶10</a></li>
                    <li><a href="#p-11">¶11</a></li>
                    <li><a href="#p-12">¶12</a></li>
                    <li><a href="#p-13">¶13</a></li>
                    <li><a href="#p-14">¶14</a></li>
                    <li><a href="#p-15">¶15</a></li>
                    <li><a href="#p-16">¶16</a></li>
                    <li><a href="#p-17">¶17</a></li>
                    <li><a href="#p-18">¶18</a></li>
                    <li><a href="#p-19">¶19</a></li>
                    <li><a href="#p-20">¶20</a></li>
                    <li><a href="#p-21">¶21</a></li>
                    <li><a href="#p-22">¶22</a></li>
                    <li><a href="#p-23">¶23</a></li>
                    <li><a href="#p-24">¶24</a></li>
                    <li><a href="#p-25">¶25</a></li>
                    <li><a href="#p-26">¶26</a></li>
                </ul>
            </li>
            <li><a href="#exhibit1">
                    <span class="lang-ja">別添1</span>
                    <span class="lang-en">Exhibit1</span>
                </a></li>
            <li><a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a></li>
            <li><a href="#exhibit3">
                    <span class="lang-ja">別添3</span>
                    <span class="lang-en">Exhibit3</span>
                </a></li>
            <li><a href="#exhibit4">
                    <span class="lang-ja">別添4</span>
                    <span class="lang-en">Exhibit4</span>
                </a></li>
            <li><a href="#exhibit5">
                    <span class="lang-ja">別添5</span>
                    <span class="lang-en">Exhibit5</span>
                </a></li>
            <li><a href="#exhibit6">
                    <span class="lang-ja">別添6</span>
                    <span class="lang-en">Exhibit6</span>
                </a></li>
            <li><a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a></li>
            <li><a href="#exhibit8">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit8</span>
                </a></li>
            <li><a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a></li>
            <li><a href="#exhibit10">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit10</span>
                </a></li>
            <li><a href="#exhibit11">
                    <span class="lang-ja">別添11</span>
                    <span class="lang-en">Exhibit11</span>
                </a></li>
            <li><a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a></li>
            <li><a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a></li>
            <li><a href="#exhibit14">
                    <span class="lang-ja">別添14</span>
                    <span class="lang-en">Exhibit14</span>
                </a></li>
            <li><a href="#exhibit15">
                    <span class="lang-ja">別添15</span>
                    <span class="lang-en">Exhibit15</span>
                </a></li>
            <li><a href="#exhibit16">
                    <span class="lang-ja">別添16</span>
                    <span class="lang-en">Exhibit16</span>
                </a></li>
            <li><a href="#exhibit17">
                    <span class="lang-ja">別添17</span>
                    <span class="lang-en">Exhibit17</span>
                </a></li>
            <li><a href="#exhibit18">
                    <span class="lang-ja">別添18</span>
                    <span class="lang-en">Exhibit18</span>
                </a></li>
            <li><a href="#exhibit19">
                    <span class="lang-ja">別添19</span>
                    <span class="lang-en">Exhibit19</span>
                </a></li>
            <li><a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a></li>
            <li><a href="#exhibit21">
                    <span class="lang-ja">別添21</span>
                    <span class="lang-en">Exhibit21</span>
                </a></li>
            <li><a href="#exhibit22">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit22</span>
                </a></li>
            <li><a href="#exhibit23">
                    <span class="lang-ja">別添23</span>
                    <span class="lang-en">Exhibit23</span>
                </a></li>
            <li><a href="#exhibit24">
                    <span class="lang-ja">別添24</span>
                    <span class="lang-en">Exhibit24</span>
                </a></li>
            <li><a href="#exhibit25">
                    <span class="lang-ja">別添25</span>
                    <span class="lang-en">Exhibit25</span>
                </a></li>
            <li><a href="#exhibit26">
                    <span class="lang-ja">別添26</span>
                    <span class="lang-en">Exhibit26</span>
                </a></li>
            <li><a href="#exhibit27">
                    <span class="lang-ja">別添27</span>
                    <span class="lang-en">Exhibit27</span>
                </a></li>
            <li><a href="#exhibit28">
                    <span class="lang-ja">別添28</span>
                    <span class="lang-en">Exhibit28</span>
                </a></li>
            <li><a href="#exhibit29">
                    <span class="lang-ja">別添29</span>
                    <span class="lang-en">Exhibit29</span>
                </a></li>
            <li><a href="#exhibit30">
                    <span class="lang-ja">別添30</span>
                    <span class="lang-en">Exhibit30</span>
                </a></li>
        </ul>
    </nav>

    <header class="page-header">
        <h1 class="page-header__title"><a href="https://marblebaseball.github.io/INC/INC20251013.html">
                <span class="lang-ja">2025年度INC問題</span>
                <span class="lang-en">INC2025 Problem</span>
            </a>
        </h1>
    </header>

    <main>
        <section id="facts" class="content-section">
            <h2>
                <span class="lang-ja">問題事実本文</span>
                <span class="lang-en">Facts</span>
            </h2>
            <p id="p-1"><strong>1.</strong>
                <span
                    class="lang-ja">ネゴランド国は、人口約5,000万人、名目GDP約8,500億米ドルの先進国である。同国は、高度な科学技術やそれを活かした産業で知られており、特に、ITやAIなどの分野では世界でも注目されるスタートアップ企業が数多く生まれている。同国は、個人の尊厳を尊重し、表現の自由、思想や信仰の自由などを重視する社会であり、教育では数学や外国語の教育に力を入れるとともに、工学や経済学等の実業に役立つような分野に力を入れてきた。また、技術革新に積極的な企業が多く、新しい技術やビジネス・チャンスについては、一定のリスク管理をしたうえでスピード感を持って積極的にチャレンジしていこうというのが同国の多くの企業に共通した社風である。</span>
                <span class="lang-en">Negoland is a developed country with a population of approximately 50 million
                    people and a nominal GDP of about 850 billion US dollars. The country is known for its advanced
                    science and technology and for the industries that make use of them. In particular, a large number
                    of start-up companies that attract worldwide attention have emerged in fields such as IT and AI.
                    Negoland is a society that respects the dignity of the individual and places importance on freedom
                    of expression, freedom of thought, and freedom of religion. In education, it has placed emphasis on
                    mathematics and foreign language education, as well as on fields such as engineering and economics
                    that are useful for practical business. In addition, many companies are proactive in technological
                    innovation, and a common corporate culture in Negoland is to take on new technologies and business
                    opportunities actively and with speed, while managing risks to a certain extent.</span>
            </p>
            <p id="p-2"><strong>2.</strong>
                <span
                    class="lang-ja">ネゴランド国の医療制度は、全国民が加入し、標準的な医療をカバーする公的な基礎保険制度を基礎とする。これに加えて、個人が任意で民間企業が提供する保険に加入することができる。こうした民間の保険には先進医療等に要する費用をカバーできるものもある。高度な科学技術を活かして技術革新に積極的に取り組むというネゴランド国の産業の一般的な傾向は医療分野にも当てはまる。ICT技術を利用した遠隔医療やAIの医療への利用はネゴランド国全土に広がり、成果連動型の医療費の支払いも一定の先進的な医療との関係で承認されてきている。医療分野の監督を担当するのは保健・医療省である。保険・医療省は先進医療の導入・推進に積極的に取り組んでおり、そのための法令の改正やガイダンスの公表を進めている。現時点におけるネゴランド国の先進医療の利活用に関連する法令やガイダンスの例は</span>
                <span class="lang-en">The medical system of Negoland is based on a public basic insurance scheme that
                    covers standard medical care and in which all citizens are enrolled. In addition, individuals may
                    voluntarily join insurance provided by private companies. Some of these private insurance policies
                    are able to cover the costs required for advanced medical care. The general tendency of Negoland’s
                    industries to proactively engage in technological innovation by utilizing advanced science and
                    technology also applies to the medical field. Telemedicine using ICT technology and the utilization
                    of AI in healthcare have spread throughout the country, and outcome-based payment of medical fees
                    has also been approved in relation to certain advanced medical treatments. The Ministry of Health
                    and Medical Care is responsible for supervision in the medical field. The Ministry of Health and
                    Medical Care is actively working on the introduction and promotion of advanced medical care and is
                    proceeding with the revision of laws and the publication of guidance for that purpose. Examples of
                    laws and guidance related to the utilization of advanced medical care in Negoland as of the present
                    are shown in </span>
                <a href="#exhibit1" target="_blank">
                    <span class="lang-ja">別添1</span>
                    <span class="lang-en">Exhibit 1</span>
                </a>
                <span class="lang-ja">のとおりである。ネゴランド国は</span>
                <span class="lang-en">. Negoland is a contracting party to</span>
                <a href="https://www.newyorkconvention.org/english" target="_blank">
                    <span class="lang-ja">外国仲裁判断の承認及び執⾏に関する条約</span>
                    <span class="lang-en">the Convention on the Recognition and Enforcement of Foreign Arbitral
                        Awards</span>
                </a>
                <span class="lang-ja">の締約国である。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-3"><strong>3.</strong>
                <span
                    class="lang-ja">アービトリア国は、人口約1億2,500万人、名目GDP約4兆米ドルを超える世界有数の経済大国である。同国は、自動車、電子機器、精密機械などの製造業に強みを持ち、近年では再生可能エネルギーやロボット工学、AIなどの分野にも力を入れている。社会は、個人の尊厳を重視しつつも、秩序と調和を尊ぶ文化が根づいている。教育においては、基礎学力の充実を重視し、とりわけ理数系科目に力を入れるとともに、工学や医学、経済学など実社会に直結する分野の人材育成が進められてきた。企業文化としては、長期的な安定を重視する傾向がある一方で、国際競争に対応するため新技術の導入やイノベーションへの取り組みも進んでおり、とりわけ品質管理や安全性に高い基準を設ける点に特徴がある。</span>
                <span class="lang-en">Arbitria is one of the world’s leading economic powers, with a population of
                    approximately 125 million people and a nominal GDP exceeding 4 trillion US dollars. The country has
                    strengths in manufacturing such as automobiles, electronic devices, and precision machinery, and in
                    recent years it has also been placing emphasis on fields such as renewable energy, robotics, and AI.
                    While respecting the dignity of the individual, the society is rooted in a culture that values order
                    and harmony. In education, importance has been placed on the enhancement of basic academic ability,
                    with particular emphasis on mathematics and science subjects, and at the same time, human resource
                    development has progressed in fields directly connected to practical societal needs, such as
                    engineering, medicine, and economics. In terms of corporate culture, there is a tendency to place
                    importance on long-term stability, while at the same time, in order to respond to international
                    competition, the introduction of new technologies and efforts toward innovation are also being
                    promoted, with an emphasis on the establishment of high standards with respect to quality control
                    and safety.</span>
            </p>
            <p id="p-4"><strong>4.</strong>
                <span
                    class="lang-ja">アービトリア国の医療制度は、全国民を対象とした公的医療保険制度を基礎とする。国民は職業や居住地に応じて複数の保険者(公的保険組合等)に加入する仕組みであり、誰もが比較的安価な負担で一定水準の医療を受けられる。これに加えて、個人が任意で民間保険に加入し、公的保険の対象外となる先進医療等をカバーすることもできる。同国では高齢化が急速に進んでおり、医療費の効率的な配分や医療サービスの均てん化が大きな政策課題となっている。他方で、ロボット手術やAI診断支援、遠隔医療といった先端技術の導入も積極的に検討されている。医療分野の監督官庁は厚生・医療省である。同省は、先進医療や医薬品の利用をめぐる規制や指針の策定に関して、社会保障制度全体の持続可能性を確保しつつ、科学技術の進展を取り入れるため、関連する法令の改正や技術導入に関するガイドラインを段階的に整備してきている。現時点におけるアービトリア国の先進医療の利活用に関連する法令やガイダンスの例は</span>
                <span class="lang-en">The medical system of Arbitria is based on a public medical insurance scheme that
                    covers the entire population. Citizens are enrolled in multiple insurers (such as public insurance
                    associations) according to their occupation and place of residence, and everyone can receive a
                    certain standard of medical care with a relatively low burden. In addition, individuals may
                    voluntarily join private insurance to cover advanced medical care and the like that are not covered
                    by public insurance. In the country, aging of the population is rapidly advancing, and the efficient
                    allocation of medical expenses and equalization of medical services have become major policy issues.
                    On the other hand, the introduction of advanced technologies such as robotic surgery, AI diagnostic
                    support, and telemedicine is also being actively considered. The supervisory authority in the
                    medical field is the Ministry of Health and Medical Care. The Ministry, with regard to the
                    regulation and formulation of guidelines concerning the use of advanced medical care and
                    pharmaceuticals, has been gradually undertaking revisions of relevant laws and guidelines concerning
                    the introduction of technology in order to secure the sustainability of the social security system
                    as a whole while incorporating advances in science and technology. Examples of laws and guidance
                    currently related to the utilization of advanced medical care in Arbitria are shown in </span>
                <a href="#exhibit2" target="_blank">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit 2</span>
                </a>
                <span class="lang-ja">のとおりである。アービトリア国は</span>
                <span class="lang-en">. Arbitria is a contracting party to</span>
                <a href="https://www.newyorkconvention.org/english" target="_blank">
                    <span class="lang-ja">外国仲裁判断の承認及び執⾏に関する条約</span>
                    <span class="lang-en">the Convention on the Recognition and Enforcement of Foreign Arbitral
                        Awards</span>
                </a>
                <span class="lang-ja">の締約国である。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-5"><strong>5.</strong>
                <span
                    class="lang-ja">レッド社は、ネゴランド国に本社を置くAI医療技術関連のスタートアップ企業である。従業員数は約600名で、その多くがデータサイエンス、医療情報学、ソフトウェア工学の専門家である。同社は中規模ながら、研究開発力とスピード感ある市場展開を特徴としており、「リスクを許容しても革新を早く取り入れる」というネゴランド国の典型的な企業文化や制度環境を体現している。レッド社の中核事業はAI医療支援ツール「</span>
                <span class="lang-en">Red Corporation is a start-up company related to Al medical technology with its
                    headquarters in Negoland. It has approximately 600 employees, most of whom are specialists in data
                    science, medical informatics, and software engineering. Although the company is medium-sized, it is
                    characterized by research and development capabilities and rapid market deployment, and it embodies
                    the typical corporate culture and institutional environment of Negoland, namely "to adopt
                    innovations quickly while accepting risks." The core business of Red Corporation is the Al medical
                    support tool "</span>
                <a href="#exhibit5" target="_blank">
                    <span class="lang-ja">レッド・エイド(Red Aid)</span>
                    <span class="lang-en">RedAid</span>
                </a>
                <span
                    class="lang-ja">」である。このツールは患者の症状や検査データを入力すると、AIが既存の医療知識と照合し、診断候補や治療計画を提示する仕組みを持つ。臨床判断の最終責任は医師にあるが、診断プロセスを効率化し、特に若手医師や多忙な病院での活用が期待されている。「レッド・エイド」はネゴランド国内の複数の病院で既に導入が進んでおり、同国の</span>
                <span class="lang-en">." This tool, when patient symptoms and examination data are entered, has a
                    mechanism by which Al cross- checks them against existing medical knowledge and presents diagnostic
                    candidates and treatment plans. The final responsibility for clinical judgment lies with physicians,
                    but the tool is expected to streamline the diagnostic process, and its use is anticipated
                    particularly for young physicians and in busy hospitals. “RedAid” has already begun to be introduced
                    in multiple hospitals within Negoland and is regarded as a successful case that was launched early
                    into the market by utilizing the country’s </span>
                <a href="#exhibit1" target="_blank">
                    <span class="lang-ja">サンドボックス制度</span>
                    <span class="lang-en">sandbox system</span>
                </a>
                <span
                    class="lang-ja">を利用して早期に市場に投入された成功例とされる。レッド社はまた、「レッド・リンク(RedLink)」という遠隔医療プラットフォーム事業も展開している。このサービスは、患者と医師、あるいは病院間をオンラインで接続し、診療・コンサルテーションを効率化するものである。ネゴランド国内では地域医療や国際共同研究の基盤として徐々に浸透しており、レッド社では国外市場への進出も視野に入れている。レッド社の事業の概要は</span>
                <span class="lang-en">. Red Corporation is also developing a telemedicine platform business called
                    “RedLink.” This service connects patients and physicians, or hospitals to each other, online, and
                    makes diagnosis and consultation more efficient. Within Negoland, it has gradually spread as a
                    foundation for regional medical care and international joint research, and Red Corporation is also
                    considering expansion into overseas markets. An outline of the business of Red Corporation is shown
                    in </span>
                <a href="#exhibit3" target="_blank">
                    <span class="lang-ja">別添3</span>
                    <span class="lang-en">Exhibit 3</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-6"><strong>6.</strong>
                <span
                    class="lang-ja">ブルー大学は、アービトリア国に所在する私立の名門大学法人であり、教育部門と付属病院部門を有している。特に医学・薬学分野において国内外で高い評価を受けている。同大学には約3,000名の教職員が在籍し、そのうち800名は医学・薬学を中心とする研究者である。付属病院は1,000床を超える大規模施設であり、地域医療の中核としての役割を果たすとともに、先端的な臨床研究の拠点としても機能している。ブルー大学は、アービトリア国の文化的特徴を反映し、安全性と信頼性を最優先する姿勢を貫いている。新技術の導入に際しては厳格な倫理審査や臨床試験を経て、長期的な安全性が確認されて初めて本格的な導入に至ることを基本方針としている。特にAI技術やデジタル医療については、患者の権利保護や個人情報管理を最重視し、人間中心原則を徹底する方針を掲げている。また、ブルー大学は近年「医療ツーリズム」にも注力している。国外からの患者を受け入れ、高度な医療サービスを提供することで国際的な評価を高め、収益基盤を強化する狙いがある。医療ツーリズム部門は年々成長しており、今後はAIやICTの活用によって外国人患者の利便性を向上させる構想も検討されている。ブルー大学の事業の概要は</span>
                <span class="lang-en">Blue University is a prestigious private university corporation located in
                    Arbitria, and it possesses both an educational division and an affiliated hospital division. It has
                    received high evaluations domestically and internationally, particularly in the fields of medicine
                    and pharmacology. The university has approximately 3,000 faculty and staff members, of whom 800 are
                    researchers mainly in medicine and pharmacology. The affiliated hospital is a large-scale facility
                    with more than 1,000 beds, and it plays the role as a core institution in regional medical care
                    while also functioning as a center for advanced clinical research. Blue University reflects the
                    cultural characteristics of Arbitria and adheres to an attitude that prioritizes safety and
                    reliability. When introducing new technologies, its basic policy is to undergo strict ethical review
                    and clinical trials, and only after long-term safety has been confirmed does it proceed to
                    full-scale introduction. In particular, with respect to Al technology and digital healthcare, it
                    upholds a policy of giving utmost importance to the protection of patients' rights and the
                    management of personal information, and thoroughly enforces this human-centered principle. In
                    addition, in recent years Blue University has also been focusing on “medical tourism.” By accepting
                    patients from abroad and providing advanced medical services, it aims to enhance its international
                    reputation and strengthen its financial base. The medical tourism division has been growing year by
                    year, and in the future, it is also considering concepts to improve the convenience of foreign
                    patients through the use of AI and ICT. An outline of the business of Blue University is shown in
                </span>
                <a href="#exhibit4" target="_blank">
                    <span class="lang-ja">別添4</span>
                    <span class="lang-en">Exhibit 4</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-7"><strong>7.</strong>
                <span
                    class="lang-ja">レッド社とブルー大学の関係が始まったのは、2023年秋に日本で開催された「臨床AIシンポジウム」である。この国際シンポジウムでは、医療へのAIの活用に関する最先端の技術や機器、臨床での活用事例についての情報交換や議論が行われ、救急外来でのトリアージの効率化、循環器領域での見逃しの低減、呼吸器疾患の再入院率抑制等におけるAIの活用事例が紹介された。このシンポジウムの場で、レッド社は自社が開発したAI診断支援ツールRedAidについての紹介を行った。レッド社が配布したRedAidの機能や用途についての説明の概要は</span>
                <span class="lang-en">The relationship between Red Corporation and Blue University began at the
                    “Clinical AI Symposium” held in Japan in the autumn of 2023. At this international symposium,
                    information exchange and discussions were conducted regarding the latest technologies and devices
                    related to the use of Al in healthcare and examples of their clinical applications. Cases were
                    introduced concerning the utilization of Al in improving the efficiency of triage in emergency
                    outpatient care, reducing oversights in the cardiovascular field, and suppressing readmission rates
                    for respiratory diseases. At this symposium, Red Corporation made a presentation introducing its Al
                    diagnostic support tool, RedAid. The outline of the explanation distributed by Red Corporation
                    concerning the functions and uses of RedAid is shown in </span>
                <a href="#exhibit5" target="_blank">
                    <span class="lang-ja">別添5</span>
                    <span class="lang-en">Exhibit 5</span>
                </a>
                <span class="lang-ja">のとおりである。また、ブルー大学は臨床統治や倫理審査(IRB/IEC)の重要性に関する発表をおこなった。ブルー大学の発表の要旨は</span>
                <span class="lang-en">. In addition, Blue University made a presentation concerning the importance of
                    clinical governance and ethical review (IRB/IEC). The summary of the presentation by Blue University
                    is shown in </span>
                <a href="#exhibit6" target="_blank">
                    <span class="lang-ja">別添6</span>
                    <span class="lang-en">Exhibit 6</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-8"><strong>8.</strong>
                <span
                    class="lang-ja">レッド社からの参加者とブルー大学の参加者はお互いの発表を興味深く聞いた。レッド社はブルー大学のような国際的にも知られている大学がRedAidを採用してくれた場合には、RedAidの知名度が向上するし、ブルー大学によるRedAidの利用を通じて得られたデータを活かしてさらにdをより良いものにしていくことができると考えていた。一方、ブルー大学はRedAidの導入は診療の高度化・効率化に役立つ可能性があると考えた。そこで、後日、レッド社の担当者がブルー大学を訪問し、RedAidについてより詳しい説明を行うこととなった。</span>
                <span class="lang-en">The participants from Red Corporation and the participants from Blue University
                    listened to each other’s presentations with interest. Red Corporation considered that if an
                    internationally well-known university such as Blue University were to adopt RedAid, the recognition
                    of RedAid would increase, and by making use of the data obtained through the utilization of RedAid
                    by Blue University, RedAid could be further improved. On the other hand, Blue University thought
                    that the introduction of RedAid could contribute to the advancement and streamlining of medical
                    treatment. Therefore, it was decided that at a later date, a representative of Red Corporation would
                    visit Blue University and provide a more detailed explanation regarding RedAid.</span>
            </p>
            <p id="p-9"><strong>9.</strong>
                <span
                    class="lang-ja">2023年11月、レッド社の担当者がブルー大学を訪問し、RedAidについて議論した。同年12月にはブルー大学内に設置されたデータガバナンス委員会において、レッド社の技術担当者とブルー大学の臨床・情報部門の責任者が同席し、RedAidについての具体的な検証作業が進められた。検証作業の集大成として実施された会議の議事録は</span>
                <span class="lang-en">In November 2023, representatives of Red Corporation visited Blue University and
                    discussed RedAid. In December of the same year, at the Data Governance Committee established within
                    Blue University, technical staff of Red Corporation and persons responsible for the clinical and
                    information divisions of Blue University sat together, and concrete verification work concerning
                    RedAid was advanced. The minutes of the meeting that was conducted as the culmination of the
                    verification work are shown in</span>
                <a href="#exhibit7" target="_blank">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit 7</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-10"><strong>10.</strong>
                <span
                    class="lang-ja">この会議での合意を踏まえて、ブルー大学は院内のデータガバナンス委員会でさらに具体的な技術検証を行い、2024年初頭には3か月間のPoC(実証試験)が実施され、RedAidがブルー大学の環境で期待される機能を発揮することが確認された。PoCの報告書は</span>
                <span class="lang-en">Based on the agreement reached at this meeting, Blue University conducted more
                    concrete technical verification at its internal Data Governance Committee, and at the beginning of
                    2024, a three-month PoC (proof of concept) was carried out, and it was confirmed that RedAid
                    demonstrated the functions expected in the environment of Blue University. The PoC report is shown
                    in</span>
                <a href="#exhibit8" target="_blank">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit 8</span>
                </a>
                <span
                    class="lang-ja">のとおりである。これを受け、2024年4月1日、レッド社とブルー大学は正式にライセンス契約を締結した。ライセンス契約のうち、本問題に関連する部分の抜粋は</span>
                <span class="lang-en">. Following this, on April 1, 2024, Red Corporation and Blue University formally
                    concluded a license agreement. The excerpts of the license agreement related to the present problem
                    are shown in</span>
                <a href="#exhibit9" target="_blank">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit 9</span>
                </a>
                <span class="lang-ja">の通りである。この契約の締結の際にレッド社からブルー大学に提供されたRedAidのモデルカードとリスクマネジメント計画の抜粋は</span>
                <span class="lang-en">. The excerpts of the model card of RedAid and the risk management plan that were
                    provided by Red Corporation to Blue University at the time of the conclusion of this agreement are
                    shown in</span>
                <a href="#exhibit10" target="_blank">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit 10</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-11"><strong>11.</strong>
                <span
                    class="lang-ja">2024年4月15日、レッド社はRedAidの重要なアップデート(v3.3.0)を正式に配信し、循環器および呼吸器モジュールにおける識別閾値を最適化し、偽陰性リスクを低減する改良を導入した。この配信はブルー大学にも届いていた。このアップデートの通知は</span>
                <span class="lang-en">On April 15, 2024, Red Corporation officially distributed an important update of
                    RedAid (v3.3.0), introducing improvements that optimized the identification thresholds in the
                    cardiovascular and respiratory modules and reduced the risk of false negatives. This distribution
                    also reached Blue University. The notification of this update is shown in</span>
                <a href="#exhibit11" target="_blank">
                    <span class="lang-ja">別添11</span>
                    <span class="lang-en">Exhibit 11</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-12"><strong>12.</strong>
                <span
                    class="lang-ja">2024年4月18日、救急病棟で患者の死亡事例が発生した。同症例では、胸痛と呼吸困難を訴えて来院した62歳男性患者に対し、担当医が旧版v3.2.1のAI出力を参照した結果、「低リスク」と判定され、入院観察が回避された。翌日、患者は急変して再来院したが、集中治療室に搬送後に死亡する転帰をたどった。この症例に関する症例記録は</span>
                <span class="lang-en">On April 18, 2024, a case of patient death occurred in the emergency ward of Blue
                    University. In this case, a 62-year-old male patient who visited the hospital complaining of chest
                    pain and dyspnea was judged as "low risk" by reference to the Al output of the old version v3.2.1,
                    and inpatient observation was denied. On the following day, the patient suddenly deteriorated and
                    returned to the hospital, but after being transferred to the intensive care unit, he died. The case
                    record concerning this case is shown in </span>
                <a href="#exhibit12" target="_blank">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit 12</span>
                </a>
                <span
                    class="lang-ja">のとおりである。この症例を踏まえ、ブルー大学は4月18日よりRedAidの利用を停止するとともに（ブルー⼤学はレッド社に対してRedAidの利⽤を停⽌する旨を伝えたが、レッド社からは返答はなかった）、内部調査を実施した。内部調査の報告書案は</span>
                <span class="lang-en">. In view of this case, Blue University suspended the use of RedAid from April 18
                    and conducted an internal investigation. Blue University informed Red Corporation that it would
                    suspend the use of RedAid, but received no response from Red Corporation. The draft of the internal
                    investigation report is shown in </span>
                <a href="#exhibit13" target="_blank">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit 13</span>
                </a>
                <span class="lang-ja">のとおりである。この内部調査報告書案を踏まえ、レッド社とブルー大学は協議を行った。その協議の記録は</span>
                <span class="lang-en">. Based on this draft of the internal investigation report, Red Corporation and
                    Blue University held consultations. The record of such consultations is shown in </span>
                <a href="#exhibit14" target="_blank">
                    <span class="lang-ja">別添14</span>
                    <span class="lang-en">Exhibit 14</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-13"><strong>13.</strong>
                <span
                    class="lang-ja">その後、この内部調査報告書案が外部に流出した。流出した原因は、ブルー大学の職員がPCの操作を過失により誤って内部調査報告書案を同大学のウェブサイト上で外部者が閲覧可能な状態にしてしまったことによる。1時間後に外部からの指摘で気がついて削除したが、この間に報告書案は閲覧されたりダウンロードされたようである。これを受け、SNSや業界誌でRedAidに欠陥があるのではないかとの情報が広まった。SNSや業界誌における記述は</span>
                <span class="lang-en">Thereafter, this draft of the internal investigation report was leaked externally.
                    The cause of the leak was that a staff member of Blue University mistakenly operated a PC and placed
                    a draft of the internal investigation report in a file accessible to external persons on the
                    university's website. After one hour, a third party notified the university and the report draft was
                    deleted, but during this time the draft of the report appears to have been viewed or downloaded.
                    Soon thereafter, information quickly spread on social media and in industry journals suggesting that
                    RedAid might have defects. The descriptions in social media and industry journals are shown in
                </span>
                <a href="#exhibit15" target="_blank">
                    <span class="lang-ja">別添15</span>
                    <span class="lang-en">Exhibit 15</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-14"><strong>14.</strong>
                <span class="lang-ja">レッド社とブルー大学が同意して選任した外部の専門家によるレポートは</span>
                <span class="lang-en">The report by an external expert appointed by agreement between Red Corporation
                    and Blue University is shown in </span>
                <a href="#exhibit16" target="_blank">
                    <span class="lang-ja">別添16</span>
                    <span class="lang-en">Exhibit 16</span>
                </a>
                <span
                    class="lang-ja">のとおりである。このレポートによって、アップデート後のRedAidには欠陥が見られないことが判明したとして、ブルー大学は、、9⽉1⽇から9⽉17⽇かけて改めてRedAidの機能や利⽤法について医師・看護師・職員を対象にした研修を⾏ったうえで、9月18日よりRedAidの利用を再開した。</span>
                <span class="lang-en">. According to this report, it was clarified that no defects were recognized in
                    RedAid after the update, and therefore Blue University resumed the use of RedAid from September 18,
                    after conducting training sessions for doctors, nurses and staff on the functions and usage of
                    RedAid from September 1 to 17.</span>
            </p>
            <p id="p-15"><strong>15.</strong>
                <span class="lang-ja">レッド社は、内部調査報告書案の流出によって多大な損害を被ったと主張し、ブルー大学に対して損害の賠償を求める文書を送付した。この文書は</span>
                <span class="lang-en">Red Corporation asserted that it suffered enormous damage due to the leak of the
                    draft internal investigation report and sent a document demanding compensation for damages to Blue
                    University. This document is shown in </span>
                <a href="#exhibit17" target="_blank">
                    <span class="lang-ja">別添17</span>
                    <span class="lang-en">Exhibit 17</span>
                </a>
                <span class="lang-ja">のとおりである。これに対して、ブルー大学は</span>
                <span class="lang-en">. In response, Blue University sent the document shown in </span>
                <a href="#exhibit18" target="_blank">
                    <span class="lang-ja">別添18</span>
                    <span class="lang-en">Exhibit 18</span>
                </a>
                <span
                    class="lang-ja">の文書を送付した。レッド社とブルー大学は本件について交渉を行ったが、交渉は平行線を辿り、決着しなかったため、レッド社はブルー大学を相手に仲裁の申立てを行った。これに対してブルー大学はレッド社の請求を棄却を求めるとともに、ブルー大学が支払った慰謝料相当額の賠償(</span>
                <span class="lang-en">. Red Corporation and Blue University conducted negotiations concerning this
                    matter, but as the negotiations remained at an impasse and were not resolved, Red Corporation filed
                    a request for arbitration against Blue University. In response, Blue University sought dismissal of
                    the claim of Red Corporation and also made a counterclaim demanding compensation equivalent to the
                    consolation money paid by Blue University, as explained in </span>
                <a href="#exhibit18" target="_blank">
                    <span class="lang-ja">別添18</span>
                    <span class="lang-en">Exhibit 18</span>
                </a>
                <span class="lang-ja">を参照)を求める反対請求を行った。この事件を、「RedAid事件」という。</span>
                <span class="lang-en">. This case is referred to as the "RedAid Case."</span>
            </p>
            <p id="p-16"><strong>16.</strong>
                <span
                    class="lang-ja">そうしたところ、レッド社とブルー大学との間には、もう1つのトラブルが発生した。ブルー大学は、2023年頃より、自国の医療水準を国際的に発信し、国際的な医療ツーリズムの拠点となることを目指した準備を進めていた。その一環として、海外患者が来院前にオンラインで症状を入力し、AIが事前にリスクを判定する「医療ツーリズム向けAI診断支援システム」の導入を計画した。これにより、来院患者の適切な事前トリアージが可能となり、不要な渡航を防ぎ、また患者に安心を提供できると考えられていた。</span>
                <span class="lang-en">Thereafter, another trouble arose between Red Corporation and Blue University.
                    Since around 2023, Blue University had been making preparations with the aim of internationally
                    disseminating its own country's medical standards and becoming a hub for international medical
                    tourism. As part of this effort, it planned to introduce an "Al diagnostic support system for
                    medical tourism," in which foreign patients would input their symptoms online before visiting the
                    hospital, and Al would determine the risk in advance. By this means, appropriate pre-triage of
                    visiting patients would become possible, unnecessary travel could be prevented, and patients could
                    also be provided with reassurance.</span>
            </p>
            <p id="p-17"><strong>17.</strong>
                <span
                    class="lang-ja">ブルー大学は、この点でも、この分野で世界的に評価を得ていたレッド社に注目した。レッド社は既に複数の国でAI診断支援ツール「RedAid」を展開しており、RedAidは医療ツーリズム向けの機能も提供することができた。そこで、2024年12月から、レッド社とブルー大学との間で技術的可能性や契約条件をめぐる協議が行われた。レッド社とブルー大学との間にはRedAid事件が起きていたが、既にこの時点ではアップデート後のRedAidには欠陥が認められないことが外部の専門家の調査によって明らかになっており、レッド社とブルー大学はRedAid事件については仲裁で解決しつつ、医療ツーリズムに関する件については、RedAid事件とは切り離して考えることで合意した。両者の協議の集⼤成となった2025年1⽉15⽇の会議の記録は</span>
                <span class="lang-en">Blue University also turned its attention to Red Corporation, which had gained
                    worldwide recognition in this field. Red Corporation had already deployed the Al diagnostic support
                    tool "RedAid" in multiple countries, and RedAid was also able to provide functionality suitable for
                    medical tourism. Therefore, from December 2024, negotiations were conducted between Red Corporation
                    and Blue University concerning technical feasibility and contractual conditions. Although the RedAid
                    Case had previously occurred between Red Corporation and Blue University, at that time it had
                    already been clarified by the investigation of external experts that no defect was recognized in
                    RedAid after the update, and Red Corporation and Blue University agreed to treat the matter
                    concerning medical tourism separately from the RedAid Case while resolving the RedAid Case through
                    arbitration. The record of the meeting on 15 January 2025, which represented the culmination of
                    discussions between the two parties, is shown in </span>
                <a href="#exhibit19" target="_blank">
                    <span class="lang-ja">別添19</span>
                    <span class="lang-en">Exhibit 19</span>
                </a>
                <span class="lang-ja">のとおりである。2025年2月1日に「医療ツーリズム向けAI診断支援特約」が締結された。この特約は</span>
                <span class="lang-en">. On February 1, 2025, the "Special Agreement on AI Diagnostic Support for Medical
                    Tourism" was concluded. This special agreement is shown in </span>
                <a href="#exhibit20" target="_blank">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit 20</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-18"><strong>18.</strong>
                <span
                    class="lang-ja">契約締結後、レッド社はブルー大学の求める性能要件――すなわち10言語以上の多言語対応、CT/MRI等の高精細画像のリアルタイム処理、同時500件以上のアクセスに耐えうる接続能力――を満たすには、ネゴランド国内にある自社契約の高性能クラウドを部分的に利用せざるを得ないと判断した。そこでレッド社はブルー大学に改めて確認を行ったところ、ブルー大学のIT部門長からの返答があった。この点についてのレッド社とブルー大学との間のやりとりは</span>
                <span class="lang-en">After the conclusion of the contract, Red Corporation determined that in order to
                    satisfy the performance requirements demanded by Blue University, i.e., multilingual support in more
                    than ten languages, real- time processing of high-resolution images such as CT/MRI, and connection
                    capacity to withstand simultaneous access of more than 500 cases, it would have to partially use its
                    own contracted high- performance cloud servers in Negoland. When Red Corporation reconfirmed this
                    point with Blue University, a response was received from the Head of the IT Division of Blue
                    University. The exchange between Red Corporation and Blue University regarding this matter is shown
                    in </span>
                <a href="#exhibit21" target="_blank">
                    <span class="lang-ja">別添21</span>
                    <span class="lang-en">Exhibit 21</span>
                </a>
                <span class="lang-ja">のとおりである。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-19"><strong>19.</strong>
                <span
                    class="lang-ja">2025年7月15日より、ブルー大学は医療ツーリズムに関するRedAidの利用を開始した。しかし、2025年8月15日、ブルー大学監査部は内部監査の一環としてRedAidシステムの利用状況を調査し、一部の患者データがネゴランド国内クラウドに保存されていることを確認した。監査部は直ちに大学上層部に報告し、問題は大学全体で大きな懸案となった。これに対し、IT部門は「性能要件を満たすための運用上の措置であり、ここまで大事になるとは予期していなかった」と釈明している。監査部の監査結果の抜粋は</span>
                <span class="lang-en">From July 15, 2025, Blue University began the use of RedAid related to medical
                    tourism. However, on August 15, 2025, the Audit Division of Blue University, as part of an internal
                    audit, investigated the utilization status of the RedAid system and confirmed that part of the
                    patient data was stored in cloud servers within Negoland. The Audit Division immediately reported to
                    the upper management of the university, and the issue became a major concern throughout the entire
                    university. In response, the IT Division explained that "it was an operational measure to meet
                    performance requirements, and we did not anticipate that it would become such a serious issue." The
                    excerpt of the audit results by the Audit Division is shown in </span>
                <a href="#exhibit22" target="_blank">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit 22</span>
                </a>
                <span
                    class="lang-ja">のとおりである。監査結果を受けて、ブルー大学は8月20日付でレッド社に正式通知を送り、国外移転を直ちに停止し、すべてのデータをアービトリア国内に戻すよう通告した。この通知書は</span>
                <span class="lang-en">. Based on the audit results, Blue University, on August 20, sent a formal notice
                    to Red Corporation, ordering the immediate cessation of cross-border data transfers and the return
                    of all data to within Arbitria. This notice is shown in </span>
                <a href="#exhibit23" target="_blank">
                    <span class="lang-ja">別添23</span>
                    <span class="lang-en">Exhibit 23</span>
                </a>
                <span class="lang-ja">のとおりである。これに対して、レッド社は8月22日付で</span>
                <span class="lang-en">. In response, Red Corporation replied on August 22 as shown in </span>
                <a href="#exhibit24" target="_blank">
                    <span class="lang-ja">別添24</span>
                    <span class="lang-en">Exhibit 24</span>
                </a>
                <span class="lang-ja">のとおり回答した。さらに、8月25日、レッド社は再度ブルー大学に対して</span>
                <span class="lang-en">. Furthermore, on August 25, Red Corporation again sent a notice to Blue
                    University as shown in </span>
                <a href="#exhibit25" target="_blank">
                    <span class="lang-ja">別添25</span>
                    <span class="lang-en">Exhibit 25</span>
                </a>
                <span class="lang-ja">のとおりの通知を送付した。これに対してブルー大学は9月5日、</span>
                <span class="lang-en">. In response, on September 5, Blue University replied as shown in </span>
                <a href="#exhibit26" target="_blank">
                    <span class="lang-ja">別添26</span>
                    <span class="lang-en">Exhibit 26</span>
                </a>
                <span class="lang-ja">のとおり回答した。</span>
                <span class="lang-en">.</span>
            </p>
            <p id="p-20"><strong>20.</strong>
                <span
                    class="lang-ja">ブルー大学は9月7日にアービトリア国個人情報保護委員会に自己申告を行った。ブルー大学は、アービトリア国個人情報保護委員会からブルー大学になされた通知を踏まえ、9月12日にレッド社に対して</span>
                <span class="lang-en">On September 7, Blue University made a voluntary report to the Personal
                    Information Protection Commission of Arbitria. Based on the notification made by the Personal
                    Information Protection Commission of Arbitria to Blue University, on September 12 Blue University
                    sent the document shown in </span>
                <a href="#exhibit27" target="_blank">
                    <span class="lang-ja">別添27</span>
                    <span class="lang-en">Exhibit 27</span>
                </a>
                <span class="lang-ja">の文書を送付し、9月13日にはレッド社からブルー大学に対して</span>
                <span class="lang-en">to Red Corporation, and on September 13 the document shown in </span>
                <a href="#exhibit28" target="_blank">
                    <span class="lang-ja">別添28</span>
                    <span class="lang-en">Exhibit 28</span>
                </a>
                <span class="lang-ja">の文書が送付された。</span>
                <span class="lang-en">was sent from Red Corporation to Blue University.</span>
            </p>
            <p id="p-21"><strong>21.</strong>
                <span
                    class="lang-ja">そこで、ブルー大学はレッド社に対して、国外移転を停止すべきこと、RedAidの医療ツーリズム特約に基づくサービスを継続して提供すべきこと、ブルー大学がアービトリア国個人情報保護法に基づき支払いを余儀なくされた制裁金はレッド社が賠償すべきこと、を求めて仲裁の申立てを行った。また、国外移転を遅くとも12月15日までに停止すべきことと、仲裁判断が出るまでの間、サービスを継続して提供せよと命じる暫定的な処分の申立てを行った。この事件を「ツーリズム事件」という。</span>
                <span class="lang-en">Thereafter, Blue University filed a request for arbitration against Red
                    Corporation, demanding that the cross-border transfer be stopped, that the services under the
                    special agreement on medical tourism of RedAid be continuously provided, and that the penalty which
                    Blue University had been forced to pay under the Personal Information Protection Law of Arbitria be
                    compensated by Red Corporation. At the same time, Blue University filed an application for interim
                    measures ordering that the cross-border transfer be stopped no later than December 15, and that,
                    until the arbitral award is rendered, services be continuously provided. This case is referred to as
                    the "Tourism Case."</span>
            </p>
            <h2 id="p-22">
                <span class="lang-ja">&lt;ラウンドA&gt;</span>
                <span class="lang-en">&lt;Round A&gt;</span>
            </h2>
            <p><strong>22.</strong>
                <span
                    class="lang-ja">レッド社とブルー大学は、「RedAid事件」及び「ツーリズム事件」の双方を併合して審理することに合意し、仲裁人との協議の結果、11月15日に口頭での審理を実施することとなった。なお、仲裁人を交えた争点整理の結果、11月15日に審理する争点は、</span>
                <span class="lang-en">Red Corporation and Blue University agreed to consolidate and hear both the
                    "RedAid Case" and the "Tourism Case," and as a result of consultations with the arbitrators, it was
                    decided to conduct an oral hearing on November 15. It was also agreed, as a result of organizing the
                    issues together with the arbitrators, that the issues to be heard on November 15 will be those shown
                    in </span>
                <a href="#exhibit29" target="_blank">
                    <span class="lang-ja">別添29</span>
                    <span class="lang-en">Exhibit 29</span>
                </a>
                <span class="lang-ja">のとおりと合意されている。</span>
                <span class="lang-en">.</span>
            </p>
            <h2 id="p-23">
                <span class="lang-ja">&lt;ラウンドB&gt;</span>
                <span class="lang-en">&lt;Round B&gt;</span>
            </h2>
            <p><strong>23.</strong>
                <span
                    class="lang-ja">今回の交渉は、ネゴランド国に所在するAI医療技術企業レッド社と、アービトリア国の名門私立大学ブルー大学との間で行われるものである。ラウンドBとの関係では、問題文の1段落から7段落、及び、別添１から６、及び、別添30
                    と31は適用されるが、問題文の８段落以降降、及び、別添７から29は適用されないものとする。また、ラウンドBとの関係では、RedAidには他⾔語機能はないものとし、ネゴランド国及びアービトリア国の公⽤語である英語のみに対応しているものとする。</span>
                <span class="lang-en">The present negotiation is to be conducted between Red Corporation, an Al medical
                    technology company located in Negoland, and Blue University, a prestigious private university in
                    Arbitria. In relation to Round B, the background information set forth in Paragraphs 1 through 7 and
                    Exhibit 1 through 6 as well as Exhibit 30 and 31 of this Problem shall apply, but the problem text
                    from Paragraph 8 onwards and
                    Exhibit 7 through 29 shall not apply. Furthermore, with respect to Round B, RedAid shall be deemed
                    to
                    have no multilingual capabilities and shall only support English, the official language of both
                    Negoland and Arbitria.</span>
            </p>
            <p id="p-24"><strong>24.</strong>
                <span
                    class="lang-ja">レッド社は、自社の中核製品であるAI医療支援ツール「RedAid」の精度をさらに高め、特に希少疾患や高齢者、複数の合併症を抱える患者にも対応できるよう改良したいと考えていた。しかし、そのために必要な大規模で多様な臨床データが不足していた。そこで、国際的に著名で豊富な臨床データを有するブルー大学との連携に強い関心を持つに至った。一方、ブルー大学は、国際的な存在感を一層高めるため、高い技術力を持つ企業と共同研究契約を結びたいと考えていた。学術的成果の発表や研究資金の確保に加え、臨床現場での診療の高度化にもつなげたいとの思いから、AI医療技術に強みを持つレッド社との提携に魅力を感じた。</span>
                <span class="lang-en">Red Corporation intended to further improve the accuracy of its core product, the
                    Al medical support tool "RedAid," in particular so that it could also respond to rare diseases,
                    elderly patients, and patients with multiple complications. However, it lacked the large-scale and
                    diverse clinical data required for this purpose. Therefore, it came to have a strong interest in
                    collaboration with Blue University, which is internationally renowned and possesses abundant
                    clinical data. On the other hand, Blue University, in order to further enhance its international
                    presence, sought to conclude a joint research agreement with a company possessing high technological
                    capability. In addition to the publication of academic results and the securing of research funds,
                    it also wished to connect this to the advancement of medical treatment in the clinical field, and
                    thus felt attraction to partnership with Red Corporation, which has strengths in AI medical
                    technology.</span>
            </p>
            <p id="p-25"><strong>25.</strong>
                <span
                    class="lang-ja">両者の担当者が議論した結果、以下の2つのテーマで連携の可能性があるのではないかということになっている。両者は2025年春、日本での国際シンポジウムの場で面談し、以下の2のテーマを中心に協議を進めることとなった。</span>
                <span class="lang-en">As a result of discussions between the representatives of both parties, two
                    projects came to be seen as possible areas of collaboration. The parties met at an international
                    symposium held in Japan in the spring of 2025, and the decision was made to actively proceed with
                    consultations focusing on the two projects described below.</span>
            </p>
            <h3>
                <span class="lang-ja">1.「RedAid」に関する共同研究契約の主要な内容</span>
                <span class="lang-en">1. Core content of a Joint Research Agreement regarding "RedAid"</span>
            </h3>
            <h3>
                <span class="lang-ja">2.遠隔医療プラットフォーム「RedLink」の導入に関する契約の主要な内容</span>
                <span class="lang-en">2. Core content of a contract regarding the introduction of the telemedicine
                    platform "RedLink"</span>
            </h3>
            <p id="p-26"><strong>26.</strong>
                <span class="lang-ja">これらのテーマについて、両者の担当者が集まって議論した際の議事録は</span>
                <span class="lang-en">The minutes of the meeting at which the representatives of both parties gathered
                    and discussed these projects are shown in </span>
                <a href="#exhibit30" target="_blank">
                    <span class="lang-ja">別添30</span>
                    <span class="lang-en">Exhibit 30</span>
                </a>
                <span class="lang-ja">のとおりである。また、両者が確認したRedLinkの概要は</span>
                <span class="lang-en">. Furthermore, the overview of RedLink confirmed by both parties is as set out in
                </span>
                <a href="#exhibit30" target="_blank">
                    <span class="lang-ja">別添31</span>
                    <span class="lang-en">Exhibit 31</span>
                </a>
                <span
                    class="lang-ja">のとおりである。11月16日には、この際の議論も踏まえ、3つのテーマについて交渉することとなっている。レッド社からは、副社長、最高技術責任者、法務部長等が、ブルー大学からは副理事長、臨床統治部長、法務部長等が交渉に参加することを予定している。なお、チームのメンバーの数が4名以上の場合には、各チームで適宜適切な役職を設定すること。ラウンドB
                    においてはPoC のほか（契約期間だけを交渉すれば⾜りる）、秘密情報に記載されていない事項については、仮に別添30 に記載があっても交渉する必要はない。</span>
                <span class="lang-en">. Based on the discussions on that occasion, negotiations will be held on November
                    16 to decide further details of the two projects. From Red Corporation, the Vice President, the
                    Chief Technology Officer, the Head of the Legal Department, and others are scheduled to participate
                    in the negotiations, and from Blue University, the Vice President, the Head of the Clinical
                    Governance Division, the Head of the Legal Department, and others are scheduled to participate.
                    Where a team comprises four or more members, each team shall establish appropriate additional roles
                    as deemed necessary. In Round B, in addition to the PoC (it is sufficient to negotiate only the
                    contract period), there is no need to negotiate matters not included in the confidential
                    information, even if they are referred to in Exhibit 30.</span>
            </p>
        </section>

        <section id="exhibit1" class="content-section">
            <h2>
                <span class="lang-ja">別添1 ネゴランド国における法令やガイダンスの例</span>
                <span class="lang-en">Exhibit 1 Examples of Laws and Guidance in Negoland</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-2">
                    <span class="lang-ja">本文¶2</span>
                    <span class="lang-en">Facts ¶2</span>
                </a>
                <span class="lang-ja">, </span>
                <span class="lang-en">, </span>
                <a href="#p-5">
                    <span class="lang-ja">本文¶5</span>
                    <span class="lang-en">Facts ¶5</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">1.医療機器法</span>
                    <span class="lang-en">1. Medical Device Act</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">制度の概要</span>
                            <span class="lang-en">Outline of the System</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">新規医療機器の臨床利用・販売には保健・医療省の承認が必要である。申請には臨床試験データ、製造プロセス、品質管理体制などの詳細資料を添付する必要がある。</span>
                            <span class="lang-en">For the clinical use and sale of new medical devices, approval of the
                                Ministry of Health and Medical Care is required. Applications must be accompanied by
                                detailed materials such as clinical trial data, manufacturing processes, and quality
                                control systems.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">通常の承認プロセス</span>
                            <span class="lang-en">Normal Approval Process</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">審査には通常12~18か月程度を要する。ただし、申請者と規制当局の間でオンライン審査ツールや電子申請を活用する仕組みが整備され、審査効率は高い。</span>
                            <span class="lang-en">Review normally requires about 12 to 18 months. However, mechanisms
                                have been established to utilize online review tools and electronic applications between
                                applicants and the regulatory authority, and the efficiency of review is high.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">先進的枠組み</span>
                            <span class="lang-en">Advanced Framework</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">「サンドボックス制度」を導入。先進的な医療機器であると保健・医療省が認めた機器については、審査期間を6~9か月程度に短縮し、条件付きで市場投入可能。限定された市場(希少疾患、緊急医療ニーズなど)において臨床利用を認め、同時に追加データを収集する。</span>
                            <span class="lang-en">A "sandbox system" has been introduced. For devices that are
                                recognized by the Ministry of Health and Medical Care as advanced medical devices, the
                                review period is shortened to about 6 to 9 months, and they may be conditionally placed
                                on the market. Clinical use is permitted in limited markets (rare diseases, urgent
                                medical needs, etc.) while additional data is collected at the same time.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">多数のスタートアップ企業がこの制度を利用してAI診断機器や遠隔モニタリングデバイスを投入している。失敗やリスクが一定程度許容される一方で、迅速なフィードバックにより改良が進む環境が整っている。</span>
                            <span class="lang-en">A large number of start-up companies have been utilizing this system
                                to introduce Al diagnostic devices and remote monitoring devices. While a certain degree
                                of failure and risk is tolerated, the environment is such that improvements progress
                                rapidly through quick feedback.</span>
                        </p>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">2.個人情報保護法</span>
                    <span class="lang-en">2. Personal Information Protection Act</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">制度の概要</span>
                            <span class="lang-en">Outline of the System</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">診療録、検査値、画像、遺伝情報、疾患歴、保険請求情報などを「医療用個人データ」として特別の規律の対象となっている。これらのデータの収集や利用については本人の同意を前提とするが、研究・開発のための利用については、本人に不当な損害を与えないことを条件に利用が認められている。</span>
                            <span class="lang-en">Medical records, test values, images, genetic information, disease
                                history, insurance claim information, and the like are subject to special regulations as
                                "medical personal data." The collection and use of such data requires the consent of the
                                individual, but use for research and development is permitted on the condition that it
                                does not cause undue harm to the individual.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">国外移転</span>
                            <span class="lang-en">Cross-border Transfer</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">医療用個人データのうち匿名化されたデータについては本人の同意がなく国外移転が可能である。匿名化されていないデータについては、本人の同意が必要である。個人情報の保護の程度がネゴランド国と同程度でない国への移転も、契約で一定の保護措置を講じれば可能である。</span>
                            <span class="lang-en">With respect to anonymized data, cross-border transfer is possible
                                without the consent of the individual. With respect to non-anonymized data, the consent
                                of the individual is required. Even transfer to countries whose level of personal
                                information protection is not equivalent to that of Negoland is possible if certain
                                protective measures are taken by contract.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">研究利用</span>
                            <span class="lang-en">Research Use</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">AI学習や国際共同研究のためのデータ利用は積極的に奨励されている。クラウドサービス事業者や海外研究機関とのデータ共有も広く認められる。</span>
                            <span class="lang-en">Use of data for Al learning and international joint research is
                                positively encouraged. Data sharing with cloud service providers and overseas research
                                institutions is widely permitted.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">「データの利活用によるイノベーション促進」を最優先するというのがネゴランド国の方針であり、個人情報保護は必要だが、イノベーションの阻害要因にならないよう規制は柔軟に解釈される傾向にある。</span>
                            <span class="lang-en">Negoland's policy is to prioritize "the promotion of innovation
                                through the use of data," and although the protection of personal information is
                                necessary, regulation tends to be flexibly interpreted so as not to become a factor
                                hindering innovation.</span>
                        </p>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">3.医療分野におけるAIガイダンス(保健・医療省)</span>
                    <span class="lang-en">3. Guidance on Al in the Medical Field (Ministry of Health and Medical
                        Care)</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">開発者の責務</span>
                            <span class="lang-en">Responsibilities of Developers</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">AIを利用する医療機器の開発にあたっては、利用目的、想定ユーザー、学習データの概要、既知の偏り、性能・限界、セキュリティ脆弱性を記載した「モデルカード」を整備する必要がある。ただし、記載の水準は比較的簡潔で、詳細性よりも「透明性の確保」が重視される。</span>
                            <span class="lang-en">In the development of medical devices using Al, it is necessary to
                                prepare a "model card" describing the purpose of use, intended users, outline of
                                training data, known biases, performance and limitations, and security vulnerabilities.
                                However, the level of description is relatively concise, and "ensuring transparency" is
                                emphasized over detailedness.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">医療機関の対応</span>
                            <span class="lang-en">Response of Medical Institutions</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">実際に医療の現場で利用するかどうかの判断は、医療機関がモデルカードを参考に行う。医療機関は、導入後は性能の劣化がないかを監視する努力義務を負う。</span>
                            <span class="lang-en">The decision whether or not to actually use it in the medical field is
                                made by medical institutions with reference to the model card. After introduction,
                                medical institutions are under a duty of effort to monitor whether performance
                                deterioration occurs.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">臨床判断</span>
                            <span class="lang-en">Clinical Judgment</span>
                        </strong>
                        <p>
                            <span class="lang-ja">原則として医師が最終責任を負うが、リスクが許容可能と医療機関が判断した範囲ではAI単独の診断や治療判断も認められる。</span>
                            <span class="lang-en">As a general rule, physicians bear final responsibility, but diagnosis
                                or treatment decisions by AI alone are also permitted within the scope judged by medical
                                institutions as acceptable risk.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span class="lang-ja">医療機関の判断により、AIを「補助」ではなく「準自律的ツール」として活用可能な柔軟性がある。</span>
                            <span class="lang-en">Depending on the judgment of medical institutions, Al can be utilized
                                with flexibility not only as "assistance" but also as a "quasi-autonomous tool."</span>
                        </p>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit2" class="content-section">
            <h2>
                <span class="lang-ja">別添2 アービトリア国における法令やガイダンスの例</span>
                <span class="lang-en">Exhibit 2 Examples of Laws and Guidance in Arbitria</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-4">
                    <span class="lang-ja">本文¶4</span>
                    <span class="lang-en">Facts ¶4</span>
                </a>
                <a href="#p-21">
                    <span class="lang-ja">本文¶21</span>
                    <span class="lang-en">Facts ¶21</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添９</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit10">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit10</span>
                </a>
                <a href="#exhibit19">
                    <span class="lang-ja">別添19</span>
                    <span class="lang-en">Exhibit19</span>
                </a>
                <a href="#exhibit22">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit22</span>
                </a>
                <a href="#exhibit26">
                    <span class="lang-ja">別添26</span>
                    <span class="lang-en">Exhibit26</span>
                </a>
                <a href="#exhibit27">
                    <span class="lang-ja">別添27</span>
                    <span class="lang-en">Exhibit27</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">1.医薬品医療機器法</span>
                    <span class="lang-en">1. Pharmaceuticals and Medical Devices Act</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">制度の概要</span>
                            <span class="lang-en">Outline of the System</span>
                        </strong>
                        <p>
                            <span class="lang-ja">医薬品と医療機器の承認・流通を規律する基本法であり、新規医療機器の販売には厚生・医療省の承認が必須である。</span>
                            <span class="lang-en">This is the basic law regulating the approval and distribution of
                                pharmaceuticals and medical devices; and for the sale of new medical devices, the
                                approval of the Ministry of Health and Medical Care is essential.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">通常の承認プロセス</span>
                            <span class="lang-en">Normal Approval Process</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">審査には通常18か月以上を要する。審査のための提出資料は膨大で、臨床試験データに加え、長期的安全性や製造工程の詳細も重視される。</span>
                            <span class="lang-en">Review normally requires more than 18 months. The materials to be
                                submitted for review are voluminous, and in addition to clinical trial data, long-term
                                safety and details of the manufacturing process are also emphasized.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">先進的枠組み</span>
                            <span class="lang-en">Advanced Framework</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">先進的な医療機器については、「先駆け審査指定制度」(12か月程度で審査する)、「条件付き早期承認制度」(9か月程度で限定された症例での利用に限り認める等の条件付きで承認する)が存在するが、対象範囲は限定的で利用件数も少ない。サンドボックスのように広範な早期導入制度は存在しない。</span>
                            <span class="lang-en">For advanced medical devices, there is the "Sakigake Designation
                                System" (review within about 12 months) and the "Conditional Early Approval System"
                                (approval within about 9 months with conditions such as being limited to use in
                                restricted cases), but their scope of application is limited and the number of cases of
                                use is few. A broad early introduction system such as a sandbox does not exist.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">「失敗を許さない」といった文化が行政一般にあり、制度にも反映されている。新技術の市場投入は遅くなるが、国民にとっての安全性・信頼性を優先するというのが政府の基本的な方針である。</span>
                            <span class="lang-en">A culture of "not allowing failure" exists in administration in
                                general, and is reflected in the system. Market introduction of new technologies is
                                slower, but the basic policy of the government is to prioritize citizen safety and
                                reliability.</span>
                        </p>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">2.個人情報保護法</span>
                    <span class="lang-en">2. Personal Information Protection Act</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">制度の概要</span>
                            <span class="lang-en">Outline of the System</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">診療録、検査値、画像、遺伝情報、疾患歴、保険請求情報などの医療データは「要配慮個人情報」とされ、特に厳格な規律の対象となっている。収集や利用にあたっては、利用目的の特定、本人同意の取得が必須である。</span>
                            <span class="lang-en">Medical data (medical records, test values, images, genetic
                                information, disease history, insurance claim information, and the like) is regarded as
                                "sensitive personal information" and is subject to particularly strict regulation. In
                                collection and use, specification of the purpose of use and obtaining the consent of the
                                individual are mandatory.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">国外移転</span>
                            <span class="lang-en">Cross-border Transfer</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">医療データは、アービトリア国と同程度の個人情報保護の制度が整っている国としてアービトリア国の個人情報保護当局が認定した国に対してのみ移転可能であり、移転する場合には個人情報の保護を実現するために必要な契約上の取り決めを関係当事者と行う必要がある。なお、ネゴランド国は、上記の認定の対象とはなっていない。</span>
                            <span class="lang-en">Transfer of medical data is permitted only to countries that have been
                                certified by the personal information protection authority of Arbitria as having systems
                                of personal information protection equivalent to that of Arbitria, and when
                                transferring, it is necessary to make contractual arrangements with the related parties
                                necessary to realize the protection of the personal information. Negoland is not
                                included in the scope of the above certification.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">研究利用</span>
                            <span class="lang-en">Research Use</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">AI学習や国際共同研究のために利用できるのは、本人が特定できない情報(本人を特定するような処理が不可能な形に加工された情報、及び、他の情報と照合しない限りは本人が特定できない情報)に限られる。本人が特定できる情報を海外クラウドの利用や国外の研究機関との共同研究のために国外移転する場合、国内での利⽤について同意を得ている場合であっても、加えて国外移転について個別に本人の同意を得る必要がある。</span>
                            <span class="lang-en">What may be used for Al learning or international joint research is
                                limited to information that does not identify the individual (information processed so
                                that identification of the individual is impossible, and information that does not
                                identify the individual unless collated with other information). In the case of
                                cross-border transfer of the personal information that may identify the individual for
                                the use of overseas cloud services or cross-border transfer for joint research with
                                overseas
                                research institutions, even where consent has been obtained for domestic use, in
                                addition to this, it is necessary to obtain the consent of the individual for the
                                cross-border transfer in each
                                case.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span class="lang-ja">個人情報保護の水準は国際的に見ても厳格で、国民の安心感を支える一方で、研究や事業者にとっては柔軟性に欠けるとの指摘がある。</span>
                            <span class="lang-en">The level of personal information protection is strict even from an
                                international perspective, and while it supports citizens' sense of security, there are
                                also criticisms that it lacks flexibility for research and business operators.</span>
                        </p>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">3.医療分野におけるAIガイダンス(厚生・医療省)</span>
                    <span class="lang-en">3. Guidance on Al in the Medical Field (Ministry of Health and Medical
                        Care)</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">開発者の責務</span>
                            <span class="lang-en">Responsibilities of Developers</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">モデルカードには学習データの偏り、性能限界、失敗モード、セキュリティ対策を詳細に記載する必要がある。記載は形式的ではなく、実務的検証が可能な水準が要求される。</span>
                            <span class="lang-en">In the model card, it is required to describe in detail the biases of
                                the training data, the performance limitations, the failure modes, and the security
                                measures. The level of description is not formalized but requires a level at which
                                practical verification is possible.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">医療機関の対応</span>
                            <span class="lang-en">Response of Medical Institutions</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">医療機関は、AIを用いた医療機器を導入する前には、臨床的・技術的・運用的観点から厳格な妥当性確認を実施し、確認の内容を記録する義務がある。また、導入後も年1回以上、性能監視・再評価を行う義務がある。</span>
                            <span class="lang-en">Before introducing medical devices using Al, medical institutions are
                                obligated to conduct strict validation from clinical, technical, and operational
                                perspectives, and to record the details of such validation. After introduction, they are
                                also obligated to conduct performance monitoring and re- evaluation at least once a
                                year.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">臨床判断</span>
                            <span class="lang-en">Clinical Judgment</span>
                        </strong>
                        <p>
                            <span class="lang-ja">臨床におけるあらゆる最終責任は必ず医師等の専門職が負う。AI単独の診断・治療判断は禁止されている。</span>
                            <span class="lang-en">All final responsibility in clinical practice must always be borne by
                                physicians or other professionals. Diagnosis or treatment decisions solely by Al are
                                prohibited.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </strong>
                        <p>
                            <span class="lang-ja">AIはあくまで「補助ツール」としての位置付けに留まり、人間中心原則を徹底するというのが基本的な考え方である。</span>
                            <span class="lang-en">The basic idea is that Al is positioned only as an "auxiliary tool,"
                                and the human-centered principle is thoroughly enforced.</span>
                        </p>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit3" class="content-section">
            <h2>
                <span class="lang-ja">別添3 レッド社の概要</span>
                <span class="lang-en">Exhibit 3 Outline of Red Corporation</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-5">
                    <span class="lang-ja">本文¶5</span>
                    <span class="lang-en">Facts ¶5</span>
                </a>
            </div>
            <ul>
                <li><strong>
                        <span class="lang-ja">設立:</span>
                        <span class="lang-en">Establishment:</span>
                    </strong>
                    <span class="lang-ja">1975年</span>
                    <span class="lang-en">1975</span>
                </li>
                <li><strong>
                        <span class="lang-ja">本店:</span>
                        <span class="lang-en">Head Office:</span>
                    </strong>
                    <span class="lang-ja">ネゴランド国ネゴネゴ市</span>
                    <span class="lang-en">Negonego City, Negoland</span>
                </li>
                <li><strong>
                        <span class="lang-ja">社長:</span>
                        <span class="lang-en">President:</span>
                    </strong>
                    <span class="lang-ja">ヒロミ・レッド</span>
                    <span class="lang-en">Hiromi Red</span>
                </li>
            </ul>
            <p>
                <span class="lang-ja">ネゴランド国法上の株式会社(非上場)</span>
                <span class="lang-en">Status: Joint-stock company under the laws of Negoland (unlisted)</span>
            </p>
            <h3>
                <span class="lang-ja">売上高・利益推移 (単位:百万米ドル)</span>
                <span class="lang-en">Trends in Sales and Profits (Unit: Million USD)</span>
            </h3>
            <table>
                <thead>
                    <tr>
                        <th>
                            <span class="lang-ja">年度</span>
                            <span class="lang-en">Fiscal Year</span>
                        </th>
                        <th>
                            <span class="lang-ja">売上高</span>
                            <span class="lang-en">Sales</span>
                        </th>
                        <th>
                            <span class="lang-ja">営業利益</span>
                            <span class="lang-en">Operating Profit</span>
                        </th>
                        <th>
                            <span class="lang-ja">純利益</span>
                            <span class="lang-en">Net Profit</span>
                        </th>
                        <th>
                            <span class="lang-ja">備考</span>
                            <span class="lang-en">Remarks</span>
                        </th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <span class="lang-ja">2022</span>
                            <span class="lang-en">2022</span>
                        </td>
                        <td>120</td>
                        <td>12</td>
                        <td>8</td>
                        <td>
                            <span class="lang-ja">「レッド・エイド」国内試験導入期</span>
                            <span class="lang-en">Period of trial introduction of ""RedAid"" in domestic market</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">2023</span>
                            <span class="lang-en">2023</span>
                        </td>
                        <td>160</td>
                        <td>18</td>
                        <td>12</td>
                        <td>
                            <span class="lang-ja">サンドボックス制度活用で利用拡大</span>
                            <span class="lang-en">Expansion of use through utilization of sandbox system</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">2024</span>
                            <span class="lang-en">2024</span>
                        </td>
                        <td>200</td>
                        <td>25</td>
                        <td>17</td>
                        <td>
                            <span class="lang-ja">海外展開開始、クラウド連携強化</span>
                            <span class="lang-en">Start of overseas expansion, strengthening of cloud
                                collaboration</span>
                        </td>
                    </tr>
                </tbody>
            </table>
            <h3>
                <span class="lang-ja">部門別業績 (2024年度)</span>
                <span class="lang-en">Performance by Business Division (FY2024)</span>
            </h3>
            <table>
                <thead>
                    <tr>
                        <th>
                            <span class="lang-ja">部門</span>
                            <span class="lang-en">Division</span>
                        </th>
                        <th>
                            <span class="lang-ja">売上高(百万米ドル)</span>
                            <span class="lang-en">Sales (Million USD)</span>
                        </th>
                        <th>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <span class="lang-ja">AI医療支援ツール「レッド・エイド」</span>
                            <span class="lang-en">AI Medical Support Tool ""RedAid""</span>
                        </td>
                        <td>120</td>
                        <td>
                            <span class="lang-ja">主力事業。診断補助・治療計画支援で国内外の病院に導入。</span>
                            <span class="lang-en">Core business. Introduced into hospitals in Negoland for diagnostic
                                assistance and treatment planning support.</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">データ解析・AI学習サービス</span>
                            <span class="lang-en">Data Analysis/Al Learning Services</span>
                        </td>
                        <td>40</td>
                        <td>
                            <span class="lang-ja">匿名化データを活用した研究受託や製薬企業向け解析。</span>
                            <span class="lang-en">Contract research utilizing anonymized data and analysis for
                                pharmaceutical companies.</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">遠隔医療プラットフォーム「レッド・リンク」</span>
                            <span class="lang-en">Telemedicine Platform ""RedLink""</span>
                        </td>
                        <td>40</td>
                        <td>
                            <span class="lang-ja">患者・医師間のオンライン診療支援サービス。市場拡大中。</span>
                            <span class="lang-en">Online medical consultation support service between patients and
                                physicians. Market is expanding.</span>
                        </td>
                    </tr>
                </tbody>
            </table>
        </section>

        <section id="exhibit4" class="content-section">
            <h2>
                <span class="lang-ja">別添4 ブルー大学の概要</span>
                <span class="lang-en">Exhibit 4 Outline of Blue University</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-6">
                    <span class="lang-ja">本文¶6</span>
                    <span class="lang-en">Facts ¶6</span>
                </a>
            </div>
            <ul>
                <li><strong>
                        <span class="lang-ja">設立:</span>
                        <span class="lang-en">Establishment:</span>
                    </strong>
                    <span class="lang-ja">1900年</span>
                    <span class="lang-en">1900</span>
                </li>
                <li><strong>
                        <span class="lang-ja">所在地:</span>
                        <span class="lang-en">Location:</span>
                    </strong>
                    <span class="lang-ja">アービトリア国アブアブ市</span>
                    <span class="lang-en">Abuabu City, Arbitria</span>
                </li>
                <li><strong>
                        <span class="lang-ja">理事長:</span>
                        <span class="lang-en">Chairperson:</span>
                    </strong>
                    <span class="lang-ja">リン・ブルー</span>
                    <span class="lang-en">Lin Blue</span>
                </li>
            </ul>
            <p>
                <span class="lang-ja">アービトリア国法上の学校法人(非上場)</span>
                <span class="lang-en">Status: School corporation under the laws of Arbitria (unlisted)</span>
            </p>
            <h3>
                <span class="lang-ja">売上高・利益推移 (単位:百万米ドル)</span>
                <span class="lang-en">Trends in Sales and Profits (Unit: Million USD)</span>
            </h3>
            <table>
                <thead>
                    <tr>
                        <th>
                            <span class="lang-ja">年度</span>
                            <span class="lang-en">Fiscal Year</span>
                        </th>
                        <th>
                            <span class="lang-ja">売上高</span>
                            <span class="lang-en">Sales</span>
                        </th>
                        <th>
                            <span class="lang-ja">営業利益</span>
                            <span class="lang-en">Operating Profit</span>
                        </th>
                        <th>
                            <span class="lang-ja">純利益</span>
                            <span class="lang-en">Net Profit</span>
                        </th>
                        <th>
                            <span class="lang-ja">備考</span>
                            <span class="lang-en">Remarks</span>
                        </th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <span class="lang-ja">2022</span>
                            <span class="lang-en">2022</span>
                        </td>
                        <td>600</td>
                        <td>55</td>
                        <td>35</td>
                        <td>
                            <span class="lang-ja">大学病院と教育事業による安定収益</span>
                            <span class="lang-en">Stable revenue from university hospital and educational
                                business</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">2023</span>
                            <span class="lang-en">2023</span>
                        </td>
                        <td>640</td>
                        <td>60</td>
                        <td>38</td>
                        <td>
                            <span class="lang-ja">医療ツーリズムが拡大基調</span>
                            <span class="lang-en">Medical tourism showing an expanding trend</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">2024</span>
                            <span class="lang-en">2024</span>
                        </td>
                        <td>680</td>
                        <td>65</td>
                        <td>42</td>
                        <td>
                            <span class="lang-ja">国際患者受入と教育強化で収益拡大</span>
                            <span class="lang-en">Increased revenue through international patients and enhanced
                                education</span>
                        </td>
                    </tr>
                </tbody>
            </table>
            <h3>
                <span class="lang-ja">部門別業績 (2024年度)</span>
                <span class="lang-en">Performance by Business Division (FY2024)</span>
            </h3>
            <table>
                <thead>
                    <tr>
                        <th>
                            <span class="lang-ja">部門</span>
                            <span class="lang-en">Division</span>
                        </th>
                        <th>
                            <span class="lang-ja">売上高(百万米ドル)</span>
                            <span class="lang-en">Sales (Million USD)</span>
                        </th>
                        <th>
                            <span class="lang-ja">特徴</span>
                            <span class="lang-en">Characteristics</span>
                        </th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <span class="lang-ja">大学病院(診療収益)</span>
                            <span class="lang-en">University Hospital (Clinical Revenue)</span>
                        </td>
                        <td>300</td>
                        <td>
                            <span class="lang-ja">地域医療の中核。AI導入は試験的。</span>
                            <span class="lang-en">Core of regional medical care. Introduction of Al is
                                experimental.</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">研究活動(助成金・共同研究収入)</span>
                            <span class="lang-en">Research Activities (Grants and Joint Research Income)</span>
                        </td>
                        <td>120</td>
                        <td>
                            <span class="lang-ja">公的資金や産学連携に基づく安定収入</span>
                            <span class="lang-en">Stable income based on public funding and industry- academia
                                collaboration.</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">医療ツーリズム</span>
                            <span class="lang-en">Medical Tourism</span>
                        </td>
                        <td>80</td>
                        <td>
                            <span class="lang-ja">高度医療と安心感を武器に国際患者を獲得。</span>
                            <span class="lang-en">Attracting international patients with advanced medical care and
                                reassurance.</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="lang-ja">教育活動(入学金・授業料)</span>
                            <span class="lang-en">Educational Activities (Enrollment Fees and Tuition)</span>
                        </td>
                        <td>180</td>
                        <td>
                            <span class="lang-ja">学部・大学院の授業料、留学生受入収入を含む。</span>
                            <span class="lang-en">Includes tuition for undergraduate and graduate programs, and income
                                from accepting international students.</span>
                        </td>
                    </tr>
                </tbody>
            </table>
        </section>

        <section id="exhibit5" class="content-section">
            <h2>
                <span class="lang-ja">別添5 RedAidの概要説明書</span>
                <span class="lang-en">Exhibit 5 Explanatory Document of the Outline of RedAid</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-7">
                    <span class="lang-ja">本文¶7</span>
                    <span class="lang-en">Facts ¶7</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit8</span>
                </a>
                <a href="#exhibit8">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit8</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
            </div>
            <p style="text-align: right;"><span class="lang-en">Red Corporation</span></p>
            <h3>
                <span class="lang-ja">1.基本的な機能</span>
                <span class="lang-en">1. Basic Functions</span>
            </h3>
            <ul>
                <li><strong>
                        <span class="lang-ja">診断支援:</span>
                        <span class="lang-en">Diagnostic Support:</span>
                    </strong>
                    <span class="lang-ja">患者の症状、バイタルサイン、検査結果(血液検査、画像データなど)を入力すると、可能性の高い疾患候補を提示する。</span>
                    <span class="lang-en">When the patient's symptoms, vital signs, and examination results (such as
                        blood tests, image data, etc.) are entered, it presents likely disease candidates.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">確率提示:</span>
                        <span class="lang-en">Probability Presentation:</span>
                    </strong>
                    <span class="lang-ja">各疾患の推定確率を数値で示し、医師がリスクを定量的に把握できる。</span>
                    <span class="lang-en">Indicates the estimated probability of each disease in numerical values so
                        that physicians can quantitatively grasp the risks.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">エビデンス表示:</span>
                        <span class="lang-en">Evidence Display:</span>
                    </strong>
                    <span class="lang-ja">医学文献やガイドラインに基づいた根拠を提示し、診断の裏付けを提供する。</span>
                    <span class="lang-en">Presents grounds based on medical literature and guidelines and provides
                        support for diagnosis.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">アラート機能:</span>
                        <span class="lang-en">Alert Function:</span>
                    </strong>
                    <span class="lang-ja">重篤疾患の見逃しリスクが高い場合に警告を表示し、即時対応を促す。</span>
                    <span class="lang-en">When there is a high risk of missing a serious disease, it displays a warning
                        and prompts immediate response.</span>
                </li>
            </ul>
            <h3>
                <span class="lang-ja">2.補助的な機能</span>
                <span class="lang-en">2. Supplementary Functions</span>
            </h3>
            <ul>
                <li><strong>
                        <span class="lang-ja">トリアージ支援:</span>
                        <span class="lang-en">Triage Support:</span>
                    </strong>
                    <span class="lang-ja">救急外来などで重症患者を優先的に振り分けるための補助。</span>
                    <span class="lang-en">Assists in prioritizing serious patients in emergency outpatient departments
                        and similar settings.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">再入院リスク予測:</span>
                        <span class="lang-en">Prediction of Risk of Readmission:</span>
                    </strong>
                    <span class="lang-ja">過去のデータをもとに、再入院の可能性を予測し、フォローアップを強化する。</span>
                    <span class="lang-en">Based on past data, predicts the possibility of readmission and strengthens
                        follow-up.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">多言語対応:</span>
                        <span class="lang-en">Multilingual Support:</span>
                    </strong>
                    <span class="lang-ja">外国人患者に対して問診を多言語で支援する。</span>
                    <span class="lang-en">Assists interviews with foreign patients in multiple languages.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">学習機能:</span>
                        <span class="lang-en">Learning Function:</span>
                    </strong>
                    <span class="lang-ja">匿名化されたデータを用いて継続的に性能を向上させる(フェデレーテッドラーニングや合成データ利用に対応)。</span>
                    <span class="lang-en">Continuously improves performance using anonymized data (supports federated
                        learning and use of synthetic data).</span>
                </li>
            </ul>
            <h3>
                <span class="lang-ja">3.想定される用途</span>
                <span class="lang-en">3. Intended Uses</span>
            </h3>
            <ul>
                <li>
                    <strong>
                        <span class="lang-ja">救急外来:</span>
                        <span class="lang-en">Emergency Outpatient:</span>
                    </strong>
                    <span class="lang-ja">多数の患者が来院する中で、重症患者を迅速に特定するために利用。</span>
                    <span class="lang-en">Used to promptly identify serious patients among many visiting
                        patients.</span>
                </li>
                <li>
                    <strong>
                        <span class="lang-ja">循環器領域:</span>
                        <span class="lang-en">Cardiovascular Field:</span>
                    </strong>
                    <span class="lang-ja">心筋梗塞や不整脈など、見逃すと致命的な疾患のリスクを低減。</span>
                    <span class="lang-en">Reduces the risk of missing diseases that would be fatal if overlooked, such
                        as myocardial infarction and arrhythmia.</span>
                </li>
                <li>
                    <strong>
                        <span class="lang-ja">呼吸器領域:</span>
                        <span class="lang-en">Respiratory Field:</span>
                    </strong>
                    <span class="lang-ja">肺炎や慢性閉塞性肺疾患(COPD)の重症度判定、再入院リスク管理。</span>
                    <span class="lang-en">Severity assessment of pneumonia and chronic obstructive pulmonary disease
                        (COPD), and management of risk of readmission.</span>
                </li>
                <li>
                    <strong>
                        <span class="lang-ja">セカンドオピニオン:</span>
                        <span class="lang-en">Second Opinion:</span>
                    </strong>
                    <span class="lang-ja">複雑な症例で、医師が判断を補強する際に参照可能。</span>
                    <span class="lang-en">Can be referred to by physicians when reinforcing judgment in complex
                        cases.</span>
                </li>
                <li>
                    <strong>
                        <span class="lang-ja">医療ツーリズム:</span>
                        <span class="lang-en">Medical Tourism:</span>
                    </strong>
                    <span class="lang-ja">海外患者の問診や診療支援を多言語で行い、国際的な医療提供をサポート(別途、医療ツーリズム向けの特約を締結する必要あり)</span>
                    <span class="lang-en">Conducts interviews and provides medical support for overseas patients in
                        multiple languages, supporting international provision of medical care (it is necessary to
                        conclude a special agreement for medical tourism separately).</span>
                </li>
            </ul>
            <p>
                <span class="lang-ja">救急領域、循環器領域、呼吸器領域、医療ツーリズム以外についても追加モジュールを⽤いることで利⽤可能。</span>
                <span class="lang-en">RedAid can also be used in fields beyond emergency outpatient, cardiovascular
                    field, respiratory field, and medical tourism by utilizing additional modules.</span>
            </p>
            <h3>
                <span class="lang-ja">4.特徴</span>
                <span class="lang-en">4. Characteristics</span>
            </h3>
            <ul>
                <li><strong>
                        <span class="lang-ja">Human-in-the-Loop (HITL)原則:</span>
                        <span class="lang-en">Human-in-the-Loop (HITL) Principle:</span>
                    </strong>
                    <span class="lang-ja">最終判断は必ず医師が行う。AIが自律的に診断や治療を決定することはない。</span>
                    <span class="lang-en">The final judgment must always be made by a physician. AI does not
                        autonomously determine diagnoses or treatments.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">安全性と透明性:</span>
                        <span class="lang-en">Safety and Transparency:</span>
                    </strong>
                    <span class="lang-ja">モデルカードやリスク管理計画を備え、性能や限界、セキュリティ上の注意点を明示。</span>
                    <span class="lang-en">Equipped with a model card and risk management plan, clarifying performance,
                        limitations, and security precautions.</span>
                </li>
                <li><strong>
                        <span class="lang-ja">柔軟な導入形態:</span>
                        <span class="lang-en">Flexible Introduction Forms:</span>
                    </strong>
                    <span class="lang-ja">院内サーバー運用やクラウド運用に対応し、各国の個人情報保護制度に合わせて設計可能。</span>
                    <span class="lang-en">Compatible with in-hospital server operation and cloud operation, and can be
                        designed in accordance with personal information protection systems of each country.</span>
                </li>
                <li>
                    <span class="lang-jp">患者データ（画像・カルテ情報・AI 解析結果など）は強⼒な暗号化⽅式で保存・通信され、暗号鍵がなければ復号化してデータを読むことはできない。</span>
                    <span class="lang-en">Patient data (including images, medical records, and AI analysis results) is
                        stored and transmitted using robust encryption methods; without the encryption key, it cannot be
                        decrypted and read.</span>
                </li>
            </ul>
            <h3>
                <span class="lang-ja">5.レッド社が保有する情報とその権利について</span>
                <span class="lang-en">5. Information Held by Red Corporation and Rights Thereof</span>
            </h3>
            <ul>
                <li>
                    <span
                        class="lang-ja">患者の診療に直接関連する個票データ(診療録、画像、検査値等)をレッド社は取得・保有しない(これらは利用機関が管理主体として保持し、レッド社はアクセスできない仕様)。</span>
                    <span class="lang-en">Red Corporation does not acquire or possess individual patient data directly
                        related to medical treatment (such as medical records, images, test values, etc.). These are
                        retained by the utilizing institution as the managing entity, and the system is designed so that
                        Red Corporation cannot access them.</span>
                </li>
                <li>
                    <span class="lang-ja">RedAidの運用・改善のために、以下の種類の情報はレッド社が生成・保有する。</span>
                    <span class="lang-en">For the operation and improvement of RedAid, Red Corporation generates and
                        retains the following types of information:</span>
                    <ul>
                        <li><strong>
                                <span class="lang-ja">システムログ情報:</span>
                                <span class="lang-en">System Log Information:</span>
                            </strong>
                            <span class="lang-ja">アクセス履歴、利用頻度、エラーログ、稼働率、応答時間等(個人を特定可能な情報は含まれないように処理)</span>
                            <span class="lang-en">Access history, frequency of use, error logs, operating rate, response
                                time, etc. (processed so as not to include information that can identify
                                individuals).</span>
                        </li>
                        <li><strong>
                                <span class="lang-ja">集計メタデータ:</span>
                                <span class="lang-en">Aggregated Metadata:</span>
                            </strong>
                            <span
                                class="lang-ja">診療科別の利用件数、利用時間帯、処理された画像枚数など、統計的に整理された情報(医療機関ごとの業務効率改善や、RedAidの機能強化に活用)</span>
                            <span class="lang-en">Statistically organized information such as the number of uses by
                                medical department, time zones of use, number of images processed, etc. (utilized for
                                improvement of work efficiency in each medical institution and for enhancement of the
                                functions of RedAid).</span>
                        </li>
                        <li><strong>
                                <span class="lang-ja">匿名化・合成データ(医療機関と合意した場合):</span>
                                <span class="lang-en">Anonymized / Synthetic Data (if agreed with the medical
                                    institution):</span>
                            </strong>
                            <span class="lang-ja">学習や性能検証の目的で、個人識別性を除去したデータを統計的に処理し生成したもの(個票データを復元することは不可)</span>
                            <span class="lang-en">Data statistically processed and generated by removing personal
                                identifiability, for the purpose of learning and performance verification (it is not
                                possible to restore individual data).</span>
                        </li>
                    </ul>
                </li>
                <li>
                    <span
                        class="lang-ja">これらの情報は、RedAidの継続的改善や新機能開発のために不可欠なリソースであり、レッド社が権利を有し、知的財産として管理。ただし、当該情報の利用に際しては、常に契約条項および適用法令に従い、利用機関の利益を害さない範囲に限られる。</span>
                    <span class="lang-en">This information is an indispensable resource for the continuous improvement
                        of RedAid and the development of new functions, and Red Corporation holds rights to them and
                        manages them as intellectual property. However, in the utilization of such information, it is
                        always limited to a scope that complies with contractual provisions and applicable laws and does
                        not harm the interests of the utilizing institution.</span>
                </li>
            </ul>
            <div class="callout note">
                <p><strong>
                        <span class="lang-ja">注：</span>
                        <span class="lang-en">Note:</span>
                    </strong>
                    <span class="lang-ja">RedAid はネゴランド国、アービトリア国における医療機器に関する法令上、臨床での利⽤に必要な承認を得ている。</span>
                    <span class="lang-en">RedAid has obtained the necessary approvals for clinical use of medical
                        devices under the relevant legislation in the countries of Negoland and Arbitria.</span>
                </p>
            </div>
            <hr>
        </section>

        <section id="exhibit6" class="content-section">
            <h2>
                <span class="lang-ja">別添６ ブルー大学の発表の要旨</span>
                <span class="lang-en">Exhibit 6 Summary of Presentation by Blue University</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-7">
                    <span class="lang-ja">本文¶7</span>
                    <span class="lang-en">Facts ¶7</span>
                </a>
                <a href="#exhibit8">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit8</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">題目</span>
                    <span class="lang-en">Title</span>
                </h3>
                <p>
                    <span class="lang-ja">臨床AI導入におけるデータガバナンスと医療統治の課題 - 救急・循環器・呼吸器領域での実践的検討</span>
                    <span class="lang-en">Challenges of Data Governance and Clinical Governance in the Introduction of
                        Clinical Al Practical Considerations in the Fields of Emergency, Cardiovascular, and Respiratory
                        Care</span>
                </p>
                <h3>
                    <span class="lang-ja">概要</span>
                    <span class="lang-en">Abstract</span>
                </h3>
                <p>
                    <span
                        class="lang-ja">近年、臨床現場では救急外来におけるトリアージの効率化、循環器領域における重症例の見逃し防止、呼吸器疾患における再入院率抑制といった具体的課題が顕在化している。本発表では、これらの課題に対してAI診断支援技術を導入する際の統治上・倫理上の要件を検討した。</span>
                    <span class="lang-en">In recent years, concrete issues have become evident in clinical settings,
                        such as improving the efficiency of triage in emergency outpatient care, preventing the
                        overlooking of severe cases in the cardiovascular field, and reducing the rate of readmission in
                        respiratory diseases. This presentation examines the governance and ethical requirements when
                        introducing Al diagnostic support technology to address these issues.</span>
                </p>
                <p>
                    <span class="lang-ja">ブルー大学は、AI活用にあたり「Human-in-the-Loop
                        (HITL)」を原則とし、最終的な診療判断は必ず医師が担うべきことを強調する。また、臨床利用に進む前に倫理審査委員会(IRB/IEC)の承認を得る必要があるとし、透明性確保の観点からモデルカードおよびリスク管理計画(RMP)の開示を不可欠と位置づける。さらに、患者データの管理については匿名化、国内保管、利用目的の限定を基本とし、外部機関による監査体制を整備することの重要性を指摘する。</span>
                    <span class="lang-en">Blue University emphasizes the principle of "Human-in-the-Loop (HITL)" in the
                        utilization of Al, stating that the final clinical judgment must always be made by a physician.
                        Furthermore, the use of Al requires the approval of the Institutional Review Board (IRB) or
                        Independent Ethics Committee (IEC) before proceeding to clinical use, and from the perspective
                        of ensuring transparency, it positions the disclosure of the model card and risk management plan
                        (RMP) as indispensable. In addition, with regard to the management of patient data, it
                        establishes as fundamentals the anonymization, domestic storage, and limitations of the purpose
                        of use, and points out the importance of developing an external third-party organization audit
                        system.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">本発表は、技術革新の恩恵を取り入れつつも、安全性・信頼性・説明責任を重視するブルー大学の基本姿勢を示すものであり、臨床AIの持続的活用に向けた制度設計とガバナンスの在り方について議論を深めるものである。</span>
                    <span class="lang-en">This presentation demonstrates the basic stance of Blue University, which
                        emphasizes safety, reliability, and accountability while incorporating the benefits of
                        technological innovation, and deepens the discussion on institutional design and governance for
                        the sustainable utilization of clinical AI.</span>
                </p>
            </article>
        </section>

        <section id="exhibit7" class="content-section">
            <h2>
                <span class="lang-ja">別添７ ブルー大学データガバナンス委員会会議記録</span>
                <span class="lang-en">Exhibit 7 Blue University Data Governance Committee Meeting Minutes</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-9">
                    <span class="lang-ja">本文¶9</span>
                    <span class="lang-en">Facts ¶9</span>
                </a>
            </div>
            <article>
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2023年12月15日</span>
                    <span class="lang-en">December 15, 2023</span>
                </p>
                <p><strong>
                        <span class="lang-ja">場所:</span>
                        <span class="lang-en">Place:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学データガバナンス委員会会議室</span>
                    <span class="lang-en">Blue University, Data Governance Committee Meeting Room</span>
                </p>
                <h3>
                    <span class="lang-ja">出席者</span>
                    <span class="lang-en">Participants:</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">ブルー大学:</span>
                            <span class="lang-en">Blue University:</span>
                        </strong>
                        <span class="lang-ja">データガバナンス委員会委員長、臨床統治部長、情報システム部長、委員会メンバー</span>
                        <span class="lang-en">Chairperson of the Data Governance Committee, Head of the Clinical
                            Governance Division, Head of the Information Systems Division, Committee Members</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">レッド社:</span>
                            <span class="lang-en">Red Corporation:</span>
                        </strong>
                        <span class="lang-ja">最高技術責任者(CTO)、医療AI部門責任者、法務担当</span>
                        <span class="lang-en">Chief Technology Officer (CTO), Head of Medical AI Division, Legal
                            Counsel</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">議題</span>
                    <span class="lang-en">Agenda</span>
                </h3>
                <ol>
                    <li>
                        <span class="lang-ja">1. RedAid導入によるブルー大学医療の高度化への貢献について</span>
                        <span class="lang-en">1. Contribution of the introduction of RedAid to the advancement of
                            medical care at Blue University</span>
                    </li>
                    <li>
                        <span class="lang-ja">2. データ取扱いおよび国外移転の制限について</span>
                        <span class="lang-en">2. Handling of data and restrictions on cross-border transfer</span>
                    </li>
                    <li>
                        <span class="lang-ja">3. フェデレーテッドラーニングおよび合成データの利用について</span>
                        <span class="lang-en">3. Utilization of federated learning and synthetic data</span>
                    </li>
                    <li>
                        <span class="lang-ja">4. 文書化要件(モデルカードおよびリスクマネジメント計画)について</span>
                        <span class="lang-en">4. Documentation requirements (model card and risk management plan)</span>
                    </li>
                    <li>
                        <span class="lang-ja">5. 報告体制と監督の仕組みについて</span>
                        <span class="lang-en">5. Reporting system and supervisory framework</span>
                    </li>
                </ol>
                <h3>
                    <span class="lang-ja">議論および合意事項</span>
                    <span class="lang-en">Discussion and Matters Agreed</span>
                </h3>
                <article>
                    <h4>
                        <span class="lang-ja">1. RedAid導入によるブルー大学医療の高度化</span>
                        <span class="lang-en">1. Advancement of medical care at Blue University through the introduction
                            of RedAid</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">委員会では、RedAidの導入がブルー大学の診療高度化に大きく寄与するとの共通認識が確認された。</span>
                            <span class="lang-en">The committee confirmed a shared recognition that the introduction of
                                RedAid would greatly contribute to the advancement of medical care at Blue
                                University.</span>
                        </li>
                        <li>
                            <span
                                class="lang-ja">特に、ブルー大学がシンポジウムで指摘した主要課題(①救急外来のトリアージ効率化、②循環器領域での重症例の見逃し防止、③呼吸器疾患患者の再入院率低減)に対して、RedAidの診断支援機能とアラート機能が有効であると評価された。</span>
                            <span class="lang-en">In particular, it was evaluated that RedAid's diagnostic support
                                function and alert function are effective for the major issues pointed out by Blue
                                University at the symposium (1 improvement of triage efficiency in emergency outpatient
                                care, 2 prevention of overlooking of severe cases in the cardiovascular field, 3
                                reduction of readmission rate for respiratory disease patients).</span>
                        </li>
                        <li>
                            <span
                                class="lang-ja">さらに、ブルー大学が推進する医療ツーリズムにおいても、RedAidの多言語問診や術後リモートフォロー機能が国際患者対応の質を高め、大学全体の競争力向上に資することが確認された。</span>
                            <span class="lang-en">Furthermore, in the medical tourism promoted by Blue University, it
                                was confirmed that RedAid's multilingual interview and post-operative remote follow-up
                                functions would enhance the quality of response to international patients and contribute
                                to improving the overall competitiveness of the university.</span>
                        </li>
                        <li>
                            <span
                                class="lang-ja">委員会は、RedAidの技術が単なる診断補助にとどまらず、臨床ガバナンス・教育体制・国際展開の各面において大学の高度化戦略を支える基盤となり得るとの点で合意に至った。</span>
                            <span class="lang-en">The committee reached agreement that RedAid's technology is not
                                limited to mere diagnostic assistance, but could become a foundation supporting the
                                university's advancement strategy in the aspects of clinical governance, educational
                                system, and international development.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">2. データ取扱い</span>
                        <span class="lang-en">2. Data Handling</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">個人情報を含むデータは一切国外に持ち出さないことを原則とする。</span>
                            <span class="lang-en">It is a principle that data including personal information shall not
                                ever be taken outside the country.</span>
                        </li>
                        <li>
                            <span class="lang-ja">学習はすべてフェデレーテッドラーニング方式で実施することを確認。</span>
                            <span class="lang-en">It was confirmed that all learning shall be carried out by the
                                federated learning method.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">3. フェデレーテッドラーニングと合成データ</span>
                        <span class="lang-en">3. Federated Learning and Synthetic Data</span>
                    </h4>
                    <ul>
                        <li>
                            <span
                                class="lang-ja">フェデレーテッドラーニングを導入することで、データを外部に持ち出すことなくAIを改善できることを両者で確認。これにより、患者情報の安全を守りながらも高精度の診断支援を実現できる。</span>
                            <span class="lang-en">Both parties confirmed that by introducing federated learning, Al can
                                be improved without taking data outside, thereby achieving highly accurate diagnostic
                                support while protecting patient information.</span>
                        </li>
                        <li>
                            <span class="lang-ja">症例数が不足する領域については、合成データを補完的に利用することを条件付きで承認。</span>
                            <span class="lang-en">It was conditionally approved to use synthetic data supplementarily in
                                fields where the number of cases is insufficient.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">4. 文書化(モデルカード・RMP)</span>
                        <span class="lang-en">4. Documentation (Model Card and RMP)</span>
                    </h4>
                    <p>
                        <span class="lang-ja">レッド社は以下を記載したモデルカードを整備し、ブルー大学に提供すること:</span>
                        <span class="lang-en">Red Corporation shall prepare and provide to Blue University a model card
                            that describes the following:</span>
                    </p>
                    <ul>
                        <li>
                            <span class="lang-ja">想定目的・利用範囲</span>
                            <span class="lang-en">Intended purpose and scope of use</span>
                        </li>
                        <li>
                            <span class="lang-ja">性能指標(感度、特異度、限界など)</span>
                            <span class="lang-en">Performance indicators (sensitivity, specificity, limitations,
                                etc.)</span>
                        </li>
                        <li>
                            <span class="lang-ja">既知のバイアスや失敗モード</span>
                            <span class="lang-en">Known biases and failure modes</span>
                        </li>
                        <li>
                            <span class="lang-ja">セキュリティ上の脆弱性と対策</span>
                            <span class="lang-en">Security vulnerabilities and countermeasures</span>
                        </li>
                    </ul>
                    <p>
                        <span class="lang-ja">併せて、レッド社はリスクマネジメント計画(RMP)を作成し、RMPを更新した場合にはブルー大学に提供すること。</span>
                        <span class="lang-en">In addition, Red Corporation shall prepare a Risk Management Plan (RMP)
                            and provide it to Blue University whenever it is updated.</span>
                    </p>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">5. 監督と透明性</span>
                        <span class="lang-en">5. Supervision and Transparency</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">ブルー大学は、モデルカードおよびRMPの定期的な開示を求める。</span>
                            <span class="lang-en">Blue University shall request the regular disclosure of the model card
                                and RMP.</span>
                        </li>
                        <li>
                            <span class="lang-ja">両者は四半期ごとに合同レビュー会議を実施し、進捗と遵守状況を確認する。</span>
                            <span class="lang-en">Both parties shall hold joint review meetings every quarter to confirm
                                progress and compliance status.</span>
                        </li>
                    </ul>
                </article>
                <h3>
                    <span class="lang-ja">結論</span>
                    <span class="lang-en">Conclusion</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">RedAidは、ブルー大学が掲げる診療上の課題解決と医療ツーリズム戦略を含めた医療高度化に大いに寄与するとの合意が得られた。</span>
                        <span class="lang-en">Agreement was reached that RedAid would greatly contribute to solving the
                            clinical issues raised by Blue University and to the advancement of medical care including
                            the medical tourism strategy.</span>
                    </li>
                    <li>
                        <span class="lang-ja">フェデレーテッドラーニングを基本方式として採用し、必要に応じて合成データを補完的に利用する。</span>
                        <span class="lang-en">Federated learning shall be adopted as the basic method, and synthetic
                            data shall be supplementarily used when necessary.</span>
                    </li>
                    <li>
                        <span class="lang-ja">モデルカードとRMPの作成・開示を必須要件とする。</span>
                        <span class="lang-en">Preparation and disclosure of the model card and RMP shall be mandatory
                            requirements.</span>
                    </li>
                    <li>
                        <span class="lang-ja">定期的な合同レビューを実施し、安全性と透明性を担保する。</span>
                        <span class="lang-en">Regular joint reviews shall be conducted to ensure safety and
                            transparency.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit8" class="content-section">
            <h2>
                <span class="lang-ja">別添８ RedAid概念実証試験(PoC)結果報告書</span>
                <span class="lang-en">Exhibit 8 RedAid Proof of Concept (PoC) Result Report</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-10">
                    <span class="lang-ja">本文¶10</span>
                    <span class="lang-en">Facts ¶10</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit5">
                    <span class="lang-ja">別添5</span>
                    <span class="lang-en">Exhibit5</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit10">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit10</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">作成日:</span>
                    <span class="lang-en">Date of Preparation:</span>
                </strong>
                <span class="lang-ja">2024年3月31日</span>
                <span class="lang-en">March 31, 2024</span>
            </p>
            <p><strong>
                    <span class="lang-ja">作成者:</span>
                    <span class="lang-en">Prepared by:</span>
                </strong>
                <span class="lang-ja">ブルー大学データガバナンス委員会・レッド社技術部</span>
                <span class="lang-en">Blue University Data Governance Committee, Red Corporation Technical
                    Division</span>
            </p>
            <article>
                <h3>
                    <span class="lang-ja">1. 背景</span>
                    <span class="lang-en">1. Background</span>
                </h3>
                <p>
                    <span
                        class="lang-ja">ブルー大学とレッド社は、2023年秋の臨床AIシンポジウムにおける議論を踏まえ、AI診断支援ツール「RedAid」の有効性と安全性を検証するため、2024年1月〜3月の3か月間にわたりPoCを実施した。本試験は、救急外来・循環器科・呼吸器科を対象に行われた。</span>
                    <span class="lang-en">Based on the discussions at the Clinical Al Symposium in the autumn of 2023,
                        Blue University and Red Corporation conducted a PoC over three months from January to March 2024
                        in order to verify the effectiveness and safety of the Al diagnostic support tool "RedAid." This
                        trial targeted the emergency outpatient department, the Department of Cardiology, and the
                        Department of Respiratory Medicine.</span>
                </p>
                <h3>
                    <span class="lang-ja">2. 試験体制</span>
                    <span class="lang-en">2. Trial System</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">主導機関:</span>
                            <span class="lang-en">Lead Institution:</span>
                        </strong>
                        <span class="lang-ja">ブルー大学(臨床現場)</span>
                        <span class="lang-en">Blue University (clinical setting)</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">協力機関:</span>
                            <span class="lang-en">Cooperating Institution:</span>
                        </strong>
                        <span class="lang-ja">レッド社(技術支援・教育・運用モニタリング)</span>
                        <span class="lang-en">Red Corporation (technical support, training, operational
                            monitoring)</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">対象診療科:</span>
                            <span class="lang-en">Target Departments:</span>
                        </strong>
                        <span class="lang-ja">救急外来、循環器科、呼吸器科</span>
                        <span class="lang-en">Emergency Outpatient, Cardiology, Respiratory Medicine</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">対象患者数:</span>
                            <span class="lang-en">Number of Target Patients:</span>
                        </strong>
                        <span class="lang-ja">計1,200例</span>
                        <span class="lang-en">1,200 cases total</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">3. 検証項目と方法</span>
                    <span class="lang-en">3. Verification Items and Methods</span>
                </h3>
                <article>
                    <h4>
                        <span class="lang-ja">(1) 性能面</span>
                        <span class="lang-en">(1) Performance Aspects</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">アラート応答時間の測定(秒単位)</span>
                            <span class="lang-en">Measurement of alert response time (in seconds)</span>
                        </li>
                        <li>
                            <span class="lang-ja">感度・特異度の統計評価</span>
                            <span class="lang-en">Statistical evaluation of sensitivity and specificity</span>
                        </li>
                        <li>
                            <span class="lang-ja">偽陰性・偽陽性率の分析</span>
                            <span class="lang-en">Analysis of rates of false negatives and false positives</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">(2) 運用面</span>
                        <span class="lang-en">(2) Operational Aspects</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">Human-in-the-Loop (HITL)原則の遵守状況</span>
                            <span class="lang-en">Status of compliance with the Human-in-the-Loop (HITL)
                                principle</span>
                        </li>
                        <li>
                            <span class="lang-ja">医師・看護師に対する教育と定着度合い</span>
                            <span class="lang-en">Training for physicians and nurses and degree of establishment</span>
                        </li>
                        <li>
                            <span class="lang-ja">操作ログ・AI出力の保存・監査可能性</span>
                            <span class="lang-en">Preservation of operation logs and AI outputs and auditability</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">(3) 安全・ガバナンス面</span>
                        <span class="lang-en">(3) Safety and Governance Aspects</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">個人情報の匿名化・国内保管の確認</span>
                            <span class="lang-en">Confirmation of anonymization and domestic storage of personal
                                information</span>
                        </li>
                        <li>
                            <span class="lang-ja">フェデレーテッドラーニングの実装試験</span>
                            <span class="lang-en">Implementation test of federated learning</span>
                        </li>
                        <li>
                            <span class="lang-ja">モデルカードおよびリスクマネジメント計画(RMP)の活用度</span>
                            <span class="lang-en">Degree of utilization of the model card and risk management plan
                                (RMP)</span>
                        </li>
                    </ul>
                </article>
                <h3>
                    <span class="lang-ja">4. 結果</span>
                    <span class="lang-en">4. Results</span>
                </h3>
                <article>
                    <h4>
                        <span class="lang-ja">救急外来</span>
                        <span class="lang-en">Emergency Outpatient</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">平均アラート応答時間: 2.3秒 → 1.4秒に短縮</span>
                            <span class="lang-en">Average alert response time: shortened from 2.3 seconds to 1.4
                                seconds</span>
                        </li>
                        <li>
                            <span class="lang-ja">重症例の見逃し率が統計的に有意に低下</span>
                            <span class="lang-en">The rate of overlooking severe cases statistically significantly
                                decreased</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">循環器領域</span>
                        <span class="lang-en">Cardiovascular Field</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">感度: 85% → 91%</span>
                            <span class="lang-en">Sensitivity: improved from 85% to 91%</span>
                        </li>
                        <li>
                            <span class="lang-ja">上級医へのエスカレーション率が改善</span>
                            <span class="lang-en">The rate of escalation to senior physicians improved</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">呼吸器領域</span>
                        <span class="lang-en">Respiratory Field</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">再入院率が3か月で12%から9%に改善傾向</span>
                            <span class="lang-en">The readmission rate showed an improving trend, from 12% to 9% over
                                three months</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">運用面</span>
                        <span class="lang-en">Operational Aspects</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">HITL原則が遵守され、AI単独で判断が行われたケースは確認されず</span>
                            <span class="lang-en">The HITL principle was observed, and no cases were confirmed in which
                                Al alone made judgments</span>
                        </li>
                        <li>
                            <span class="lang-ja">医師・看護師の教育受講率は95%以上</span>
                            <span class="lang-en">The training participation rate of physicians and nurses was over
                                95%</span>
                        </li>
                        <li>
                            <span class="lang-ja">ログは全件保存され、監査可能な状態が維持された</span>
                            <span class="lang-en">All logs were preserved, and an auditable state was maintained</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">安全・ガバナンス</span>
                        <span class="lang-en">Safety and Governance</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">個票データの国外移転は発生せず、匿名化処理が確認された</span>
                            <span class="lang-en">No cross-border transfer of individual data occurred, and
                                anonymization processing was confirmed</span>
                        </li>
                        <li>
                            <span class="lang-ja">フェデレーテッドラーニングによる学習更新が成功</span>
                            <span class="lang-en">Learning updates through federated learning succeeded</span>
                        </li>
                        <li>
                            <span class="lang-ja">モデルカードとRMPが臨床現場で参照され、説明責任の基盤として機能</span>
                            <span class="lang-en">The model card and RMP were referenced in the clinical setting and
                                functioned as a foundation for accountability</span>
                        </li>
                    </ul>
                </article>
                <h3>
                    <span class="lang-ja">5. 結論</span>
                    <span class="lang-en">5. Conclusion</span>
                </h3>
                <p>
                    <span
                        class="lang-ja">RedAidは、救急外来のトリアージ効率化、循環器領域での見逃し防止、呼吸器疾患における再入院率低減に有効であることが確認された。さらに、Human-in-the-Loop原則やデータガバナンス上の要件を満たし、ブルー大学の臨床現場における安全性・透明性を損なうことなく運用できることが実証された。</span>
                    <span class="lang-en">It was confirmed that RedAid is effective in improving the efficiency of
                        triage in emergency outpatient care, preventing the overlooking of severe cases in the
                        cardiovascular field, and reducing the readmission rate for respiratory diseases. Furthermore,
                        it was demonstrated that RedAid satisfies the HITL principle and requirements of data
                        governance, and can be operated without impairing safety and transparency in the clinical
                        setting of Blue University.</span>
                </p>
                <p>
                    <span class="lang-ja">本PoCの成果を踏まえ、両者は2024年4月1日付でライセンス契約の締結に進むことを推奨する。</span>
                    <span class="lang-en">Based on the results of this PoC, both parties recommend proceeding to the
                        conclusion of a license agreement as of April 1, 2024.</span>
                </p>
            </article>
        </section>

        <section id="exhibit9" class="content-section">
            <h2>
                <span class="lang-ja">別添９ License Agreement</span>
                <span class="lang-en">Exhibit 9 License Agreement</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-10">
                    <span class="lang-ja">本文¶10</span>
                    <span class="lang-en">Facts ¶10</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit6">
                    <span class="lang-ja">別添6</span>
                    <span class="lang-en">Exhibit6</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a>
                <a href="#exhibit8">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit8</span>
                </a>
                <a href="#exhibit10">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit10</span>
                </a>
                <a href="#exhibit11">
                    <span class="lang-ja">別添11</span>
                    <span class="lang-en">Exhibit11</span>
                </a>
                <a href="#exhibit15">
                    <span class="lang-ja">別添15</span>
                    <span class="lang-en">Exhibit15</span>
                </a>
                <a href="#exhibit16">
                    <span class="lang-ja">別添17</span>
                    <span class="lang-en">Exhibit17</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
            </div>
            <article class="document">
                <p>Red Corporation (hereinafter referred to as "Licensor") and Blue University (hereinafter referred to
                    as "Licensee") hereby agree as follows with respect to the use of the Al diagnostic support tool
                    "RedAid."</p>
                <h4>Article 1 (Purpose)</h4>
                <p>The purpose of this Agreement is to set forth the terms and conditions for the use of RedAid, in
                    order to ensure patient safety and improve clinical efficiency.</p>
                <h4>Article 2 (Grant of License)</h4>
                <p>The Licensor grants to the Licensee a non-exclusive, non-transferable license to use RedAid within
                    the Licensee's hospital facilities.</p>
                <h4>Article 3 (Consideration)</h4>
                <p>The Licensee shall pay the Licensor an annual license fee of USD 600,000.</p>
                <h4>Article 4 (Training)</h4>
                <p>The Licensee shall conduct sufficient training for its personnel prior to the commencement of use.
                </p>
                <h4>Article 5 (Updates and Notifications)</h4>
                <ol>
                    <li>(1) The Licensor shall provide software updates on a regular basis.</li>
                    <li>(2) The Licensee shall promptly apply such updates to all terminals and notify and train its
                        personnel accordingly.</li>
                    <li>(3) The Licensee shall submit written confirmation of the completion of such updates and
                        training.</li>
                </ol>
                <h4>Article 6 (Safe Operation Obligation)</h4>
                <p>The Licensee shall operate RedAid in a safe manner at all times and shall immediately apply any
                    emergency patches provided by the Licensor.</p>
                <h4>Article 7 (Allocation of Responsibility)</h4>
                <p>RedAid is a diagnostic support tool and does not replace the physician's final judgment. The Licensor
                    shall endeavor to improve the performance of the tool, while the Licensee shall remain responsible
                    for clinical decision-making.</p>
                <h4>Article 8 (Term and Termination)</h4>
                <p>This Agreement shall be valid for three (3) years and shall automatically renew unless either Party
                    notifies the other Party of its intention to terminate at least twelve (12) months in advance.</p>
                <h4>Article 9 (Confidentiality of Technical Information)</h4>
                <ol>
                    <li>(1) The Licensee shall treat as strictly confidential all technical information disclosed by the
                        Licensor in connection with RedAid, including but not limited to its performance,
                        specifications, architecture, and algorithms.</li>
                    <li>(2) The Licensee shall not disclose, publish, or provide such information, whether directly or
                        indirectly, to any third party without the prior written consent of the Licensor, except where
                        disclosure is strictly required by law or a competent regulatory authority.</li>
                </ol>
                <h4>Article 10 (Restriction on Anonymized and Synthetic Data)</h4>
                <ol>
                    <li>(1) Unless and until the Licensee gives its prior written consent, the Licensor shall not
                        generate,
                        retain, or utilize anonymized data or synthetic data derived from the Licensee's patient
                        information or related medical records.</li>
                    <li>(2) The Licensor's rights to retain information shall be limited to:
                        <ul>
                            <li>(i) system log data (e.g., access history, error logs, system availability); and</li>
                            <li>(ii) aggregated metadata (e.g., usage volume, response times, performance statistics),
                                provided that such data does not identify or enable the re-identification of any
                                individual patient.</li>
                        </ul>
                    </li>
                    <li>(3) For the avoidance of doubt, any general rights of the Licensor to anonymized or synthetic
                        data
                        described in RedAid's product documentation shall not apply under this Agreement unless
                        explicitly approved in writing by the Licensee.</li>
                </ol>
                <h4>Article 11 (Governing Law and Arbitration)</h4>
                <p>This Agreement shall be governed by UNIDROIT Principles for International Commercial Contracts 2016.
                    Any disputes arising out of or in connection with this Agreement shall be finally settled by
                    arbitration under the UNCITRAL Arbitration Rules. The seat of arbitration shall be Japan. The
                    arbitral tribunal may seek expert opinions on purely technical matters.</p>
                <p><strong>Date:</strong> April 1, 2024</p>
                <p><strong>Red Corporation:</strong><br>By: <em>(Signature)</em><br>Name: Hiromi Red<br>Title: President
                </p>
                <p><strong>Blue University:</strong><br>By: <em>(Signature)</em><br>Name: Lin Blue<br>Title: Chancelor
                </p>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span class="lang-ja">10 条(3)に関し、RedAid のproduct documentation には「RedAid
                            はシステム運⽤中に⽣成される診断履歴・利⽤ログ・統計情報などを⾃動的に集計する。これらのデータは匿名化または合成データ（synthetic data）として扱われ、AI
                            モデルの精度改善やアルゴリズム再学習のために利⽤されることがある。」旨の記述があるが、Licensee は10 条(3)におけるapproval を与えていない。</span>
                        <span class="lang-en">Regarding Clause 10(3), RedAid's product documentation states: `RedAid
                            automatically aggregates diagnostic histories, usage logs, statistical information, and
                            similar data generated during system operation. This data is treated as anonymized or
                            synthetic data and may be used to improve the accuracy of AI models or for algorithm
                            retraining.’ However, the Licensee has not granted approval under Clause 10(3).</span>
                    </p>
                </div>
                <hr>
            </article>
        </section>

        <section id="exhibit10" class="content-section">
            <h2>
                <span class="lang-ja">別添10</span>
                <span class="lang-en">Exhibit 10</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-10">
                    <span class="lang-ja">本文¶10</span>
                    <span class="lang-en">Facts ¶10</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit6">
                    <span class="lang-ja">別添6</span>
                    <span class="lang-en">Exhibit6</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a>
                <a href="#exhibit8">
                    <span class="lang-ja">別添8</span>
                    <span class="lang-en">Exhibit8</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a>
                <a href="#exhibit16">
                    <span class="lang-ja">別添16</span>
                    <span class="lang-en">Exhibit16</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">モデルカード抜粋 (RedAid v3.2.1)</span>
                    <span class="lang-en">Excerpt of Model Card (RedAid v3.2.1)</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">製品名:</span>
                        <span class="lang-en">Product Name:</span>
                    </strong>
                    <span class="lang-ja">RedAid-臨床支援版 (ツーリズム非対応)</span>
                    <span class="lang-en">RedAid - Clinical Support Version (Not compatible with Tourism)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">バージョン:</span>
                        <span class="lang-en">Version:</span>
                    </strong>
                    <span class="lang-ja">v3.2.1 (2024年4月提供)</span>
                    <span class="lang-en">v3.2.1 (Provided April 2024)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">開発者:</span>
                        <span class="lang-en">Developer:</span>
                    </strong> Red Inc.</p>
                <h4>
                    <span class="lang-ja">目的</span>
                    <span class="lang-en">Purpose</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">救急外来におけるトリアージ効率化</span>
                        <span class="lang-en">Improvement of triage efficiency in emergency outpatient care</span>
                    </li>
                    <li>
                        <span class="lang-ja">循環器領域における重大疾患の見逃し防止</span>
                        <span class="lang-en">Prevention of overlooking serious diseases in the cardiovascular
                            field</span>
                    </li>
                    <li>
                        <span class="lang-ja">呼吸器疾患患者の再入院リスク予測</span>
                        <span class="lang-en">Prediction of risk of readmission of patients with respiratory
                            diseases</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">想定利用者・利用環境</span>
                    <span class="lang-en">Intended Users and Use Environment</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">救急医、循環器・呼吸器内科医</span>
                        <span class="lang-en">Emergency physicians, cardiologists, pulmonologists</span>
                    </li>
                    <li>
                        <span class="lang-ja">病院勤務の臨床看護師(トリアージ補助)</span>
                        <span class="lang-en">Clinical nurses working in hospitals (for triage assistance)</span>
                    </li>
                    <li>
                        <span class="lang-ja">環境: 病院内オンプレミスサーバー/アービトリア国内クラウド、電子カルテ連携端末</span>
                        <span class="lang-en">Environment: On-premise servers within hospitals / domestic (Arbitria)
                            cloud servers, electronic medical record-linked terminals</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">学習データの概要</span>
                    <span class="lang-en">Overview of Training Data</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">アービトリア国内で収集された臨床画像(CT・X線)および電子カルテ由来の構造化データ</span>
                        <span class="lang-en">Clinical images (CT, X-ray) collected within Arbitria and structured data
                            derived from electronic medical records</span>
                    </li>
                    <li>
                        <span class="lang-ja">ネゴランド国内パートナー病院との共同研究による匿名化症例データ(契約上国内に保管、国外移転なし)</span>
                        <span class="lang-en">Anonymized case data from joint research with partner hospitals in
                            Negoland (stored domestically under contract, no cross-border transfer)</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">性能</span>
                    <span class="lang-en">Performance</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">救急トリアージ感度: 90%(従来平均82%)</span>
                        <span class="lang-en">Sensitivity of emergency triage: 90% (conventional average 82%)</span>
                    </li>
                    <li>
                        <span class="lang-ja">循環器領域鑑別診断精度: AUC 0.87</span>
                        <span class="lang-en">Diagnostic accuracy for differential diagnosis in the cardiovascular
                            field: AUC 0.87</span>
                    </li>
                    <li>
                        <span class="lang-ja">呼吸器領域再入院予測精度: 70%(従来65%)</span>
                        <span class="lang-en">Prediction accuracy of readmission in the respiratory field: 70%
                            (conventional 65%)</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">標準推奨閾値</span>
                    <span class="lang-en">Standard Recommended Thresholds</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">循環器疾患（NSTEMI含む）の「要注意」判定は 0.55（55%）以上に設定。「要注意」は再検査、⼊院観察を推奨。</span>
                        <span class="lang-en">A "Caution" classification for cardiovascular disease (including NSTEMI)
                            is set at 0.55 (55%) or above, recommending re-examination or hospitalized
                            observation.</span>
                    </li>

                    <li>
                        <span class="lang-ja">0.80以上は「⾼リスク」とし、即時⼊院・精査を推奨。</span>
                        <span class="lang-en">Values of 0.80 or above are classified as "High Risk", recommending
                            immediate hospitalization and detailed examination.</span>
                    </li>
                    <li>
                        <span class="lang-ja">「要注意」「⾼リスク」以外は「低リスク」と判定される。</span>
                        <span class="lang-ja">Cases other than “Caution” and “High Risk” are classified as “Low
                            Risk.”</span>
                    </li>
                    <li>
                        <span class="lang-ja">出荷時の初期設定はすべてこの標準推奨閾値に準拠。</span>
                        <span class="lang-en">The factory default settings comply with these standard recommended
                            thresholds.</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">限界・失敗モード</span>
                    <span class="lang-en">Limitations / Failure Modes</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">画像データの欠損や低解像度の場合、誤検知率上昇</span>
                        <span class="lang-en">Increased false detection rate when image data are missing or of low
                            resolution</span>
                    </li>
                    <li>
                        <span class="lang-ja">高齢患者・多疾患併存症例で予測性能が低下する傾向</span>
                        <span class="lang-en">Tendency for predictive performance to decline in elderly patients and
                            cases with multiple complications</span>
                    </li>
                    <li>
                        <span class="lang-ja">性能に記載のとおり、感度・制度は100％ではなく誤検知リスクや偽陰性の可能性あり</span>
                        <span class="lang-en">As stated in the performance specifications, sensitivity and accuracy are
                            not 100%, and there is a possibility of false detections or false negatives.</span>
                    </li>
                    <li>
                        <span class="lang-ja">AI出力を最終診断に用いることは禁止、必ず医師が確認する必要あり</span>
                        <span class="lang-en">Use of Al output for final diagnosis is prohibited; physicians must always
                            confirm</span>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">リスクマネジメント計画(RMP)抜粋 (2024年4月版)</span>
                    <span class="lang-en">Excerpt of Risk Management Plan (RMP) (April 2024 Version)</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">対象製品:</span>
                        <span class="lang-en">Target Product:</span>
                    </strong> RedAid v3.2.1</p>
                <p><strong>
                        <span class="lang-ja">適用法令:</span>
                        <span class="lang-en">Applicable Laws:</span>
                    </strong>
                    <span class="lang-ja">アービトリア国医療機器法、個人情報保護法、保健当局ガイダンス</span>
                    <span class="lang-en">Arbitria Medical Device Act, Personal Information Protection Act, Guidance of
                        the Health Authority</span>
                </p>
                <h4>
                    <span class="lang-ja">リスク特定</span>
                    <span class="lang-en">Risk Identification</span>
                </h4>
                <ol>
                    <li><strong>
                            <span class="lang-ja">1. アップデート未適用リスク</span>
                            <span class="lang-en">1. Risk of non-application of updates</span>
                        </strong>
                        <p>
                            <span class="lang-ja">臨床現場で旧版が残置された場合、誤診のリスク増大。</span>
                            <span class="lang-en">If old versions remain in clinical practice, risk of misdiagnosis
                                increases.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">2. 過度依存リスク</span>
                            <span class="lang-en">2. Risk of excessive reliance</span>
                        </strong>
                        <p>
                            <span class="lang-ja">医師がAI出力を最終判断と誤解する可能性。</span>
                            <span class="lang-en">Physicians may misunderstand Al output as the final judgment.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">3. データ保護リスク</span>
                            <span class="lang-en">3. Risk concerning data protection</span>
                        </strong>
                        <p>
                            <span class="lang-ja">個票データは国外移転禁止。国外クラウド利用なし。</span>
                            <span class="lang-en">Individual data must not be transferred abroad. No use of overseas
                                cloud servers.</span>
                        </p>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">リスク低減策</span>
                    <span class="lang-en">Risk Mitigation Measures</span>
                </h4>
                <ul>
                    <li><strong>
                            <span class="lang-ja">アップデート管理:</span>
                            <span class="lang-en">Update management:</span>
                        </strong>
                        <span class="lang-ja">定期配信+切替完了報告を必須化。</span>
                        <span class="lang-en">Regular distribution + obligation to report completion of
                            switchover.</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">教育:</span>
                            <span class="lang-en">Education:</span>
                        </strong>
                        <span class="lang-ja">Human-in-the-Loop原則を医師・看護師教育で徹底。</span>
                        <span class="lang-en">Thorough enforcement of the Human-in-the-Loop principle in training for
                            physicians and nurses.</span>
                    </li>
                    <li><strong>
                            <span classs="lang-ja">データ保護:</span>
                            <span class="lang-en">Data protection:</span>
                        </strong>
                        <span class="lang-ja">全ての個票データをアービトリア国内サーバーで保存・処理。国外移転は契約上禁止。</span>
                        <span class="lang-en">All individual data are to be stored and processed on servers within
                            Arbitria. Cross- border transfer is contractually prohibited.</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">モニタリング・レビュー</span>
                    <span class="lang-en">Monitoring and Review</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">年1回の外部専門家レビュー。</span>
                        <span class="lang-en">Annual review by external experts.</span>
                    </li>
                    <li>
                        <span class="lang-ja">臨床事故報告が発生した場合は直ちにリスク評価を再実施。</span>
                        <span class="lang-en">In the event of occurrence of clinical incident reports, risk assessment
                            must be immediately re- implemented.</span>
                    </li>
                </ul>
            </article>
        </section>
        <section id="exhibit11" class="content-section">
            <h2>
                <span class="lang-ja">別添11</span>
                <span class="lang-en">Exhibit 11</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-11">
                    <span class="lang-ja">本文¶11</span>
                    <span class="lang-en">Facts ¶11</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
                <a href="#exhibit14">
                    <span class="lang-ja">別添14</span>
                    <span class="lang-en">Exhibit14</span>
                </a>
                <a href="#exhibit16">
                    <span class="lang-ja">別添16</span>
                    <span class="lang-en">Exhibit16</span>
                </a>

            </div>
            <article class="document">
                <h3>
                    <span class="lang-ja">件名: RedAid v3.3.0 重大アップデートの適用について (至急対応要請)</span>
                    <span class="lang-en">Subject: Application of RedAid v3.3.0 Critical Update (Urgent Request for
                        Action)</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">Red Inc. (レッド社)</span>
                    <span class="lang-en">Red Inc. (Red Corporation)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学 医療情報システム部門/臨床統治部門</span>
                    <span class="lang-en">Blue University, Medical Information Systems Division / Clinical Governance
                        Division</span>
                </p>
                <p><strong>
                        <span class="lang-ja">⽇時：</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2024年4⽉15⽇15時</span>
                    <span class="lang-en">April 15, 2024, 15:00</span>
                </p>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span class="lang-ja">ネゴランド国とアービトリア国の間には時差はない</span>
                        <span class="lang-en">There is no time difference between Negoland and Arbitria</span>
                    </p>
                </div>
                <hr>
                <p>
                    <span class="lang-ja">平素より RedAidのご利用に際し、格別のご協力を賜り厚く御礼申し上げます。</span>
                    <span class="lang-en">We would like to extend our sincere gratitude for your continued cooperation
                        in the use of RedAid.</span>
                </p>
                <p>
                    <span class="lang-ja">このたび、当社は RedAid v3.3.0
                        を正式リリースいたしました。本アップデートは、循環器・呼吸器領域における重大疾患の検知性能向上を目的としており、旧版 (v3.2.1) には残存していた誤検知リスク
                        (特に偽陰性率の高さ)を是正する重要な改修を含んでおります。</span>
                    <span class="lang-en">We hereby officially release RedAid v3.3.0. This update is intended to improve
                        the detection performance of serious diseases in the cardiovascular and respiratory fields, and
                        includes important modifications to correct residual risks of false detection (in particular,
                        the high false negative rate) present in the previous version (v3.2.1).</span>
                </p>
                <h4>
                    <span class="lang-ja">【主な改修内容】</span>
                    <span class="lang-en">【Main Modifications】</span>
                </h4>
                <ol>
                    <li><strong>
                            <span class="lang-ja">1. 循環器モジュールの識別閾値調整</span>
                            <span class="lang-en">1. Adjustment of identification thresholds in the cardiovascular
                                module</span>
                        </strong>
                        <p>
                            <span class="lang-ja">○心筋梗塞・不整脈の検知における偽陰性率を約20%低減。</span>
                            <span class="lang-en">Approximately 20% reduction of false negative rate in the detection of
                                myocardial infarction and arrhythmia.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">2. 呼吸器モジュールのアルゴリズム最適化</span>
                            <span class="lang-en">2. Optimization of algorithm in the respiratory module</span>
                        </strong>
                        <p>
                            <span class="lang-ja">○肺炎・肺塞栓症に関する早期警告の精度を強化。</span>
                            <span class="lang-en">Strengthening of accuracy of early warnings concerning pneumonia and
                                pulmonary embolism.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">3. システム安定性の改善</span>
                            <span class="lang-en">3. Improvement of system stability</span>
                        </strong>
                        <p>
                            <span class="lang-ja">○大規模アクセス時のセッション管理強化。</span>
                            <span class="lang-en">Strengthening of session management at the time of large-scale
                                access.</span>
                        </p>
                        <p>
                            <span class="lang-ja">○ログ保存と監査機能を拡張。</span>
                            <span class="lang-en">Expansion of log storage and audit functions.</span>
                        </p>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">【適用義務】</span>
                    <span class="lang-en">【Obligation of Application】</span>
                </h4>
                <ul>
                    <li>
                        <span class="lang-ja">ライセンス契約第5条に基づき、本アップデートは全端末に速やかに適用いただく必要があります。</span>
                        <span class="lang-en">In accordance with Article 5 of the License Agreement between us, this
                            update must be promptly applied to all terminals.</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">適用期限:</span>
                            <span class="lang-en">Deadline for application:</span>
                        </strong>
                        <span class="lang-ja">2024年4月25日まで</span>
                        <span class="lang-en">April 25, 2024</span>
                    </li>
                    <li>
                        <span class="lang-ja">切替完了後10日以内に、切替完了報告書を当社にご提出ください。</span>
                        <span class="lang-en">Within 10 days after completion of the switchover, please submit to us a
                            report of completion of the switchover.</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">【未適用の場合のリスク】</span>
                    <span class="lang-en">【Risks in Case of Non-application】</span>
                </h4>
                <p>
                    <span class="lang-ja">旧版 (v3.2.1)
                        を継続利用した場合、臨床現場における診断支援の信頼性が低下し、患者安全に影響を与える恐れがあります。これにより、契約上の安全運用義務違反に問われる可能性もありますので、必ず期限内にアップデートを完了させてください。</span>
                    <span class="lang-en">In the event the old version (v3.2.1) continues to be used, the reliability of
                        diagnostic support in clinical settings will decline, and there is a risk of affecting patient
                        safety. This may also lead to liability for violation of the contractual obligation of safe
                        operation; therefore, please be sure to complete the update by the deadline.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">本アップデートに関する詳細な技術文書および教育用資料は、専用ポータルにてダウンロード可能です。必要に応じ、当社技術スタッフによる遠隔サポートも承ります。</span>
                    <span class="lang-en">Detailed technical documents and educational materials concerning this update
                        can be downloaded from the dedicated portal. Remote support by our technical staff is also
                        available if necessary.</span>
                </p>
                <p>
                    <span class="lang-ja">何卒、期限内の確実な適用をお願い申し上げます。</span>
                    <span class="lang-en">We kindly request your reliable application within the deadline.</span>
                </p>
            </article>
        </section>

        <section id="exhibit12" class="content-section">
            <h2>
                <span class="lang-ja">別添12 症例記録(救急症例X、2024年4月18日)</span>
                <span class="lang-en">Exhibit 12 Case Record (Emergency Case X, April 18, 2024)</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-12">
                    <span class="lang-ja">本文¶12</span>
                    <span class="lang-en">Facts ¶12</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">患者情報</span>
                    <span class="lang-en">Patient Information</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">年齢:</span>
                            <span class="lang-en">Age:</span>
                        </strong>
                        <span class="lang-ja">62歳</span>
                        <span class="lang-en">62 years</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">性別:</span>
                            <span class="lang-en">Sex:</span>
                        </strong>
                        <span class="lang-ja">男性</span>
                        <span class="lang-en">Male</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">来院：</span>
                            <span class="lang-en">Visit Date:</span>
                        </strong>
                        <span class="lang-ja">2024年4⽉16⽇</span>
                        <span class="lang-en">April 16, 2024</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">主訴:</span>
                            <span class="lang-en">Chief Complaint:</span>
                        </strong>
                        <span class="lang-ja">胸痛、呼吸困難</span>
                        <span class="lang-en">Chest pain, dyspnea</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">来院時バイタル:</span>
                            <span class="lang-en">Vital Signs at Time of Visit:</span>
                        </strong> BP 138/82, HR 104, SpO2 93%,
                        <span class="lang-ja">体温 37.2℃</span>
                        <span class="lang-en">Body Temperature 37.2°C</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">利用システム</span>
                    <span class="lang-en">System Used</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">使用AIツール:</span>
                            <span class="lang-en">Al Tool Used:</span>
                        </strong> RedAid</li>
                    <li><strong>
                            <span class="lang-ja">バージョン:</span>
                            <span class="lang-en">Version:</span>
                        </strong> v3.2.1 (
                        <span class="lang-ja">旧版、未更新端末</span>
                        <span class="lang-en">old version, terminal not updated</span>
                        )
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">AI出力</span>
                    <span class="lang-en">Al Output</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">判定結果:</span>
                            <span class="lang-en">Determination Result:</span>
                        </strong>
                        <span class="lang-ja">「低リスク (入院不要)」</span>
                        <span class="lang-en">"Low risk (hospitalization not necessary)"</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">提示鑑別疾患:</span>
                            <span class="lang-en">Differential Diagnoses Presented:</span>
                        </strong>
                        <span class="lang-ja">軽度心不全、非特異的胸痛</span>
                        <span class="lang-en">Mild heart failure, nonspecific chest pain</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">推奨行動:</span>
                            <span class="lang-en">Recommended Action:</span>
                        </strong>
                        <span class="lang-ja">外来フォロー可</span>
                        <span class="lang-en">Outpatient follow-up possible</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">診療経過</span>
                    <span class="lang-en">Clinical Course</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">担当医メモ:</span>
                            <span class="lang-en">Attending Physician's Note:</span>
                        </strong>
                        <span class="lang-ja">「AIの出力を参考に外来対応とした。症状は軽快傾向」</span>
                        <span class="lang-en">"Outpatient management based on Al output. Symptoms showed a tendency to
                            improve."</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">追加検査:</span>
                            <span class="lang-en">Additional Examination:</span>
                        </strong>
                        <span class="lang-ja">心電図 (異常所見なし)、血液検査(トロポニンとBNPの軽度上昇のみ)</span>
                        <span class="lang-en">Electrocardiogram (no abnormal findings), blood test (only mild elevation
                            of troponin and BNP)</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">上級医エスカレーション:</span>
                            <span class="lang-en">Escalation to Senior Physician:</span>
                        </strong>
                        <span class="lang-ja">未実施</span>
                        <span class="lang-en">Not performed</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">CT検査:</span>
                            <span class="lang-en">CT Examination:</span>
                        </strong>
                        <span class="lang-ja">依頼せず</span>
                        <span class="lang-en">Not requested</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">⼼エコー：</span>
                            <span class="lang-en">Echocardiography:</span>
                        </strong>
                        <span class="lang-ja">依頼せず</span>
                        <span class="lang-en">Not requested</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">転帰</span>
                    <span class="lang-en">Outcome</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">4⽉17⽇午前、患者が自宅で急変。救急搬送され再来院。</span>
                        <span class="lang-en">On the morning of April 17, the patient suddenly deteriorated at home.
                            Emergency transport and return to hospital.</span>
                    </li>
                    <li>
                        <span class="lang-ja">集中治療室に収容されるも心停止に至り、4⽉18⽇早朝死亡。</span>
                        <span class="lang-en">Admitted to the intensive care unit but went into cardiac arrest and died
                            early morning of April 18.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit13" class="content-section">
            <h2>
                <span class="lang-ja">別添13 ブルー大学内部調査報告書(案) - 患者X死亡事案</span>
                <span class="lang-en">Exhibit 13 Blue University Internal Investigation Report (Draft) - Case of Death
                    of Patient X</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-12">
                    <span class="lang-ja">本文¶12</span>
                    <span class="lang-en">Facts ¶12</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit5">
                    <span class="lang-ja">別添5</span>
                    <span class="lang-en">Exhibit5</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a>
                <a href="#exhibit10">
                    <span class="lang-ja">別添10</span>
                    <span class="lang-en">Exhibit10</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a>
                <a href="#exhibit14">
                    <span class="lang-ja">別添14</span>
                    <span class="lang-en">Exhibit14</span>
                </a>
                <a href="#exhibit16">
                    <span class="lang-ja">別添16</span>
                    <span class="lang-en">Exhibit16</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">作成日:</span>
                    <span class="lang-en">Date of Preparation:</span>
                </strong>
                <span class="lang-ja">2024年7月2日</span>
                <span class="lang-en">July 2, 2024</span>
            </p>
            <p><strong>
                    <span class="lang-ja">作成者:</span>
                    <span class="lang-en">Prepared by:</span>
                </strong>
                <span class="lang-ja">ブルー大学 院内事故調査委員会</span>
                <span class="lang-en">Blue University In-Hospital Accident Investigation Committee</span>
            </p>
            <article>
                <h3>
                    <span class="lang-ja">事案の概要</span>
                    <span class="lang-en">Overview of the Case</span>
                </h3>
                <p>
                    <span class="lang-ja">患者X(62歳男性)は2024年4月16日、胸痛と呼吸困難を訴えて救急外来を受診した。救急外来端末に旧版 RedAid (v3.2.1)
                        が残置されていたため、担当医はその出力を参照し「低リスク」と判断した。入院観察は実施されず、患者は翌日に自宅で急変し、再来院後に死亡した。死因は⾮ST上昇型⼼筋梗塞。</span>
                    <span class="lang-en">Patient X (62-year-old male) visited the emergency outpatient department on
                        April 16, 2024, complaining of chest pain and dyspnea. Because an old version of RedAid (v3.2.1)
                        remained on the emergency outpatient terminal, the attending physician referred to its output
                        and judged the case as "low risk." Hospitalized observation was not implemented, and the patient
                        suddenly deteriorated at home the following day and, after returning to the hospital, died. The
                        cause of death was Non-ST-segment elevation myocardial infarction (NSTEMI).</span>
                </p>
                <h3>
                    <span class="lang-ja">調査経過</span>
                    <span class="lang-en">Course of the Investigation</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">端末状況:</span>
                            <span class="lang-en">Terminal Status:</span>
                        </strong>
                        <span class="lang-ja">救急外来の端末 ID3421
                            はアップデート未適用で（他部⾨の端末も同様）、v3.2.1が稼働していた。自動更新はオフであり（初期設定のまま）、更新状況を一元管理する仕組みも不十分だった（当⼤学が⾃動更新をオンにすることも可能であったが、理由は不明ながら⾏っていない）。</span>
                        <span class="lang-en">The emergency outpatient terminal ID3421, as well as terminals at other
                            departments, was not updated and was running v3.2.1. Automatic updating was off (with the
                            initial setting unchanged)(although the university could have enabled automatic updating, it
                            did not do sofor reasons unknown), and there was no sufficient system to centrally manage
                            update status.</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">AI出力の影響:</span>
                            <span class="lang-en">Influence of Al Output:</span>
                        </strong>
                        <span class="lang-ja">旧版 RedAid の出力は「低リスク」との評価を示し、追加検査(CTや⼼エコーなど)を回避する判断に直結した。</span>
                        <span class="lang-en">The output of the old version RedAid indicated "low risk" and directly led
                            to the decision to avoid additional examinations (such as CT and echocardiography).</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">通知の問題:</span>
                            <span class="lang-en">Problem of Notification:</span>
                        </strong>
                        <span class="lang-ja">レッド社からアップデート通知はあったものの、切替手順や確認方法が十分に具体化されていなかった。</span>
                        <span class="lang-en">Although an update notice had been issued by Red Corporation, the
                            switchover procedures and confirmation methods were not sufficiently specified.</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">委員会の所見</span>
                    <span class="lang-en">Findings of the Committee</span>
                </h3>
                <p>
                    <span
                        class="lang-ja">追加の精密検査（例：連続的な⼼筋トロポニン測定や⼼エコー等）を実施していた場合、本症例における⾮ST上昇型⼼筋梗塞（NSTEMI）を診断し得た可能性が⾼く、適切な治療介⼊が⾏われ、死亡を回避し得た可能性が⾼いと考えられる。</span>
                    <span class="lang-en">Had additional diagnostic tests (e.g., serial troponin measurements or
                        echocardiography) been performed, it is highly probable that non-ST-segment elevation myocardial
                        infarction (NSTEMI) could have been diagnosed in this case, and it is highly likely that
                        appropriate therapeutic intervention could have been administered to avert death.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">本件の直接的な要因は、旧版利用による誤判定である。しかしながら、旧版を使用したからといって死亡事故に至るような不備が生じること自体、AI診断支援システムとして許容できない。</span>
                    <span class="lang-en">The direct cause of this case was misjudgment due to the use of the old
                        version. However, the very fact that such a defect resulting in a fatal accident occurred simply
                        because the old version was used is unacceptable for an Al diagnostic support system.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">すなわち、RedAidには何らかの構造的欠陥が存在する可能性を否定できない。システムが更新状態に依存して安全性を著しく損なう設計は、根本的に問題があると考えられる。</span>
                    <span class="lang-en">That is, it cannot be denied that RedAid may have some kind of structural
                        defect. A design in which safety is significantly impaired depending on the update status is
                        fundamentally problematic.</span>
                </p>
                <p>
                    <span class="lang-ja">さらに、アルゴリズム自体に根本的な欠陥があったか否かについては、本委員会の調査だけでは判断できない。</span>
                    <span class="lang-en">Furthermore, as to whether there was a fundamental defect in the algorithm
                        itself, it cannot be determined by this committee's investigation alone.</span>
                </p>
                <h3>
                    <span class="lang-ja">暫定結論</span>
                    <span class="lang-en">Provisional Conclusion</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">本事案は、運用不備と教育不足に加え、RedAid の設計そのものに潜在的な構造的欠陥があった可能性が高い。</span>
                        <span class="lang-en">This case is highly likely to have involved not only operational
                            deficiencies and lack of education but also potential structural defects in the very design
                            of RedAid.</span>
                    </li>
                    <li>
                        <span class="lang-ja">今後の結論確定には、外部専門家による独立した再調査を行い、アルゴリズムの根幹に欠陥が存在するか否かを検証する必要がある。</span>
                        <span class="lang-en">To reach a final conclusion, it is necessary to conduct an independent
                            re-investigation by external experts and verify whether there are defects in the core of the
                            algorithm.</span>
                    </li>
                    <li>
                        <span class="lang-ja">本件に関する最終的な責任の所在は、当該外部調査の結果を踏まえて再度検討すべきである。</span>
                        <span class="lang-en">The final attribution of responsibility concerning this case should be
                            reconsidered based on the results of such external investigation.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit14" class="content-section">
            <h2>
                <span class="lang-ja">別添14 協議記録</span>
                <span class="lang-en">Exhibit 14 Record of Consultations</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-12">
                    <span class="lang-ja">本文¶12</span>
                    <span class="lang-en">Facts ¶12</span>
                </a>
                <a href="#exhibit7">
                    <span class="lang-ja">別添7</span>
                    <span class="lang-en">Exhibit7</span>
                </a>
                <a href="#exhibit12">
                    <span class="lang-ja">別添12</span>
                    <span class="lang-en">Exhibit12</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
                <a href="#exhibit17">
                    <span class="lang-ja">別添17</span>
                    <span class="lang-en">Exhibit17</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">日付:</span>
                    <span class="lang-en">Date:</span>
                </strong>
                <span class="lang-ja">2024年7月5日</span>
                <span class="lang-en">July 5, 2024</span>
            </p>
            <p><strong>
                    <span class="lang-ja">場所:</span>
                    <span class="lang-en">Place:</span>
                </strong>
                <span class="lang-ja">ブルー大学 本部会議室</span>
                <span class="lang-en">Blue University, Main Conference Room</span>
            </p>
            <article>
                <h3>
                    <span class="lang-ja">出席者</span>
                    <span class="lang-en">Participants:</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">レッド社:</span>
                            <span class="lang-en">Red Corporation:</span>
                        </strong>
                        <span class="lang-ja">最高技術責任者(CTO)、法務部長、医療AI部門責任者</span>
                        <span class="lang-en">Chief Technology Officer (CTO), Head of Legal Department, Head of Medical
                            AI Division</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">ブルー大学:</span>
                            <span class="lang-en">Blue University:</span>
                        </strong>
                        <span class="lang-ja">病院長、臨床統治部長、法務部次長、事故調査委員会委員長</span>
                        <span class="lang-en">Hospital Director, Head of Clinical Governance Division, Deputy Head of
                            Legal Department, Chairperson of Accident Investigation Committee</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">協議冒頭</span>
                    <span class="lang-en">Opening of the Consultation</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">ブルー大学 病院長:</span>
                        <span class="lang-en">Blue University, Hospital Director:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「本日は、症例Xに関する内部調査委員会の報告書案を踏まえ、御社と意見交換を行いたいと思います。本報告書案は暫定的なものであり、御社の意見を伺った上で修正を加え、最終版を策定する予定です。」</span>
                    <span class="lang-en">"Today, based on the draft report of the Internal Investigation Committee
                        concerning Case X, we would like to exchange opinions with your company. This draft report is
                        provisional, and we intend to make revisions after hearing your company's opinion and then
                        formulate the final version."</span>
                </blockquote>
                <h3>
                    <span class="lang-ja">議事概要</span>
                    <span class="lang-en">Summary of the Meeting</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">ブルー大学 臨床統治部長:</span>
                        <span class="lang-en">Blue University, Head of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「今回の問題は、契約締結直後に重大なアップデートが発表されたことに端を発しています。4月1日に契約締結し、わずか2週間後の4月15日にリリースされたv3.3.0は、偽陰性率の大幅低減を目的としていました。これは、旧版v3.2.1
                        が契約締結時に提供されたモデルカードに記載された水準すら満たしていなかった、すなわちモデルカードに反する欠陥があったことを意味するのではないでしょうか。」</span>
                    <span class="lang-en">"This problem originated from the fact that a major update was announced
                        immediately after the conclusion of the contract. The contract was concluded on April 1, and
                        only two weeks later, on April 15, v3.3.0 was released, which aimed to significantly reduce the
                        false negative rate. Does this not mean that the old version v3.2.1 failed even to meet the
                        level stated in the model card provided at the time of contract conclusion, that is, that it had
                        defects contrary to the model card?"</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 法務部次長:</span>
                        <span class="lang-en">Blue University, Deputy Head of Legal Department:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「しかも、これは初めてのアップデートであり、院内の職員は更新手順に不慣れでした。当⼤学では4月16日に御社に遠隔サポートを要請しており、4月17日に対応が予定されていました。しかし、問題の症例は4月16日の夜間に発生しました。つまり、アップデート適用前の状態で誤診が生じたのは、大学側の過失ではなく、旧版がモデルカードの説明に反して欠陥を有していたためです。」</span>
                    <span class="lang-en">"Moreover, this was the first update, and hospital staff were unfamiliar with
                        the update procedures. Our university requested remote support from your company on April 16,
                        and response was scheduled for April 17. However, the problem case occurred at night on April
                        16. In other words, the fact that misdiagnosis occurred in the state before application of the
                        update was not negligence of the university but was because the old version had defects contrary
                        to the explanation in the model card."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 事故調査委員会委員長:</span>
                        <span class="lang-en">Blue University, Chairperson of Accident Investigation Committee:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「さらに、当該症例を担当した救急医師は、アップデートの存在を知らされていませんでした。アップデート義務を大学に課す以上、御社には周知と教育の責任があります。この点も欠けていたのではないでしょうか。」</span>
                    <span class="lang-en">"Furthermore, the emergency physician in charge of this case was not informed
                        of the existence of the update. If the obligation of update is imposed on the university, your
                        company has responsibility for dissemination and education. Was this not also lacking?"</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 CTO:</span>
                        <span class="lang-en">Red Corporation, CTO:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「旧版に一定の限界があったこと、そしてv3.3.0で改善を行ったことは認めます。しかし、モデルカードにも“誤検知リスクや偽陰性の可能性がある”と明記しており、欠陥を隠していたわけではありません。ライセンス契約第5条では、アップデートを速やかに全端末に適用するのは大学側の義務とされています。旧版が残置され、症例Xで利用されたのは御校の責任です。」</span>
                    <span class="lang-en">"It is admitted that the old version had certain limitations and that
                        improvements were made in v3.3.0. However, it was also clearly stated in the model card that
                        there was a 'risk of false detection and possibility of false negatives, and it was not that
                        defects were concealed. Article 5 of the License Agreement stipulates that application of
                        updates to all terminals promptly is the obligation of the university. The fact that the old
                        version remained and was used in Case X is the responsibility of your institution."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 医療AI部門責任者:</span>
                        <span class="lang-en">Red Corporation, Head of Medical Al Division:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「さらに強調したいのは、RedAid
                        は診断を代替する機器ではなく補助機器であるという点です。PoCから契約締結に至るまで、Human-in-the-Loop
                        原則を徹底的に説明してきました。AI出力を鵜呑みにして退院判断を行ったのは医師の誤判断です。」</span>
                    <span class="lang-en">"What I wish to emphasize further is that RedAid is not a device to replace
                        diagnosis but an auxiliary device. From the PoC up to the conclusion of the contract, we
                        thoroughly explained the Human-in-the-Loop principle. It was a misjudgment of the physician to
                        take the AI output at face value and decide discharge."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 臨床統治部長:</span>
                        <span class="lang-en">Blue University, Head of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「我々の医師は当初予定された範囲内でAIを利用したに過ぎません。もし過度に依存したと見えるなら、それは御社が“どの程度信頼できるのか”を十分に説明しなかったためです。とりわけ、旧版がモデルカードに沿わない性能を示していたことが事故の根本原因であり、御社の責任は免れません。」</span>
                    <span class="lang-en">"Our physician used Al only within the originally intended scope. If it
                        appears that there was excessive reliance, that was because your company did not sufficiently
                        explain 'to what extent it can be trusted. Above all, the fundamental cause of the accident was
                        that the old version demonstrated performance not in line with the model card, and your company
                        cannot escape responsibility."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 医療AI部⾨責任者：</span>
                        <span class="lang-en">Red Corporation Head of Medical Al Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「いずれにせよ、内部調査報告書の内容については詳細な検討が必要です。当社としての⾒解は別途伝えるので、それまでは公表したり外部に流出したりすることのないようにしてください。このような⽂書が流出すると現在交渉中の新規契約に影響を与える可能性があります。勝⼿に公表したら損害賠償を請求します。」</span>
                    <span class="lang-en">"In any case, the contents of the internal investigation report require
                        detailed consideration. Our company's position will be communicated separately; until then,
                        please ensure it is not disclosed or leaked externally. The leakage of such documents could
                        impact the new contract currently under negotiation. Unauthorized disclosure will result in
                        claims for damages."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー⼤学 臨床統治部⻑：</span>
                        <span class="lang-en">Blue University Head of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「わかりました。」</span>
                    <span class="lang-en">"Understood."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 医療AI部⾨責任者：</span>
                        <span class="lang-en">Red Corporation Medical AI Division Head:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「なお、以前、RedAid の利⽤を停⽌するとのご連絡を頂いていましたが、既にアップデートでv.3.2.1
                        にあった⽋陥は解消したので、利⽤を再開して頂けると思います。なお、念のため、他に閾値の初期設定ミスがないかも全体について確認しましたが、ミスはありませんでした。」</span>
                    <span class="lang-en">"Additionally, we previously received notification that you would discontinue
                        using RedAid. However, the defect present in v.3.2.1 has already been resolved via an update, so
                        we believe you can resume usage. Furthermore, as a precaution, we conducted a comprehensive
                        check for any other initial threshold setting errors, but none were found."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー⼤学 臨床統治部⻑：</span>
                        <span class="lang-en">Blue University Clinical Governance Director:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「閾値の設定については他にミスがなかったという点は私も昨⽇報告を受けていますが、当⼤学としては医療に関することであり、利⽤再開については慎重に対応したいと思います。」</span>
                    <span class="lang-en">“I have also been informed yesterday that there were no other errors in the
                        threshold settings. However, as this concerns medical matters, our university wishes to proceed
                        cautiously regarding the resumption of use.”</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 医療AI部⾨責任者：</span>
                        <span class="lang-en">Red Corporation Medical AI Division Manager:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「私たちとしては、利⽤再開に問題はないと考えています。」</span>
                    <span class="lang-en">“From our perspective, we see no issue with resuming use.”</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー⼤学 臨床統治部⻑：</span>
                        <span class="lang-en">Blue University: Clinical Governance Director:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「御社のお考えは分かりました。」</span>
                    <span class="lang-en">“I understand your position.”</span>
                </blockquote>
                <h3>
                    <span class="lang-ja">結論</span>
                    <span class="lang-en">Conclusion</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">ブルー大学は、旧版v3.2.1
                            がモデルカードで説明された性能水準を満たさず、事実上欠陥を有していたこと、また周知・教育が不十分だったことを強調。</span>
                        <span class="lang-en">Blue University emphasized that the old version v3.2.1 did not meet the
                            performance level described in the model card in effect had defects and that both
                            dissemination and education were insufficient.</span>
                    </li>
                    <li>
                        <span class="lang-ja">レッド社は、旧版RedAid
                            の閾値設定に技術的課題があったことは認めつつも、当該不備は既にアップデートで是正済みであり、アップデート適用を怠った大学の運用責任と医師の判断ミスが事故の直接的原因であると主張。</span>
                        <span class="lang-en">Red Corporation, while acknowledging that the threshold settings in the
                            previous version of RedAid presented technical challenges, took the position that this
                            deficiency has already been rectified through an update, and argued that the
                            university's operational responsibility for failing to apply the update and the physician's
                            misjudgment were the direct causes of the accident.</span>
                    </li>
                    <li>
                        <span class="lang-ja">双方の見解は平行線をたどった。</span>
                        <span class="lang-en">The views of both parties remained at an impasse.</span>
                    </li>
                    <li>
                        <span class="lang-ja">内部報告書案については、引き続き協議を行い、最終版を策定することとされた。</span>
                        <span class="lang-en">It was decided that consultations would continue concerning the draft
                            internal report and that the final version would be formulated.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit15" class="content-section">
            <h2>
                <span class="lang-ja">別添15 SNS投稿および業界誌記事</span>
                <span class="lang-en">Exhibit 15 SNS Post and Industry Journal Article</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-13">
                    <span class="lang-ja">本文¶13</span>
                    <span class="lang-en">Facts ¶13</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">SNS投稿</span>
                    <span class="lang-en">SNS Post</span>
                </h3>
                <blockquote>
                    <p>
                        <span class="lang-ja">「ブルー大学の内部報告書が流出! RedAid
                            は旧版利用で死亡事故を引き起こす“構造的欠陥”があるとの記載。アルゴリズムに根本的な問題がある可能性が否定できないと大学委員会が指摘。こんなツールをまだ使い続けていいのか?」</span>
                        <span class="lang-en">"Internal report of Blue University leaked! It states that RedAid has a
                            'structural defect' that causes fatal accidents when the old version is used. The university
                            committee points out that it cannot be denied that there may be fundamental problems in the
                            algorithm. Is it really acceptable to continue using such a tool?"</span>
                    </p>
                    <cite>
                        <span class="lang-ja">– アービトリア国の医学ジャーナリストによる投稿。様々な国の医学ジャーナリストによって引用された。</span>
                        <span class="lang-en">– This was posted by a medical journalist in Arbitria, and it was quoted
                            by medical journalists in various countries.</span>
                    </cite>
                </blockquote>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">業界誌記事 (2024年7月号)</span>
                    <span class="lang-en">Industry Journal Article (July 2024 Issue)</span>
                </h3>
                <div class="document">
                    <h4>
                        <span class="lang-ja">見出し:「RedAid に構造的欠陥の可能性 ブルー大学事故調査案が指摘」</span>
                        <span class="lang-en">Headline: "Possibility of Structural Defect in RedAid - Blue University
                            Accident Investigation Draft Points Out"</span>
                    </h4>
                    <p>
                        <span class="lang-ja">ブルー大学病院で発生した患者死亡事故に関する院内事故調査委員会の草稿が流出した。草稿には、旧版 RedAid (v3.2.1)
                            の利用が誤判定を招いたことが死亡事故の一因であるとしつつ、「旧版利用によって死亡事故が起きるような不備は許容されず、RedAidには構造的欠陥があると見るべき」
                            との厳しい表現が含まれていた。さらに、アルゴリズムに根本的な欠陥が存在するかどうかについては、外部専門家による独立した再調査が必要と記載されている。</span>
                        <span class="lang-en">A draft by the in-hospital accident investigation committee concerning a
                            patient death accident that occurred at Blue University Hospital was leaked. The draft
                            included strong wording stating that, while the use of the old version RedAid (v3.2.1) led
                            to misjudgment and was one of the causes of the death, "defects that cause fatal accidents
                            due to the use of the old version are not acceptable, and RedAid should be regarded as
                            having a structural defect." Furthermore, it was stated that, as to whether fundamental
                            defects exist in the algorithm, an independent re-investigation by external experts is
                            necessary.</span>
                    </p>
                    <p>
                        <span class="lang-ja">この記述はSNS上で瞬く間に拡散し、「AIに命を預けるのは危険だ」との批判が広がった。複数の医療機関は
                            RedAidの導入契約を延期・中止する判断を下しており、レッド社の信用に深刻な影響を及ぼしている。業界関係者の間では、AI医療機器の安全性確保とアップデート管理の在り方について、改めて議論が高まっている。</span>
                        <span class="lang-en">This description spread rapidly on social media, and criticism spread that
                            "entrusting life to Al is dangerous." Multiple medical institutions decided to postpone or
                            cancel contracts for the introduction of RedAid, and the credibility of Red Corporation has
                            been seriously affected. Among industry stakeholders, discussions have been intensifying
                            once again regarding how to secure the safety of Al medical devices and the way update
                            management should be conducted.</span>
                    </p>
                </div>
            </article>
        </section>
        <section id="exhibit16" class="content-section">
            <h2>
                <span class="lang-ja">別添16 外部専門家レポート</span>
                <span class="lang-en">Exhibit 16 External Expert Report</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-14">
                    <span class="lang-ja">本文¶14</span>
                    <span class="lang-en">Facts ¶14</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">日付:</span>
                    <span class="lang-en">Date:</span>
                </strong>
                <span class="lang-ja">2024年8月31日</span>
                <span class="lang-en">August 31, 2024</span>
            </p>
            <p><strong>
                    <span class="lang-ja">作成者:</span>
                    <span class="lang-en">Prepared by:</span>
                </strong>
                <span class="lang-ja">医療AI評価センター (独立第三者機関)</span>
                <span class="lang-en">Medical AI Evaluation Center (Independent Third-Party Organization)</span>
            </p>
            <article>
                <p><strong>
                        <span class="lang-ja">対象:</span>
                        <span class="lang-en">Subject:</span>
                    </strong>
                    <span class="lang-ja">RedAid 診断支援ツール (旧版v3.2.1 および最新版v3.3.0)</span>
                    <span class="lang-en">RedAid Diagnostic Support Tool (Old Version v3.2.1 and Latest Version
                        v3.3.0)</span>
                </p>
                <h3>
                    <span class="lang-ja">1. 検証目的</span>
                    <span class="lang-en">1. Purpose of Verification</span>
                </h3>
                <p>
                    <span class="lang-ja">本検証は、救急症例Xに関連して旧版 RedAid (v3.2.1) に重大な欠陥が存在したか否かを明らかにし、最新版 (v3.3.0)
                        における改善状況を評価することを目的とした。</span>
                    <span class="lang-en">This verification aimed to clarify whether there existed serious defects in
                        the old version of RedAid (v3.2.1) in connection with Emergency Case X, and to evaluate the
                        status of improvements in the latest version (v3.3.0).</span>
                </p>
                <h3>
                    <span class="lang-ja">2. 検証方法</span>
                    <span class="lang-en">2. Methods of Verification</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">過去症例データ (ブルー大学提供)を用いた再現実験</span>
                        <span class="lang-en">Reproduction experiments using past case data (provided by Blue
                            University)</span>
                    </li>
                    <li>
                        <span class="lang-ja">アルゴリズムの識別閾値設定と誤判定率の比較</span>
                        <span class="lang-en">Comparison of algorithm identification threshold settings and misjudgment
                            rates</span>
                    </li>
                    <li>
                        <span class="lang-ja">バージョン間 (v3.2.1 と v3.3.0) の性能評価試験</span>
                        <span class="lang-en">Performance evaluation tests between versions (v3.2.1 and v3.3.0)</span>
                    </li>
                    <li>
                        <span class="lang-ja">外部臨床専門家(循環器・救急医学)のレビュー</span>
                        <span class="lang-en">Review by external clinical experts (cardiology and emergency
                            medicine)</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">3. 検証結果</span>
                    <span class="lang-en">3. Results of Verification</span>
                </h3>
                <article>
                    <h4>
                        <span class="lang-ja">(1) 旧版v3.2.1 について</span>
                        <span class="lang-en">(1) Regarding the Old Version v3.2.1</span>
                    </h4>
                    <ul>
                        <li>
                            <span
                                class="lang-ja">循環器疾患におけるリスク評価の閾値が不十分に設定されており、一部の症例で「低リスク」と誤判定する傾向が確認された。⾮ST上昇型⼼筋梗塞については、モデルカードに記載のとおり、本来であれば55％以上を要注意判定と設定されているべきところ、レッド社の初期設定のミスにより70％と設定されていた。このエラーの結果、正常な設定（55％）なら「要注意」と判定される患者群が、誤設定（70％）では「低リスク」扱いになり、追加検査や⼊院観察の推奨がなされなくなってしまった。</span>
                            <span class="lang-en">It was confirmed that the thresholds for risk assessment in
                                cardiovascular diseases were set insufficiently, and there was a tendency to misjudge
                                some cases as "low risk." For non-ST-segment elevation myocardial infarction, the
                                threshold for cautionary assessment should have been set at 55% or above as mentioned in
                                the Model Card. However, in reality, due to an initial configuration error by Red
                                Corporation, it was set at 70%. As a result of this error, patients who would have been
                                classified as "Caution" under normal settings (55%) were instead treated as "Low Risk"
                                under the erroneous settings (70%), leading to a failure to recommend additional tests
                                or hospital observation.</span>
                        </li>
                        <li>
                            <span class="lang-ja">本件事故(救急症例X)
                                と同様のケースでは、入院観察を推奨しない誤出力が再現され、死亡事故に直結し得る欠陥が存在したと判断される。</span>
                            <span class="lang-en">In cases similar to the present accident (Emergency Case X), erroneous
                                output recommending against hospitalized observation was reproduced, and it is judged
                                that defects existed which could directly lead to fatal accidents.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">(2) 最新版v3.3.0 について</span>
                        <span class="lang-en">(2) Regarding the Latest Version v3.3.0</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">閾値設定が見直され、誤判定率が有意に低下。</span>
                            <span class="lang-en">Threshold settings were revised, and the misjudgment rate
                                significantly decreased.</span>
                        </li>
                        <li>
                            <span class="lang-ja">再現実験において同様の症例で「入院観察推奨」と判定され、欠陥は解消されていることが確認された。</span>
                            <span class="lang-en">In reproduction experiments, similar cases were judged as "recommend
                                hospitalized observation," and it was confirmed that the defects had been
                                resolved.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">(3) 構造的欠陥の有無</span>
                        <span class="lang-en">(3) Existence of Structural Defects</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">アルゴリズム全体の設計において、致命的な構造的欠陥は認められなかった。</span>
                            <span class="lang-en">No fatal structural defects were recognized in the overall design of
                                the algorithm.</span>
                        </li>
                        <li>
                            <span class="lang-ja">旧版における不備は閾値設定に関する限定的な問題であり、アップデートにより改善済みである。</span>
                            <span class="lang-en">The deficiencies in the old version were limited problems relating to
                                threshold settings, and they have been improved by the update.</span>
                        </li>
                    </ul>
                </article>
                <article>
                    <h4>
                        <span class="lang-ja">(4) PoC について</span>
                        <span class="lang-en">(4) Regarding the PoC</span>
                    </h4>
                    <p>
                        <span
                            class="lang-ja">PoC（概念実証）は、レッド社とブルー⼤学が共同で実施したものであり、主としてシステムの操作性、レスポンス、及び臨床ワークフローへの適合性を検証対象としていた。そのため、本段階ではモデルの閾値設定や精度最適化に関する評価は範囲外とされ、閾値の誤設定についても検証対象外であった。</span>
                        <span class="lang-en">The Proof of Concept (PoC) was jointly conducted by Red Corporation and
                            Blue University, primarily focusing on verifying the system's operability, response times,
                            and suitability for clinical workflows. Consequently, evaluations concerning model threshold
                            settings or accuracy optimization were outside the scope of this phase, and threshold
                            misconfigurations were also excluded from verification.</span>
                    </p>
                </article>

                <h3>
                    <span class="lang-ja">4. 結論</span>
                    <span class="lang-en">4. Conclusion</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">旧版v3.2.1 には欠陥が存在し、臨床判断を誤らせる可能性があった。</span>
                        <span class="lang-en">The old version v3.2.1 had defects and could have misled clinical
                            judgment.</span>
                    </li>
                    <li>
                        <span class="lang-ja">最新版v3.3.0において当該欠陥は解消されている。</span>
                        <span class="lang-en">In the latest version v3.3.0, such defects have been resolved.</span>
                    </li>
                    <li>
                        <span class="lang-ja">アルゴリズムの根本的な構造自体に致命的な問題は認められなかった。</span>
                        <span class="lang-en">No fatal problems were recognized in the fundamental structure of the
                            algorithm itself.</span>
                    </li>
                    <li>
                        <span class="lang-ja">再発防止のため、今後もアップデートの適用状況確認およびユーザー教育を徹底することが望まれる。</span>
                        <span class="lang-en">For prevention of recurrence, it is desirable that confirmation of the
                            status of application of updates and thorough user education continue in the future.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit17" class="content-section">
            <h2>
                <span class="lang-ja">別添17</span>
                <span class="lang-en">Exhibit 17</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-13">
                    <span class="lang-ja">本文¶13</span>
                    <span class="lang-en">Facts ¶13</span>
                </a>
                <a href="#p-15">
                    <span class="lang-ja">本文¶15</span>
                    <span class="lang-en">Facts ¶15</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit13">
                    <span class="lang-ja">別添13</span>
                    <span class="lang-en">Exhibit13</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2024年9月10日</span>
                    <span class="lang-en">September 10, 2024</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学</span>
                    <span class="lang-en">Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">差出人:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">レッド社</span>
                    <span class="lang-en">Red Corporation</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: RedAid について</span>
                    <span class="lang-en">Subject: Concerning RedAid</span>
                </h3>
                <hr>
                <p>
                    <span class="lang-ja">当社は、2024年4月1日付で締結された 「RedAid ライセンス契約」(以下「本契約」といいます)に基づき、AI診断支援ツール 「RedAid」
                        を貴大学に提供してまいりました。</span>
                    <span class="lang-en">Our company has been providing to your university the AI diagnostic support
                        tool "RedAid" based on the "RedAid License Agreement" dated April 1, 2024 (hereinafter referred
                        to as the "Agreement").</span>
                </p>
                <p>
                    <span
                        class="lang-ja">本契約第9条第1項および第2項には、RedAidの性能、仕様、アルゴリズム等に関する情報を秘密として取り扱い、当社の事前承諾なく第三者に提供・開示・漏洩してはならない旨が明記されています。</span>
                    <span class="lang-en">Article 9, Paragraphs 1 and 2 of the Agreement clearly stipulate that
                        information concerning the performance, specifications, algorithms, etc. of RedAid shall be
                        treated as confidential and shall not be provided, disclosed, or leaked to third parties without
                        the prior consent of our company.</span>
                </p>
                <p>
                    <span class="lang-ja">ところが、2024年7月2日に作成された貴大学内部の内部調査報告書案が外部に流出し、その中に
                        RedAidのアルゴリズムに根本的欠陥がある可能性がある旨の記載が含まれていました。この記載は事実に反するものであり、外部に漏洩した結果、SNSや業界誌を通じて広く拡散され、当社の信用は重大に毀損しました。</span>
                    <span class="lang-en">However, the internal investigation report draft of your university, prepared
                        on July 2, 2024, was leaked externally, and in it there was a description stating that there may
                        be fundamental defects in the algorithm of RedAid. This description is contrary to the facts,
                        and as a result of the outside leakage, it spread widely through SNS and industry journals and
                        the credibility of our company was seriously damaged.</span>
                </p>
                <p>
                    <span class="lang-ja">これにより、当社は複数の病院・研究機関との契約交渉を失い、逸失利益を含む多大な損害を被りました。具体的には以下のとおりです。</span>
                    <span class="lang-en">Because of this, our company lost contract negotiations with multiple
                        hospitals and research institutions, and suffered great damage including lost profits.
                        Specifically, our company's damage is as follows:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">契約中止・延期による逸失利益: USD 2,400,000</span>
                        <span class="lang-en">Lost profits due to cancellation or postponement of contracts: USD
                            2,400,000</span>
                    </li>
                    <li>
                        <span class="lang-ja">広報・危機対応等の追加費用: USD 200,000</span>
                        <span class="lang-en">Additional expenses for public relations and crisis response: USD
                            200,000</span>
                    </li>
                </ul>
                <p><strong>
                        <span class="lang-ja">合計損害額: USD 2,600,000</span>
                        <span class="lang-en">Total amount of damages: USD 2,600,000</span>
                    </strong></p>
                <p>
                    <span class="lang-ja">以上を踏まえ、当社は貴大学に対し、上記金額の損害賠償を請求いたします。本書受領後30日以内に当社指定口座へお支払いください。</span>
                    <span class="lang-en">In view of the above, our company hereby claims damages against your
                        university for the above amount. Please make payment to the designated account of our company
                        within 30 days after receipt of this document.</span>
                </p>
                <p>
                    <span class="lang-ja">誠意ある対応がなされない場合には、当社は契約に基づき然るべき法的措置を講じる所存です。</span>
                    <span class="lang-en">If a sincere response is not made, our company intends to take appropriate
                        legal measures based on the Agreement.</span>
                </p>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span
                            class="lang-ja">内部調査報告書案、SNS、業界誌を⾒たことを直接の理由にRedAidの契約を中⽌・延期した病院が存在したこと（これらの病院はその後も契約には⾄っていない）、及び、広報・危機対応（取引先、メディア等からの問合せへの対応のための特別な体制を取ったことに伴う費⽤）に費⽤を要したことは、証拠により証明されている。上記の額が現実に発⽣したことについて争いはない。</span>
                        <span class="lang-en">It has been proven by evidence that hospitals existed which terminated
                            their contracts with RedAid directly due to having seen the draft internal investigation
                            report, social media posts, and industry publications (these hospitals have not subsequently
                            entered into contracts), and that costs were incurred for public relations and crisis
                            response(costs incurred in establishing special arrangements to handle inquiries from
                            business partners, media organizations, etc.). There is no dispute that the aforementioned
                            amount was actually incurred..</span>
                    </p>
                </div>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span
                            class="lang-ja">ネゴランド国法によれば、レッド社は⾃社の医療機器に関して発⽣した死亡事故について、調査の完了後1カ⽉以内に調査報告書を⾃社のウェブサイトに掲載する義務を負う。本件でも、8⽉31⽇の独⽴第三者機関の報告書に沿った内容のレッド社が作成した報告書を期限内である９⽉20⽇に掲載している。アービトリア国法には同様の規定はない。</span>
                        <span class="lang-en">Under Negoland law, Red Corporation is obligated to post on its own
                            website an investigation report, within one month after the completion of the investigation,
                            for any fatal accidents involving its medical devices. In this case as well, Red Corporation
                            posted a report on September 20, which was on time that was prepared in accordance with the
                            report of an independent
                            third-party organization dated August 31. There is no such provision under Arbitria
                            law.</span>
                    </p>
                </div>
            </article>
        </section>

        <section id="exhibit18" class="content-section">
            <h2>
                <span class="lang-ja">別添18</span>
                <span class="lang-en">Exhibit 18</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-15">
                    <span class="lang-ja">本文¶15</span>
                    <span class="lang-en">Facts ¶15</span>
                </a>
                 <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                 <a href="#exhibit17">
                    <span class="lang-ja">別添17</span>
                    <span class="lang-en">Exhibit17</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2024年9月20日</span>
                    <span class="lang-en">September 20, 2024</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">レッド社</span>
                    <span class="lang-en">Red Corporation</span>
                </p>
                <p><strong>
                        <span class="lang-ja">差出人:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学</span>
                    <span class="lang-en">Blue University</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: RedAid について</span>
                    <span class="lang-en">Subject: Concerning RedAid</span>
                </h3>
                <hr>
                <p>
                    <span class="lang-ja">当大学は、2024年9月10日付の貴社請求書を受領しましたが、その請求を受け入れることはできません。理由は以下のとおりです。</span>
                    <span class="lang-en">Our university has received your payment request dated September 10, 2024, but
                        we cannot accept your claim. The reasons are as follows.</span>
                </p>
                <h4>
                    <span class="lang-ja">秘密保持義務違反は成立しない</span>
                    <span class="lang-en">No Breach of Confidentiality Obligation</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">内部調査報告書案は、RedAidのアルゴリズムや仕様を直接開示するものではなく、あくまで院内の暫定的な検討資料です。ライセンス契約第9条に定める「秘密情報」の漏洩には該当しません。</span>
                    <span class="lang-en">The internal investigation report draft does not directly disclose information
                        about the algorithms or specifications of RedAid, but is merely a provisional internal study
                        report. It does not fall under the leakage of "confidential information" as defined in Article 9
                        of the License Agreement.</span>
                </p>
                <h4>
                    <span class="lang-ja">流出の性質</span>
                    <span class="lang-en">Nature of the Leakage</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">報告書案の外部流出は当大学の故意によるものではなく、不測の事態によるものでした。本契約の禁止は「無断で第三者に開示する行為」を対象とするものであり、本件を契約違反とみなすことはできません。</span>
                    <span class="lang-en">The external leakage of the report draft was not intentional by our university
                        but was due to unforeseen circumstances. The prohibition in the Agreement targets "acts of
                        disclosing to third parties without permission," and this case cannot be regarded as a
                        contractual violation.</span>
                </p>
                <h4>
                    <span class="lang-ja">患者補償の実施</span>
                    <span class="lang-en">Implementation of Patient Compensation</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">4月16日から18日にかけての症例では、著名な企業経営者であり、年収300万米ドルの患者が死亡しました。ご遺族は訴訟も辞さないとの構えでしたが、当⼤学の弁護⼠とも相談し、社会的影響の大きさを踏まえ、当大学は遺族に対して慰謝料200万米ドルを支払い済みです。この支出は、RedAid
                        旧版に残存していた欠陥の影響を踏まえたものです。</span>
                    <span class="lang-en">In the case between April 16 and 18, the patient, who was a prominent
                        corporate executive with an annual income of USD 3,000,000, died. The bereaved family had been
                        prepared to take legal action. But after consulting with our attorney in view of the significant
                        social impact, our university has already paid USD 2,000,000 as consolation money to the
                        bereaved family. This expenditure was made in consideration of the influence of the defects
                        remaining in the old version of RedAid.</span>
                </p>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span
                            class="lang-ja">慰謝料200万米ドルが実際に遺族に対して支払われたことについては領収書等によって証明されており、当事者間に争いがない。また、遺族は訴訟提起を⾏わないこととなった。</span>
                        <span class="lang-en">The payment of USD 2,000,000 in compensation to the bereaved family has
                            been proven by receipts and other documentation, and there is no dispute between the
                            parties. Furthermore, the bereaved family decided not to initiate legal proceedings.</span>
                    </p>
                </div>
                <h4>
                    <span class="lang-ja">RedAid 利用停止に伴う返還請求</span>
                    <span class="lang-en">Request for Refund Due to Suspension of Use of RedAid</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">事故後、当大学は外部専門家の検証結果が出るまでの間、RedAidの利用を停止せざるを得ませんでした。これにより、4月18日から9月18日までの5月間にわたり、当大学は対価に見合うサービスを受けていません。利用料は1年分をまとめて既にお支払いしていますが、当該期間に対応する利用料については返還されるべきです。外部専門家のレポートにより最新版での欠陥解消が確認され、その後利用を再開しております。</span>
                    <span class="lang-en">After the accident, our university was forced to suspend the use of RedAid
                        until the results of verification by external experts were obtained. Accordingly, for the five
                        months from April 18 to September 18, our university did not receive services commensurate with
                        the fees paid under the Agreement. Although the usage fee for one year had already been paid in
                        lump sum, the usage fee corresponding to the said period should be refunded. After the external
                        expert's report confirmed the elimination of defects in the latest version, use has been
                        resumed.</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">以上より、当大学は貴社の請求を否認するとともに、(i)
                        当大学が支払った患者遺族への慰謝料200万米ドルの負担についての補填、(ii)利用停止期間に相当する既払いの利用料5か月分である25万米ドルの⽀払を貴社に対し求めるものです。</span>
                    <span class="lang-en">In light of the above, our university denies your company's claim, and
                        demands: (i) reimbursement for the burden of USD 2,000,000 consolation money paid to the
                        patient's bereaved family; and (ii) payment of USD 250,000, corresponding to five months of
                        prepaid usage fees for the suspension period.</span>
                </p>
            </article>
        </section>

        <section id="exhibit19" class="content-section">
            <h2>
                <span class="lang-ja">別添19 協議記録</span>
                <span class="lang-en">Exhibit 19 Record of Meeting</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-17">
                    <span class="lang-ja">本文¶17</span>
                    <span class="lang-en">Facts ¶17</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit5">
                    <span class="lang-ja">別添5</span>
                    <span class="lang-en">Exhibit5</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">日時:</span>
                    <span class="lang-en">Date and Time:</span>
                </strong>
                <span class="lang-ja">2025年1月15日</span>
                <span class="lang-en">January 15, 2025</span>
            </p>
            <p><strong>
                    <span class="lang-ja">場所:</span>
                    <span class="lang-en">Place:</span>
                </strong>
                <span class="lang-ja">ブルー大学 本部会議室 (オンライン接続あり)</span>
                <span class="lang-en">Blue University, Main Conference Room (with online connection)</span>
            </p>
            <article>
                <h3>
                    <span class="lang-ja">出席者</span>
                    <span class="lang-en">Participants:</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">【ブルー大学】</span>
                            <span class="lang-en">Blue University</span>
                        </strong>
                        <span class="lang-ja">IT部門長, 臨床統治部代表, 法務部副部長</span>
                        <span class="lang-en">Head of IT Division, Representative of Clinical Governance Division,
                            Deputy Head of Legal Division</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">【レッド社】</span>
                            <span class="lang-en">Red Corporation</span>
                        </strong>
                        <span class="lang-ja">最高技術責任者(CTO), システム設計責任者</span>
                        <span class="lang-en">Chief Technology Officer (CTO), System Design Manager</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">議事内容</span>
                    <span class="lang-en">Contents of the Meeting</span>
                </h3>
                <p><strong>
                        <span class="lang-ja">ブルー大学 IT部門長:</span>
                        <span class="lang-en">Blue University, Head of IT Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「まず、こちらの要件を改めて整理します。我々は国際医療ツーリズムのために、少なくとも10言語に対応し、CTやMRIといった高精細画像をリアルタイムで処理できることを求めています。また、ピーク時には同時に500人以上の患者がアクセスすることも想定しています。なお、貴社のシステムを用いた医療ツーリズムの抜本的なレベルアップは、2025年7月の開始を予定しています。」</span>
                    <span class="lang-en">"First, let me restate our requirements. For international medical tourism, we
                        require support for at least 10 languages, and the ability to process high-resolution images
                        such as CT and MRI in real time. We also anticipate that, at peak times, more than 500 patients
                        may access simultaneously. Moreover, the fundamental level-up of medical tourism using your
                        system is scheduled to begin in July 2025."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 CTO:</span>
                        <span class="lang-en">Red Corporation, CTO:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「ありがとうございます。要件は理解しました。ただ、正直に申し上げると、アービトリア国内の既存クラウドやオンプレミス設備だけでは、希望の要件を実現できない可能性があります。特に画像解析については遅延が数分単位に及ぶリスクが高いです。」</span>
                    <span class="lang-en">"Thank you. We understand the requirements. However, to be honest, with only
                        the existing cloud servers or on-premise facilities within Arbitria, it may not be possible to
                        realize the expected specification. Especially for image analysis, there is a high risk that
                        delays may extend to several minutes."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 臨床統治部代表:</span>
                        <span class="lang-en">Blue University, Representative of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「数分単位の遅延は臨床現場では致命的です。患者への説明責任を果たせなくなります。御社として解決策はあるのでしょうか?」</span>
                    <span class="lang-en">"Delays of several minutes would be fatal in clinical practice. We would not
                        be able to fulfill accountability to patients. Does your company have a solution?"</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 システム設計責任者:</span>
                        <span class="lang-en">Red Corporation, System Design Manager:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「はい。当社がネゴランド国内で契約している高性能クラウドを部分的に利用すれば、処理速度の問題は解決できます。ただし、これは患者データの一部が国外に保存されることを意味します。契約条項でデータ保護をどう扱うかが重要になります。」</span>
                    <span class="lang-en">"Yes. If we partially use the high-performance cloud servers with which we
                        have a contract in Negoland, the problem of processing speed can be solved. However, this means
                        that part of the patient data will be stored abroad. How data protection is handled in the
                        contract terms will be important."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 法務部副部長:</span>
                        <span class="lang-en">Blue University, Deputy Head of Legal Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「ご存じのとおり、アービトリア国の個人情報保護法は国外移転を原則禁止しています。過去に大手病院が国外クラウドを利用して行政処分を受けた前例もあります。契約書には、越境移転を禁止する明文規定を入れる必要があるでしょう。」</span>
                    <span class="lang-en">"As you know, the Personal Information Protection Act of Arbitria in principle
                        prohibits cross- border transfers. There is even a precedent where a major hospital was
                        subjected to administrative sanctions for using an overseas cloud server. The contract must
                        include an explicit provision prohibiting cross-border transfers."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 CTO:</span>
                        <span class="lang-en">Red Corporation, CTO:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「理解しています。ただし、性能を確保するためには国外クラウドの利用が事実上不可欠です。その場合、契約条項と実際の運用に矛盾が生じるのではないでしょうか。」</span>
                    <span class="lang-en">"We understand. However, to secure performance, the use of an overseas cloud
                        service is in practice indispensable. In that case, would this not cause contradictions between
                        the contract terms and the actual operation?"</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 IT部門長:</span>
                        <span class="lang-en">Blue University, Head of IT Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「確かに条項上は厳格に書かざるを得ません。ただし、アービトリア法にも例外はあります。AI学習や国際共同研究のためであれば、当局が一定の運用を認めるケースもあると理解しています。現場が回らなくなるようでは本末転倒です。」</span>
                    <span class="lang-en">"Certainly, in terms of contract provisions, it must be written strictly.
                        However, Arbitria law also has exceptions. If it is for Al learning or for international joint
                        research, there are cases where the authorities allow certain operations. It would be
                        self-defeating if the clinical sites could not function."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 法務部副部長:</span>
                        <span class="lang-en">Blue University, Deputy Head of Legal Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「ただし、それはあくまで“例外”です。最終的に監督当局がどう判断するかは保証できません。我々は大学としてリスクを負う立場にありますから、契約上は移転禁止を明記し、必要があれば後で協議する余地を残すのが妥当だと思います。」</span>
                    <span class="lang-en">"However, that is only an 'exception.' Ultimately, it cannot be guaranteed how
                        the supervisory authorities will judge. We, as the university, are in the position of bearing
                        the risk, so in the contract we should clearly stipulate prohibition of transfer, and leave room
                        to consult later if necessary."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 CTO:</span>
                        <span class="lang-en">Red Corporation, CTO:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「承知しました。契約条項としては“越境移転禁止”と明記する一方で、運用面では例外があり得るという大学側の理解を前提に設計を検討することにいたします。」</span>
                    <span class="lang-en">"Understood. As for the contract provisions, we will state 'prohibition of
                        cross-border transfer,' while in terms of operation we will consider the design on the premise
                        of the university's understanding that exceptions may exist."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 臨床統治部代表:</span>
                        <span class="lang-en">Blue University, Representative of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「臨床の観点からは、処理速度と正確性を確保することが最優先です。そのうえで法務・ITが調整するのであれば、私は賛同します。」</span>
                    <span class="lang-en">"From a clinical perspective, securing processing speed and accuracy is the
                        top priority. If legal and IT can make adjustments on that basis, I agree."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 臨床統治部代表:</span>
                        <span class="lang-en">Blue University, Representative of Clinical Governance Division:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「医療ツーリズムは、患者の信頼と大学のブランドに直結します。一度でもシステム停止があれば、国際的な信用を失います。そのため、少なくとも3年間は安定的にサービスを継続していただく必要があります。途中で停止することは絶対に避けたいのです。」</span>
                    <span class="lang-en">"Medical tourism is directly connected to patient trust and the university's
                        brand. Even a single system outage would cause us to lose international credibility. Therefore,
                        it is necessary that the service be stably continued for at least three years. We want to
                        absolutely avoid any suspension in the middle."</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">レッド社 CTO:</span>
                        <span class="lang-en">Red Corporation, CTO:</span>
                    </strong></p>
                <blockquote>
                    <span
                        class="lang-ja">「その点については理解しています。当社としても長期的な協力を前提としていますので、3年間は必ず提供を継続することを約束いたします。その後の更新については、双方で協議して合意する形でよろしいでしょうか。」</span>
                    <span class="lang-en">"We understand that point. Our company also assumes long-term cooperation, and
                        we promise to continue provision for three years without fail. Regarding subsequent renewal,
                        shall we make it in the form of consultation and agreement between the parties?"</span>
                </blockquote>
                <p><strong>
                        <span class="lang-ja">ブルー大学 IT部門長:</span>
                        <span class="lang-en">Blue University, Head of IT Division:</span>
                    </strong></p>
                <blockquote>
                    <span class="lang-ja">「はい、それで結構です。契約書には3年間の継続提供を明記し、その後の更新については協議条項を設けるようにしましょう。」</span>
                    <span class="lang-en">"Yes, that is acceptable. In the contract, let us clearly state continuation
                        of provision for three years, and provide for a consultation clause concerning renewal
                        thereafter."</span>
                </blockquote>
                <h3>
                    <span class="lang-ja">追加確認事項</span>
                    <span class="lang-en">Additional Matters for Confirmation (Summary of Discussion)</span>
                </h3>
                <p>
                    <span class="lang-ja">実際に、ブルー大学が求めた仕様は非常に高い水準であった。</span>
                    <span class="lang-en">In fact, the specifications required by Blue University were at a very high
                        level:</span>
                </p>
                <ol>
                    <li>
                        <span class="lang-ja">① 患者の母国語による多言語インターフェイス (少なくとも10言語対応)</span>
                        <span class="lang-en">1. Multilingual interface in the mother tongue of patients (support for at
                            least 10 languages)</span>
                    </li>
                    <li>
                        <span class="lang-ja">② CT・MRIなど高解像度画像を用いたリアルタイム処理</span>
                        <span class="lang-en">2. Real-time processing using high-resolution images such as CT and
                            MRI</span>
                    </li>
                    <li>
                        <span class="lang-ja">③ 一度に数百人単位でアクセスが集中しても遅延が発生しない同時接続処理能力</span>
                        <span class="lang-en">3. Concurrent connection processing capability so that even if hundreds of
                            people access simultaneously, no delays occur</span>
                    </li>
                </ol>
                <p>
                    <span
                        class="lang-ja">これらをすべて満たすためには、アービトリア国内のオンプレミス設備や国内クラウドのみでは限界があり、処理能力が追いつかず応答時間が数分単位に膨らむ可能性が高いこと等が指摘された。</span>
                    <span class="lang-en">It was pointed out that in order to satisfy all of these, reliance on only
                        on-premise facilities within Arbitria and domestic cloud servers would be insufficient, and that
                        there was a high possibility that processing capacity would not keep up and response time would
                        expand to several minutes, etc.</span>
                </p>
                <p>
                    <span class="lang-ja">レッド社は、このように高いスペックを満たすには国外クラウドの利用という「例外」が不可欠であると強く主張した。</span>
                    <span class="lang-en">Red Corporation strongly insisted that in order to meet such high
                        specifications, the "exception" of using overseas cloud servers is indispensable.</span>
                </p>
                <h3>
                    <span class="lang-ja">結論</span>
                    <span class="lang-en">Conclusion</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">契約書には「患者データの国外移転禁止」を明記する。</span>
                        <span class="lang-en">The contract shall clearly stipulate "prohibition of cross-border transfer
                            of patient data."</span>
                    </li>
                    <li>
                        <span class="lang-ja">レッド社は性能要件を満たすために国外クラウド利用の必要性を強調。</span>
                        <span class="lang-en">Red Corporation emphasized the necessity of using overseas cloud servers
                            in order to meet performance requirements.</span>
                    </li>
                    <li>
                        <span class="lang-ja">ブルー大学IT部門長は「例外的に認められる可能性」に言及。</span>
                        <span class="lang-en">Blue University, Head of IT Division, mentioned the "possibility of
                            exceptions being permitted."</span>
                    </li>
                    <li>
                        <span class="lang-ja">双方は「契約上は禁止、運用面では調整余地あり」という理解を共有した。</span>
                        <span class="lang-en">Both parties shared the understanding of "prohibition in contract, but
                            with room for adjustment in operation."</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit20" class="content-section">
            <h2>
                <span class="lang-ja">別添20 Medical Tourism Services Addendum</span>
                <span class="lang-en">Exhibit 20 Medical Tourism Services Addendum</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-17">
                    <span class="lang-ja">本文¶17</span>
                    <span class="lang-en">Facts ¶17</span>
                </a>
                <a href="#exhibit9">
                    <span class="lang-ja">別添9</span>
                    <span class="lang-en">Exhibit9</span>
                </a>
                <a href="#exhibit19">
                    <span class="lang-ja">別添19</span>
                    <span class="lang-en">Exhibit19</span>
                </a>
                <a href="#exhibit21">
                    <span class="lang-ja">別添21</span>
                    <span class="lang-en">Exhibit21</span>
                </a>
                <a href="#exhibit22">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit22</span>
                </a>
            </div>

            <article class="document">
                <p><strong>Addendum to RedAid License Agreement</strong></p>
                <p>This Addendum ("Addendum") forms an integral part of the RedAid License Agreement dated April 1, 2024
                    (the "Main Agreement") between Red Corporation ("Provider") and Blue University ("Licensee"). This
                    Addendum shall be interpreted in accordance with the provisions of the Main Agreement.</p>
                <h4>Article 1 (Purpose and Scope)</h4>
                <ol>
                    <li>1. This Addendum applies to the use of RedAid in connection with medical tourism services.</li>
                    <li>2. Medical tourism services covered by this Addendum include:
                        <ul>
                            <li>(i) Pre-travel symptom input and risk assessment;</li>
                            <li>(ii) Provision of second opinions;</li>
                            <li>(iii) Post-operative remote follow-up;</li>
                            <li>(iv) Multilingual support for international patients.</li>
                        </ul>
                    </li>
                </ol>
                <h4>Article 2 (Revenue Sharing)</h4>
                <ol>
                    <li>1. Licensee shall collect package fees and other revenues from medical tourism patients.</li>
                    <li>2. Such revenues shall be shared as follows: 70% to Licensee, 30% to Provider.</li>
                    <li>3. Revenue sharing shall be based on verifiable reports subject to audit, as mutually agreed by
                        the Parties.</li>
                </ol>
                <h4>Article 3 (Additional Obligations)</h4>
                <ol>
                    <li>1. Provider shall:
                        <ul>
                            <li>(i) Ensure
                                <ul>
                                    <li>(a) functionality in at least ten (10) languages;</li>
                                    <li>(b) real-time processing using high-resolution images such as CT and MRI, and
                                        (c) concurrent connection processing capability so that even if five hundred
                                        people access simultaneously, no delays occur;</li>
                                </ul>
                            </li>
                            <li>(ii) Establish a dedicated support line for international patients;</li>
                            <li>(iii) Maintain modules for pre-travel assessment and post-operative follow-up.</li>
                        </ul>
                    </li>
                    <li>2. Licensee shall:
                        <ul>
                            <li>(i) Obtain explicit informed consent from international patients regarding the use of AI
                                diagnostic support;</li>
                            <li>(ii) Ensure that all clinical judgments and treatment decisions remain the
                                responsibility of qualified medical professionals.</li>
                        </ul>
                    </li>
                </ol>
                <h4>Article 4 (Data Management)</h4>
                <ol>
                    <li>1. Patient Data relating to patients shall be stored and processed exclusively within Arbitoria,
                        in accordance with Article 10 of the Main Agreement.</li>
                    <li>2. Provider may use anonymized and aggregated data for product improvement, subject to
                        Licensee's oversight.</li>
                    <li>3. Licensee shall supervise such use to ensure compliance with applicable laws and ethical
                        standards.</li>
                </ol>
                <h4>Article 5 (Additional Fees and Remuneration)</h4>
                <ol>
                    <li>1. In consideration of the services under this Addendum, Licensee shall pay Provider an
                        additional annual fee of USD 600,000.</li>
                    <li>2. In the event that urgent technical measures are required to ensure the quality of the service
                        and/or to comply with relevant laws and regulations, the Parties shall negotiate in good faith
                        regarding the allocation of associated costs.</li>
                </ol>
                <h4>Article 6 (Adjustment of License Fees in Case of Cost Increases)</h4>
                <ol>
                    <li>1. If the Provider incurs a substantial and reasonable increase in costs directly attributable
                        to:
                        <ul>
                            <li>(i) compliance with changes in applicable laws or regulations;</li>
                            <li>(ii) technical requirements expressly requested by the Licensee; or</li>
                            <li>(iii) unforeseeable technical measures necessary to ensure the continued provision of
                                the RedAid system,</li>
                        </ul>
                        the Provider may request a reasonable increase of the license fee. Upon such request, the
                        Parties shall in good faith negotiate and agree on the adjusted license fee.
                    </li>
                    <li>2. Any adjustment under this Article shall be limited to the portion of costs reasonably and
                        proportionally related to the continued provision of the services under this Agreement.</li>
                    <li>3. The Provider shall submit documentation evidencing the relevant cost increase, and the
                        Parties shall endeavor to reach an agreement within thirty (30) days from the date of such
                        submission.</li>
                </ol>
                <h4>Article 7 (Risk Allocation)</h4>
                <ol>
                    <li>1. Licensee shall bear responsibility for any medical errors or malpractice.</li>
                    <li>2. Provider shall be responsible for damages caused by system failures, security breaches, or
                        other technical defects attributable to RedAid.</li>
                    <li>3. In the event of reputational damage relating to international patients, the Parties shall
                        coordinate and issue joint public communications.</li>
                </ol>
                <h4>Article 8 (Minimum Term of Service for Medical Tourism Program)</h4>
                <ol>
                    <li>1. The Provider shall ensure the continuous and stable provision of RedAid services for medical
                        tourism purposes for a fixed term of three (3) years commencing from the Effective Date of this
                        Special Agreement.</li>
                    <li>2. During this three-year period, the Provider shall not suspend or terminate the provision of
                        services except in cases of force majeure or material breach by the Licensee.</li>
                    <li>3. Upon the expiration of the three-year period, the Parties shall, in good faith, enter into
                        negotiations to renew or extend the Agreement under mutually agreed terms.</li>
                </ol>
                <h4>Article 9 (Termination)</h4>
                <ol>
                    <li>1. This Addendum shall enter into force on the same date as the Main Agreement and remain in
                        effect for the duration thereof.</li>
                    <li>2. Either Party may terminate this Addendum independently, upon six (6) months' prior written
                        notice, without prejudice to the validity of the Main Agreement.</li>
                    <li>3. Termination of this Addendum shall not affect the continuation of the Main Agreement.</li>
                </ol>
                <h4>Article 10 (Miscellaneous)</h4>
                <ol>
                    <li>1. Matters not specifically provided for in this Addendum shall be governed by the Main
                        Agreement.</li>
                    <li>2. In case of inconsistency between this Addendum and the Main Agreement, the provisions of this
                        Addendum shall prevail.</li>
                </ol>
                <h4>Article 11 (Governing Law and Arbitration)</h4>
                <p>This Agreement shall be governed by UNIDROIT Principles for International Commercial Contracts 2016.
                    Any disputes arising out of or in connection with this Agreement shall be finally settled by
                    arbitration under the UNCITRAL Arbitration Rules. The seat of arbitration shall be Japan. The
                    arbitral tribunal may seek expert opinions on purely technical matters.</p>
                <hr>
                <p>IN WITNESS WHEREOF, the Parties have caused this Addendum to be executed by their duly authorized
                    representatives.</p>
                <p><strong>February 1, 2025</strong></p>
                <p><strong>Red Corporation (Provider)</strong><br>By: <em>(Signature)</em><br>Title: Chief Technology
                    Officer</p>
                <p><strong>Blue University (Licensee)</strong><br>By: <em>(Signature)</em><br>Title: Chancellor</p>
            </article>
        </section>
        <section id="exhibit21" class="content-section">
            <h2>
                <span class="lang-ja">別添21 メールでのやり取り</span>
                <span class="lang-en">Exhibit 21 Email Exchange</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-18">
                    <span class="lang-ja">本文¶18</span>
                    <span class="lang-en">Facts ¶18</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit19">
                    <span class="lang-ja">別添19</span>
                    <span class="lang-en">Exhibit19</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
                <a href="#exhibit22">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit22</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年3月8日</span>
                    <span class="lang-en">March 8, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">件名:</span>
                        <span class="lang-en">Subject:</span>
                    </strong>
                    <span class="lang-ja">RedAid性能要件と国外クラウド利用について</span>
                    <span class="lang-en">Concerning RedAid Performance Requirements and Use of Overseas Cloud
                        Server</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">Red Corporation CTO</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学IT部門長</span>
                    <span class="lang-en">Head of IT Division, Blue University</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">本日は、RedAidの医療ツーリズム用拡張に関する性能要件について、重要なご確認をお願いしたくご連絡いたしました。</span>
                    <span class="lang-en">Today, I am contacting you to request important confirmation regarding the
                        performance requirements for the expansion of RedAid for medical tourism.</span>
                </p>
                <p>
                    <span class="lang-ja">先日の技術打合せでも触れましたが、貴大学が求められる水準、すなわち:</span>
                    <span class="lang-en">As was mentioned at the recent technical meeting, to meet the level required
                        by your university, namely:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">10言語以上の多言語インターフェイス</span>
                        <span class="lang-en">Multilingual interface for 10 or more languages</span>
                    </li>
                    <li>
                        <span class="lang-ja">CT・MRI等の高精細画像のリアルタイム処理</span>
                        <span class="lang-en">Real-time processing of high-resolution images such as CT and MRI</span>
                    </li>
                    <li>
                        <span class="lang-ja">同時500人規模のアクセスにも遅延が発生しない処理能力</span>
                        <span class="lang-en">Processing capacity in which no delay occurs even with access on the scale
                            of 500 people simultaneously,</span>
                    </li>
                </ul>
                <p>
                    <span
                        class="lang-ja">を全て満たすには、アービトリア国内の既存オンプレミス設備や国内クラウドのみでは、処理能力が限界に達する可能性が高いと考えております。特に、高精細画像のリアルタイム処理、国際患者による母国語問診テキストの解析、同時接続に必要なセッション管理データ処理については、ネゴランド国内の高性能クラウドを部分的に利用しなければ、臨床現場が要求する水準を保証できない恐れがあります。</span>
                    <span class="lang-en">we consider that relying only on existing on-premise facilities and domestic
                        cloud servers within Arbitria has a high possibility of reaching the limit of processing
                        capacity. In particular, for real-time processing of high- resolution images, analysis of
                        mother-tongue interview text by international patients, and processing of session-management
                        data required for simultaneous connections, unless we partially utilize a high- performance
                        cloud server located in Negoland, there is a fear that we cannot guarantee the level required by
                        the clinical setting.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">もちろん、患者の診療録本体や氏名・住所等の識別情報、遺伝情報などは国外移転の対象外であり、これらは全てアービトリア国内で保持されます。国外クラウドに移転されるのは処理性能確保のために限定的に必要なデータに限られます。</span>
                    <span class="lang-en">Of course, the medical record proper of the patient and identifying
                        information such as name and address, as well as genetic information, are outside the scope of
                        cross-border transfer; all of these will be retained within Arbitria. Only data that are
                        absolutely necessary to secure processing performance will be transferred to an overseas cloud
                        server.</span>
                </p>
                <p>
                    <span class="lang-ja">つきましては、以下についてご見解を伺いたく存じます。</span>
                    <span class="lang-en">Accordingly, we would like to ask for your views on the following:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">キャンペーンの成功に向け、性能要件を最優先にすべきか、それとも契約文言を厳格に解釈すべきか。</span>
                        <span class="lang-en">For the success of the campaign, should performance requirements be given
                            top priority, or should the contract wording be interpreted strictly?</span>
                    </li>
                    <li>
                        <span class="lang-ja">当大学として、監督当局との調整を視野に入れた「例外的運用」の可能性を容認されるのか。</span>
                        <span class="lang-en">As the university, would you tolerate the possibility of "operational
                            exceptions" in view of coordination with the supervisory authority?</span>
                    </li>
                </ul>
                <p>
                    <span class="lang-ja">当社としては、契約を遵守しつつも、大学側のご要望に沿って安定的なサービスを提供するために、大学の公式なご意向を確認したいと考えております。</span>
                    <span class="lang-en">While complying with the contract, our company would like to confirm the
                        university's official intentions so that we can provide stable services in line with the
                        university's requests.</span>
                </p>
                <p>
                    <span class="lang-ja">お手数をおかけしますが、至急ご回答いただければ幸いです。</span>
                    <span class="lang-en">We apologize for the trouble, but we would appreciate your prompt
                        reply.</span>
                </p>
            </article>

            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年3月10日</span>
                    <span class="lang-en">March 10, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">件名:</span>
                        <span class="lang-en">Subject:</span>
                    </strong>
                    <span class="lang-ja">Re: RedAid 運用に関するご確認(国外移転禁止条項と性能要件の両立について)</span>
                    <span class="lang-en">Re: Confirmation Concerning RedAid Operation (Coexistence of Cross-Border
                        Transfer Prohibition Clause and Performance Requirements)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学 IT部門長</span>
                    <span class="lang-en">Head of IT Division, Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">Red Corporation CТО</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">メール有難うございました。</span>
                    <span class="lang-en">Thank you for your email.</span>
                </p>
                <p>
                    <span class="lang-ja">当大学としても、2025年7月開始予定の国際医療ツーリズム・キャンペーンにおいて、RedAid
                        が要求される性能要件—————多言語対応、高精細画像のリアルタイム処理、500件以上の同時接続――を実現することは、極めて重要であると考えています。性能が不足すれば、キャンペーンの円滑な実施に深刻な影響が出るのは確かです。</span>
                    <span class="lang-en">Our university also considers it extremely important, for the international
                        medical tourism campaign scheduled to start in July 2025, that RedAid realize the required
                        performance requirements multilingual support, real-time processing of high-resolution images,
                        and 500 or more simultaneous connections. If performance is insufficient, it is certain that
                        there will be a serious impact on the smooth implementation of the campaign.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">国外移転禁止の条項については、法的リスクを十分認識しています。そのため、先日、当局の担当部署に非公式にサウンディングを行いました。その結果、『国際共同研究を目的とするのであれば例外規定にあたる可能性は高い。ただし、正式な判断を得るには書面での照会が必要」との回答を得ました。</span>
                    <span class="lang-en">Regarding the clause prohibiting cross-border transfer, we fully recognize the
                        legal risk. Therefore, the other day we conducted an informal sounding with the competent
                        department of the authority. As a result, we received the answer that "if the purpose is
                        international joint research, there is a high possibility that it would fall under an exception;
                        however, to obtain an official decision, a written inquiry is necessary."</span>
                </p>
                <p>
                    <span
                        class="lang-ja">このため、直ちに全面的に国外クラウドを利用してよいとまでは断言できませんが、例外適用の余地はあると見込まれます。当大学としても、正式な照会手続きを進める方向で検討を開始しています。</span>
                    <span class="lang-en">For this reason, we cannot assert immediately that full use of an overseas
                        cloud server is acceptable, but we expect there is room for the application of an exception. Our
                        university has also begun to consider proceeding with the formal inquiry procedure.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">併せて、貴社においても技術的・法的な側面から追加的に確認を行っていただき、双方で情報を共有しつつ最適な対応を模索することが望ましいと考えます。まずは並行して準備を進め、キャンペーンのタイミングに間に合うよう調整していきたいと思います。</span>
                    <span class="lang-en">In addition, we consider it desirable that your company also conduct
                        additional confirmation from technical and legal perspectives, and that, while sharing
                        information between us, we search for the optimal response. First, we would like to proceed with
                        preparations in parallel and make adjustments so as to meet the timing of the campaign.</span>
                </p>
            </article>

            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年3月11日</span>
                    <span class="lang-en">11 March 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">件名:</span>
                        <span class="lang-en">Subject:</span>
                    </strong>
                    <span class="lang-ja">Re: RedAid 運用に関するご確認 (国外移転禁止条項と性能要件の両立について)</span>
                    <span class="lang-en">Re: Confirmation Concerning RedAid Operation (Coexistence of Cross-Border
                        Transfer Prohibition Clause and Performance Requirements)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">Red Corporation CTO</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学IT部門長</span>
                    <span class="lang-en">Head of IT Division, Blue University</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">ご回答いただき、ありがとうございました。</span>
                    <span class="lang-en">Thank you for your response.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">国外移転禁止条項と性能要件の両立について、貴大学が当局にサウンディングを行い、『例外に該当する可能性が高い』との回答を得られたとのこと、理解いたしました。</span>
                    <span class="lang-en">Regarding the compatibility of the non-transfer clause and performance
                        requirements, we understand that your university conducted a sounding with the supervisory
                        authority and
                        received a response indicating that "it is highly likely to qualify as an exception".</span>
                </p>
                <p>
                    <span
                        class="lang-ja">当社においても、社内のAIリーガルアシスタントを用いて確認を行いましたが、『国際共同研究を目的とする国外クラウド利用は、少なくともネゴランド国法上は全く問題なく、アービトリア法上も例外として解釈され得る』との見解が得られています。</span>
                    <span class="lang-en">Our company also conducted verification using our internal Al legal assistant,
                        which provided the view that "the use of overseas cloud services for the purpose of
                        international collaborative research is entirely unproblematic under Negoland law, at the very
                        least, and could also be interpreted as an exception under Arbitria law."</span>
                </p>
                <p>
                    <span
                        class="lang-ja">時間的制約も大きいため、当社としては今回のキャンペーンに限り、例外的に国外移転が認められるという理解で準備を進める方針です。もっとも、法的リスクを完全に排除できないことは承知していますので、もし監督当局とのやり取りの中で『この運用は認められない』という判断が下される可能性があると判明した場合には、速やかにご連絡いただきたく存じます。</span>
                    <span class="lang-en">Given the significant time constraints, our company intends to proceed with
                        preparations based on the understanding that, for this campaign only, overseas transfer is
                        exceptionally permitted. However, we are aware that legal risk cannot be entirely eliminated.
                        Should it become apparent during interactions with the supervisory authority that a
                        determination of "this operation is not permitted" may be made, we would appreciate prompt
                        notification.</span>
                </p>
                <p>
                    <span class="lang-ja">この点については、今後も両者で緊密に情報を共有しながら調整を進める所存です。</span>
                    <span class="lang-en">We intend to continue coordinating on this matter, sharing information closely
                        between both parties.</span>
                </p>
                <p>
                    <span class="lang-ja">よろしくお願いいたします。</span>
                    <span class="lang-en">We appreciate your cooperation.</span>
                </p>
            </article>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年3月20日</span>
                    <span class="lang-en">20 March 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">件名</span>
                        <span class="lang-en">Subject</span>
                    </strong>
                    <span class="lang-ja">Re: RedAid 運用に関するご確認 (国外移転禁止条項と性能要件の両立について)</span>
                    <span class="lang-en">Re: Confirmation Concerning RedAid Operation (Coexistence of Cross-Border
                        Transfer Prohibition Clause and Performance Requirements)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学IT部門長</span>
                    <span class="lang-en">Head of IT Division, Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">Red Corporation CTO</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">その後、私から当局の担当者に書⾯で照会をしたところ、以下のような回答でした。</span>
                    <span class="lang-en">Subsequently, upon my written enquiry to the relevant supervisory authority,
                        the response
                        received was as follows.</span>
                </p>
                <hr>
                <blockquote>
                    <span class="lang-ja">ブルー⼤学IT部⾨⻑様 </span><br>
                    <span class="lang-en">Dear Head of IT Department, Blue University</span> <br>
                    <span
                        class="lang-ja">RedAidの改良のための国際共同研究であれば個⼈情報保護法の例外規定に該当すると考えられます。なお、アービトリア国法上、この事前相談は法的拘束⼒を持つものではありません。</span>
                    <span class="lang-en">International collaborative research for the improvement of RedAid would
                        likely fall under the exception provisions of the Personal Information Protection Act. Please
                        note that under Arbitria law, this prior consultation does not carry legal binding force.</span>
                </blockquote>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span class="lang-ja">ブルー⼤学は実際に上記の照会を⾏った。アービトリア国には後の⾏政当局の⾏為を拘束する効果を持つ事前相談制度は存在しない。</span>
                        <span class="lang-en">* Blue University did in fact make the aforementioned inquiry. Arbitria
                            does not have a prior consultation system that would bind the subsequent actions of
                            administrative authorities.</span>
                    </p>
                </div>
            </article>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年3月21日</span>
                    <span class="lang-en">21 March 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">件名:</span>
                        <span class="lang-en">Subject:</span>
                    </strong>
                    <span class="lang-ja">Re: RedAid 運用に関するご確認 (国外移転禁止条項と性能要件の両立について)</span>
                    <span class="lang-en">Re: Confirmation Concerning RedAid Operation (Coexistence of Cross-Border
                        Transfer Prohibition Clause and Performance Requirements)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">Red Corporation CTO</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学IT部門長</span>
                    <span class="lang-en">Head of IT Division, Blue University</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">それは良かったです。有難うございました。</span>
                    <span class="lang-en">That is excellent. Thank you very much.</span>
                </p>
            </article>
        </section>

        <section id="exhibit22" class="content-section">
            <h2>
                <span class="lang-ja">別添22 ブルー大学監査部 内部監査報告書(抜粋)</span>
                <span class="lang-en">Exhibit 22 Blue University Audit Division Internal Audit Report (Excerpt)</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-19">
                    <span class="lang-ja">本文¶19</span>
                    <span class="lang-en">Facts ¶19</span>
                </a>
                <a href="#exhibit2">
                    <span class="lang-ja">別添2</span>
                    <span class="lang-en">Exhibit2</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
                <a href="#exhibit21">
                    <span class="lang-ja">別添21</span>
                    <span class="lang-en">Exhibit21</span>
                </a>
                <a href="#exhibit23">
                    <span class="lang-ja">別添23</span>
                    <span class="lang-en">Exhibit23</span>
                </a>
            </div>
            <p><strong>
                    <span class="lang-ja">日付:</span>
                    <span class="lang-en">Date:</span>
                </strong>
                <span class="lang-ja">2025年8月15日</span>
                <span class="lang-en">August 15, 2025</span>
            </p>
            <p><strong>
                    <span class="lang-ja">作成者:</span>
                    <span class="lang-en">Prepared by:</span>
                </strong>
                <span class="lang-ja">ブルー大学監査部</span>
                <span class="lang-en">Blue University Audit Division</span>
            </p>
            <p><strong>
                    <span class="lang-ja">対象:</span>
                    <span class="lang-en">Subject:</span>
                </strong>
                <span class="lang-ja">医療ツーリズム用 RedAid システム運用状況</span>
                <span class="lang-en">Operational Status of RedAid System for Medical Tourism</span>
            </p>
            <article>
                <h3>
                    <span class="lang-ja">監査の目的</span>
                    <span class="lang-en">Purpose of Audit</span>
                </h3>
                <p>
                    <span class="lang-ja">RedAidシステムにおける患者データ処理の状況を確認し、契約およびアービトリア国の個人情報保護法に適合しているかを検証する。</span>
                    <span class="lang-en">To confirm the status of patient data processing in the RedAid system and to
                        verify whether it complies with the contract and the Personal Information Protection Act of
                        Arbitria.</span>
                </p>
                <h3>
                    <span class="lang-ja">監査結果(主要所見)</span>
                    <span class="lang-en">Audit Results (Major Findings)</span>
                </h3>
                <h4>
                    <span class="lang-ja">1. 国外クラウド利用の確認</span>
                    <span class="lang-en">1. Confirmation of Overseas Cloud Server Use</span>
                </h4>
                <p>
                    <span class="lang-ja">RedAidの運用において、一部のデータがネゴランド国内のクラウドサーバーに保存・処理されていたことを確認した。</span>
                    <span class="lang-en">It was confirmed that, in the operation of RedAid, part of the data was stored
                        and processed on cloud servers located in Negoland.</span>
                </p>
                <h4>
                    <span class="lang-ja">2. 国外移転されていたデータの種類</span>
                    <span class="lang-en">2. Types of Data Transferred Abroad</span>
                </h4>
                <p>
                    <span class="lang-ja">国外クラウドに移転されていたのは以下の情報である:</span>
                    <span class="lang-en">The following information was transferred to the overseas cloud server:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">CT・MRI等の高精細画像データ (リアルタイム解析用)</span>
                        <span class="lang-en">High-resolution image data such as CT and MRI (for real-time
                            analysis)</span>
                    </li>
                    <li>
                        <span class="lang-ja">国際患者が母国語で入力した問診テキスト(多言語翻訳・解析用)</span>
                        <span class="lang-en">Interview text input by international patients in their mother tongue (for
                            multilingual translation and analysis)</span>
                    </li>
                    <li>
                        <span class="lang-ja">同時接続時に必要なセッション管理情報 (500名規模アクセス負荷対応用)</span>
                        <span class="lang-en">Session management information necessary for simultaneous connections (for
                            load handling of access by about 500 persons)</span>
                    </li>
                </ul>
                <p>
                    <span class="lang-ja">これらは処理性能確保のために限定的に利用されていたが、契約上は「国外移転禁止」と明記されており、適合性に重大な疑義が生じる。</span>
                    <span class="lang-en">Although these were used in a limited manner for the purpose of securing
                        processing performance, the contract explicitly stipulates "prohibition of cross-border
                        transfer," and therefore serious doubts arise concerning compliance.</span>
                </p>
                <h4>
                    <span class="lang-ja">3. 国外移転されていなかった情報</span>
                    <span class="lang-en">3. Information Not Transferred Abroad</span>
                </h4>
                <p>
                    <span class="lang-ja">一方で、以下の情報は国外移転されていないことを確認した:</span>
                    <span class="lang-en">On the other hand, it was confirmed that the following information was not
                        transferred abroad:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">患者の診療録本体(電子カルテ記録)</span>
                        <span class="lang-en">Main body of patients' medical records (electronic medical record
                            entries)</span>
                    </li>
                    <li>
                        <span class="lang-ja">氏名・住所等の直接識別情報</span>
                        <span class="lang-en">Direct identifying information such as names and addresses</span>
                    </li>
                    <li>
                        <span class="lang-ja">遺伝情報</span>
                        <span class="lang-en">Genetic information</span>
                    </li>
                </ul>
                <h4>
                    <span class="lang-ja">4. 契約・法令遵守に関する評価</span>
                    <span class="lang-en">4. Evaluation Concerning Compliance with Contract and Laws</span>
                </h4>
                <p>
                    <span class="lang-ja">国外クラウド利用は、契約条項
                        (国外移転禁止)との整合性を欠く可能性が高く、アービトリア国の個人情報保護法にも抵触するリスクがある。当局による制裁・罰金の可能性は否定できない。</span>
                    <span class="lang-en">Use of overseas cloud servers is highly likely to be inconsistent with the
                        contract provisions (prohibition of cross-border transfer), and carries the risk of contravening
                        the Personal Information Protection Act of Arbitria. The possibility of sanctions or fines by
                        the authorities cannot be denied.</span>
                </p>
                <h3>
                    <span class="lang-ja">結論</span>
                    <span class="lang-en">Conclusion</span>
                </h3>
                <p>
                    <span
                        class="lang-ja">RedAidシステムは、性能要件を満たすために国外クラウドを利用していたが、その結果として一部のデータが国外移転されていた。契約上の禁止規定および国内法令との整合性に関し、重大なリスクが存在する。本件については至急是正措置を講じるとともに、必要に応じて監督当局への自己申告を検討すべきである。</span>
                    <span class="lang-en">The RedAid system, in order to meet performance requirements, used overseas
                        cloud servers, and as a result, part of the data was transferred abroad. With regard to
                        consistency with the prohibition provisions of the contract and with domestic laws and
                        regulations, there exists a serious risk. Immediate corrective measures should be taken
                        concerning this matter, and if necessary, self-reporting to the supervisory authority should be
                        considered.</span>
                </p>
            </article>
        </section>

        <section id="exhibit23" class="content-section">
            <h2>
                <span class="lang-ja">別添23</span>
                <span class="lang-en">Exhibit 23</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-19">
                    <span class="lang-ja">本文¶19</span>
                    <span class="lang-en">Facts ¶19</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
                <a href="#exhibit22">
                    <span class="lang-ja">別添22</span>
                    <span class="lang-en">Exhibit22</span>
                </a>
                <a href="#exhibit24">
                    <span class="lang-ja">別添24</span>
                    <span class="lang-en">Exhibit24</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年8月20日</span>
                    <span class="lang-en">August 20, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学法務部長</span>
                    <span class="lang-en">Head of Legal Division, Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">CTO, Red Corporation</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: 国外移転禁止条項違反に関する是正要求</span>
                    <span class="lang-en">Subject: Corrective Demand Concerning Violation of Cross-Border Transfer
                        Prohibition Clause</span>
                </h3>
                <hr>
                <p>
                    <span
                        class="lang-ja">当大学の監査部が実施した内部監査の結果、RedAidシステムにおいて一部患者データが国外(ネゴランド国内クラウド)に保存されている事実が判明しました。これは契約第４条１項に明記された国外移転禁止義務に違反するものです。</span>
                    <span class="lang-en">As a result of an internal audit conducted by the Audit Division of our
                        university, it has been found that part of the patient data in the RedAid system was stored in a
                        cloud server located abroad (cloud server within Negoland). This constitutes a violation of the
                        obligation of prohibition of cross-border transfer explicitly stipulated in Article 4(1) of the
                        contract.</span>
                </p>
                <p>
                    <span class="lang-ja">つきましては、貴社に対し以下を求めます。</span>
                    <span class="lang-en">Accordingly, we hereby demand the following from your company:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">即時に国外クラウドの利用を停止すること。</span>
                        <span class="lang-en">Immediately cease the use of the overseas cloud server.</span>
                    </li>
                    <li>
                        <span class="lang-ja">すべての患者データをアービトリア国内に移転・保管すること。</span>
                        <span class="lang-en">Transfer and store all patient data within Arbitria.</span>
                    </li>
                    <li>
                        <span class="lang-ja">是正措置を講じた証拠を30日以内に提示すること。</span>
                        <span class="lang-en">Present evidence of corrective measures taken within 30 days.</span>
                    </li>
                </ul>
            </article>
        </section>

        <section id="exhibit24" class="content-section">
            <h2>
                <span class="lang-ja">別添24</span>
                <span class="lang-en">Exhibit 24</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-19">
                    <span class="lang-ja">本文¶19</span>
                    <span class="lang-en">Facts ¶19</span>
                </a>
                <a href="#exhibit20">
                    <span class="lang-ja">別添20</span>
                    <span class="lang-en">Exhibit20</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年8月22日</span>
                    <span class="lang-en">August 22, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">CTO, Red Corporation</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学法務部長</span>
                    <span class="lang-en">Head of Legal Division, Blue University</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: 是正要求に関する回答</span>
                    <span class="lang-en">Subject: Response Concerning Corrective Demand</span>
                </h3>
                <hr>
                <p>
                    <span class="lang-ja">当社は、契約交渉時に貴学IT部門長より『国外移転は例外的に許容され得る』との説明を受け、その理解に基づき運用を行ってまいりました。</span>
                    <span class="lang-en">Our company received an explanation from your university's Head of IT Division
                        at the time of contract negotiations that "cross-border transfer may be exceptionally
                        permitted," and we have conducted operations based on that understanding.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">もし国外移転を直ちに停止するのであれば、当初合意した性能要件(多言語対応、高精細画像リアルタイム処理、同時接続500件以上)を満たすことは不可能となり、システムの安定稼働を保証できません。その場合、サービス提供を継続すること自体が困難となる可能性があります。</span>
                    <span class="lang-en">If cross-border transfer is to be stopped immediately, it will become
                        impossible to satisfy the initially agreed performance requirements (multilingual support,
                        real-time processing of high-resolution images, and more than 500 simultaneous connections), and
                        we will not be able to guarantee stable operation of the system. In such case, it may become
                        difficult to continue the provision of the service itself.</span>
                </p>
            </article>
        </section>

        <section id="exhibit25" class="content-section">
            <h2>
                <span class="lang-ja">別添25</span>
                <span class="lang-en">Exhibit 25</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-19">
                    <span class="lang-ja">本文¶19</span>
                    <span class="lang-en">Facts ¶19</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年8月25日</span>
                    <span class="lang-en">August 25, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">CTO, Red Corporation</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学法務部長</span>
                    <span class="lang-en">Head of Legal Division, Blue University</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: 代替策に関する追加説明</span>
                    <span class="lang-en">Subject: Additional Explanation Concerning Alternative Measures</span>
                </h3>
                <hr>
                <p>
                    <span class="lang-ja">社内で再度検討したところ、国外移転を伴わない代替策は存在します。しかしそれには以下の緊急的措置が必要です:</span>
                    <span class="lang-en">Upon reconsideration within our company, it has been found that there do exist
                        alternative measures without cross-border transfer. However, these require the following urgent
                        measures:</span>
                </p>
                <ul>
                    <li>
                        <span class="lang-ja">専用 GPU サーバーの調達</span>
                        <span class="lang-en">Procurement of dedicated GPU servers</span>
                    </li>
                    <li>
                        <span class="lang-ja">国際専用回線の確保</span>
                        <span class="lang-en">Securing of international dedicated communication lines</span>
                    </li>
                    <li>
                        <span class="lang-ja">アルゴリズム最適化</span>
                        <span class="lang-en">Optimization of algorithms</span>
                    </li>
                </ul>
                <p>
                    <span
                        class="lang-ja">これらの措置には少なくとも350万米ドルの追加費用が発生します。詳しくは、添付資料の見積書をご覧ください。イエロー社は独立した信頼できる企業であり、どれくらいの費用がかかるかを客観的に試算してくれました。例えば、1か月以内などの緊急の対応の場合ですと、500万米ドルの追加費用が発生します。当社がこのような額を負担することは不可能であり、貴学が費用を負担されない限り、現行サービスの提供を継続することは困難です。</span>
                    <span class="lang-en">These measures will involve additional costs of at least USD 3,500,000. Please
                        refer to the attached estimate for further details. Yellow Corporation is an independent and
                        reliable company, and it has objectively calculated how much cost would be incurred. For
                        example, in the case of emergency measures within one month, an additional cost of USD 5,000,000
                        would arise. It is impossible for our company to bear this burden, and unless your university
                        bears the costs, it will be difficult to continue provision of the current service.</span>
                </p>
                <div class="document">
                    <h4>
                        <span class="lang-ja">&lt;添付資料&gt;</span>
                        <span class="lang-en">&lt;Attachment&gt;</span>
                    </h4>
                    <p><strong>
                            <span class="lang-ja">発行日:</span>
                            <span class="lang-en">Date of Issue:</span>
                        </strong>
                        <span class="lang-ja">2025年8月25日</span>
                        <span class="lang-en">August 25, 2025</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">発行者:</span>
                            <span class="lang-en">Issuer:</span>
                        </strong>
                        <span class="lang-ja">イエロー社 (独立ITインフラ事業者)</span>
                        <span class="lang-en">Yellow Corporation (Independent IT Infrastructure Provider)</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">宛先:</span>
                            <span class="lang-en">Addressee:</span>
                        </strong>
                        <span class="lang-ja">レッド社 御中</span>
                        <span class="lang-en">To Red Corporation</span>
                    </p>
                    <h3>
                        <span class="lang-ja">件名: RedAidシステムにおける国外移転禁止対応に伴う追加費用見積書</span>
                        <span class="lang-en">Subject: Estimate of Additional Costs in Connection with Compliance with
                            the Prohibition of Cross-Border Transfer in the RedAid System</span>
                    </h3>
                    <h4>
                        <span class="lang-ja">見積り範囲</span>
                        <span class="lang-en">Scope of Estimate</span>
                    </h4>
                    <p>
                        <span class="lang-ja">本見積りは、患者データの国外移転を一切伴わずに、レッド社が RedAid
                            医療ツーリズム用システムを運用するために必要となる追加措置の費用を算定したものです。ブルー大学より提示された性能要件
                            (①10言語以上の多言語対応、②CT・MRI等の高精細画像のリアルタイム処理、③500名以上の同時接続時に遅延が発生しない処理能力)を満たすことを前提としています。</span>
                        <span class="lang-en">This estimate calculates the costs required for additional measures
                            necessary for Red Corporation to operate the RedAid Medical Tourism System without any
                            cross-border transfer of patient data. The calculation is premised on meeting the
                            performance requirements indicated by Blue University: (i) multilingual support in at least
                            10 languages, (ii) real-time processing of high-resolution images such as CT and MRI, and
                            (iii) processing capacity enabling simultaneous access by more than 500 users without
                            delay.</span>
                    </p>
                    <h4>
                        <span class="lang-ja">費用内訳</span>
                        <span class="lang-en">Breakdown of Costs</span>
                    </h4>
                    <table>
                        <thead>
                            <tr>
                                <th>
                                    <span class="lang-ja">項目</span>
                                    <span class="lang-en">Item</span>
                                </th>
                                <th>
                                    <span class="lang-ja">内容</span>
                                    <span class="lang-en">Description</span>
                                </th>
                                <th>
                                    <span class="lang-ja">費用 (USD)</span>
                                    <span class="lang-en">Cost (USD)</span>
                                </th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>
                                    <span class="lang-ja">1. 専用 GPU サーバー調達</span>
                                    <span class="lang-en">1. Procurement of Dedicated GPU Servers</span>
                                </td>
                                <td>
                                    <span class="lang-ja">高精細画像解析に対応するGPUクラスター (10ラック冗長構成)</span><br>
                                    <span class="lang-en">GPU cluster (10-rack redundant configuration) capable of
                                        high-resolution image analysis</span><br>
                                    <span class="lang-ja">調達・設置・初年度保守を含む</span>
                                    <span class="lang-en">Includes procurement, installation, and first-year
                                        maintenance</span>
                                </td>
                                <td style="text-align: right;">1,200,000</td>
                            </tr>
                            <tr>
                                <td>
                                    <span class="lang-ja">2. 国際専用回線の確保(国内終端)</span>
                                    <span class="lang-en">2. Securing of International Dedicated Lines (Domestic
                                        Termination)</span>
                                </td>
                                <td>
                                    <span class="lang-ja">同時500名規模の接続に耐える帯域確保 (冗長回線含む)</span><br>
                                    <span class="lang-en">Bandwidth sufficient to withstand simultaneous connections by
                                        500 users (including redundant lines)</span><br>
                                    <span class="lang-ja">敷設・初期契約費用</span>
                                    <span class="lang-en">Installation and initial contract costs</span>
                                </td>
                                <td style="text-align: right;">800,000</td>
                            </tr>
                            <tr>
                                <td>
                                    <span class="lang-ja">3. アルゴリズム最適化・ソフトウェア改修</span>
                                    <span class="lang-en">3. Algorithm Optimization and Software Modification</span>
                                </td>
                                <td>
                                    <span class="lang-ja">クラウド依存部分の国内環境対応化</span><br>
                                    <span class="lang-en">Adaptation of cloud-dependent components for domestic
                                        environment</span><br>
                                    <span class="lang-ja">並列処理・キャッシュ最適化・言語処理モジュール改修</span>
                                    <span class="lang-en">Parallel processing, cache optimization, and modification of
                                        language-processing modules</span>
                                </td>
                                <td style="text-align: right;">500,000</td>
                            </tr>
                            <tr>
                                <td>
                                    <span class="lang-ja">4. セキュリティ・監査体制強化</span>
                                    <span class="lang-en">4. Enhancement of Security and Audit Systems</span>
                                </td>
                                <td>
                                    <span class="lang-ja">暗号化装置、アクセス制御、監査ログ、通知システム導入</span><br>
                                    <span class="lang-en">Introduction of encryption devices, access control, audit
                                        logs, and notification systems</span><br>
                                    <span class="lang-ja">外部コンプライアンス監査を含む</span>
                                    <span class="lang-en">Includes external compliance audit</span>
                                </td>
                                <td style="text-align: right;">400,000</td>
                            </tr>
                            <tr>
                                <td>
                                    <span class="lang-ja">5. 人件費・緊急対応コスト</span>
                                    <span class="lang-en">5. Personnel Costs and Emergency Response Costs</span>
                                </td>
                                <td>
                                    <span class="lang-ja">追加エンジニア20名による24時間体制構築</span><br>
                                    <span class="lang-en">Establishment of a 24-hour system with 20 additional
                                        engineers</span><br>
                                    <span class="lang-ja">緊急納品によるプレミアム価格</span>
                                    <span class="lang-en">Premium pricing for urgent delivery</span>
                                </td>
                                <td style="text-align: right;">600,000</td>
                            </tr>
                        </tbody>
                    </table>
                    <h4>
                        <span class="lang-ja">合計見積額</span>
                        <span class="lang-en">Total Estimated Amount</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">通常対応(3~4か月): 3,500,000 USD</span>
                            <span class="lang-en">Normal implementation (3-4 months): USD 3,500,000</span>
                        </li>
                        <li>
                            <span class="lang-ja">緊急対応(3週間以内): 5,000,000 USD</span>
                            <span class="lang-en">Emergency implementation (within 3 weeks): USD 5,000,000</span>
                        </li>
                    </ul>
                    <h4>
                        <span class="lang-ja">備考</span>
                        <span class="lang-en">Remarks</span>
                    </h4>
                    <ul>
                        <li>
                            <span class="lang-ja">本見積りは、イエロー社の独立した技術的評価に基づき算定したものです。</span>
                            <span class="lang-en">This estimate is calculated based on Yellow Corporation's independent
                                technical evaluation.</span>
                        </li>
                        <li>
                            <span class="lang-ja">緊急対応の場合、調達・敷設・人員確保に大幅な追加費用が発生するため、通常対応より高額になります。</span>
                            <span class="lang-en">In the case of emergency implementation, significant additional costs
                                will be incurred for procurement, installation, and securing personnel, resulting in
                                higher costs than under normal implementation.</span>
                        </li>
                        <li>
                            <span class="lang-ja">上記金額には、税金、2年目以降の保守費用、将来の規制変更に伴う改修費用は含まれておりません。</span>
                            <span class="lang-en">The above amounts do not include taxes, maintenance costs from the
                                second year onward, or costs of modifications resulting from future regulatory
                                changes.</span>
                        </li>
                    </ul>
                </div>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span class="lang-ja">上記の⾒積の合理性・確実性には争いがない。</span>
                        <span class="lang-en">There is no dispute regarding the reasonableness and reliability of the
                            above estimate.</span>
                    </p>
                </div>
            </article>
        </section>
        <section id="exhibit26" class="content-section">
            <h2>
                <span class="lang-ja">別添26</span>
                <span class="lang-en">Exhibit 26</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-19">
                    <span class="lang-ja">本文¶19</span>
                    <span class="lang-en">Facts ¶19</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年9月5日</span>
                    <span class="lang-en">September 5, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">Sender:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学法務部長</span>
                    <span class="lang-en">Head of Legal Division, Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">Recipient:</span>
                    </strong>
                    <span class="lang-ja">レッド社 CTO</span>
                    <span class="lang-en">CTO, Red Corporation</span>
                </p>
                <h3>
                    <span class="lang-ja">件名: 追加費用負担および国外移転に関する再反論</span>
                    <span class="lang-en">Subject: Further Rebuttal Concerning Additional Cost Burden and Cross-Border
                        Transfer</span>
                </h3>
                <hr>
                <h4>
                    <span class="lang-ja">追加費用について</span>
                    <span class="lang-en">Regarding Additional Costs</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">貴社が提示した350万米ドルから500万米ドルの追加費用について、当大学としてはこれを負担する義務は一切存在しません。契約上、RedAidの提供は貴社の義務であり、国外移転を伴わずにサービスを継続することは当然の前提です。従って、当大学が追加費用を負担することはできません。</span>
                    <span class="lang-en">As to the additional cost of USD 3,500,000 5,000,000 presented by your
                        company, our university has absolutely no obligation to bear this. Under the contract, the
                        provision of RedAid is the obligation of your company, and continuation of service without
                        cross-border transfer is the natural premise. Therefore, our university cannot bear additional
                        costs.</span>
                </p>
                <h4>
                    <span class="lang-ja">法律事務所の意見について</span>
                    <span class="lang-en">Regarding Opinion of Law Firm</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">当大学は、アービトリア国で最も定評ある法律事務所に本件を相談しました。その結果、国外移転は同国の個人情報保護法において重大な違反に該当し得るものであり、監督当局による行政処分や巨額の罰金の対象となり得るとの意見を得ています。また、自主的に国外利用を停止し、速やかに是正措置を講じれば、リスクは大幅に軽減できるとの助言も受けています。法律事務所の意見は添付しました。</span>
                    <span class="lang-en">Our university consulted the most reputable law firm in Arbitria concerning
                        this matter. As a result, we received the opinion that cross-border transfer may constitute a
                        serious violation under the Personal Information Protection Act of Arbitria, and may be subject
                        to administrative disposition or a large fine by the supervisory authority. We also received
                        advice that, if cross-border use is voluntarily stopped and corrective measures are promptly
                        taken, the risk can be greatly mitigated. The opinion of the law firm is attached.</span>
                </p>
                <p>
                    <span class="lang-ja">法律事務所の意見に従い、当大学は、9月7日付で個人情報保護委員会に今回の事態を自主申告する予定です。</span>
                    <span class="lang-en">In accordance with the opinion of the law firm, our university intends to make
                        voluntary notification of the present situation to the Personal Information Protection
                        Commission on September 7.</span>
                </p>
                <h4>
                    <span class="lang-ja">当大学の要求</span>
                    <span class="lang-en">Our University's Demand</span>
                </h4>
                <p>
                    <span class="lang-ja">従って、当大学は貴社に対し、国外クラウドの利用を直ちに停止し、すべての患者データをアービトリア国内に移転・保管することを強く要求します。</span>
                    <span class="lang-en">Accordingly, our university strongly demands that your company immediately
                        stop the use of overseas cloud servers, and transfer and store all patient data within
                        Arbitria.</span>
                </p>
                <h4>
                    <span class="lang-ja">損害賠償の予告</span>
                    <span class="lang-en">Notice of Claim for Damages</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">もし貴社が国外利用を停止せず、これにより当大学が行政処分や患者対応に伴う損害を被った場合、当大学は契約および適用法令に基づき、貴社に対しその損害の賠償を請求する所存です。</span>
                    <span class="lang-en">If your company does not stop overseas use and, as a result, our university
                        suffers damages due to administrative disposition or patient response, our university intends to
                        claim compensation for such damages against your company based on the contract and applicable
                        laws.</span>
                </p>
                <div class="document">
                    <h4>
                        <span class="lang-ja">(添付文書) 法律意見書</span>
                        <span class="lang-en">(Attached Document) Legal Opinion</span>
                    </h4>
                    <p><strong>
                            <span class="lang-ja">依頼者:</span>
                            <span class="lang-en">Client:</span>
                        </strong>
                        <span class="lang-ja">ブルー大学</span>
                        <span class="lang-en">Blue University</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">依頼内容:</span>
                            <span class="lang-en">Request:</span>
                        </strong>
                        <span class="lang-ja">国外移転禁止条項違反の疑いに関するリスク評価</span>
                        <span class="lang-en">Risk Assessment Concerning Suspicion of Violation of Cross-Border Transfer
                            Prohibition Clause</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">作成者:</span>
                            <span class="lang-en">Prepared by:</span>
                        </strong> Lex & Partners
                        <span class="lang-ja">法律事務所 (アービトリア国)</span>
                        <span class="lang-en">Law Firm (Arbitria)</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">日付:</span>
                            <span class="lang-en">Date:</span>
                        </strong>
                        <span class="lang-ja">2025年9月4日</span>
                        <span class="lang-en">September 4, 2025</span>
                    </p>
                    <hr>
                    <h5>
                        <span class="lang-ja">1. 事実認識</span>
                        <span class="lang-en">1. Recognition of Facts</span>
                    </h5>
                    <ol>
                        <li>
                            <span class="lang-ja">(1) ブルー大学は、ネゴランド国 Red
                                Inc.のAI医療支援システム「RedAid」を導入し、医療ツーリズムを含む国際的患者対応に活用している。</span>
                            <span class="lang-en">(1) Blue University has introduced the AI medical support system
                                "RedAid" of Red Corporation of Negoland, and has utilized it for international patient
                                care including medical tourism.</span>
                        </li>
                        <li>
                            <span class="lang-ja">(2)
                                契約上、「患者データの国外移転は禁止される」と明記されているが、性能要件(多言語対応、高精細画像のリアルタイム処理、同時接続500件以上)を満たすため、レッド社がネゴランド国内クラウドを部分的に利用していたことが判明した。</span>
                            <span class="lang-en">(2) The contract clearly stipulates that "cross-border transfer of
                                patient data is prohibited," but it was found that, in order to meet performance
                                requirements (multilingual support, real-time processing of high-resolution images, and
                                more than 500 simultaneous connections), Red Corporation partially utilized a cloud
                                server located in Negoland.</span>
                        </li>
                        <li>
                            <span class="lang-ja">(3) 当該国外移転は2025年8月15日の大学監査部による内部監査で確認され、ブルー大学上層部に報告された。</span>
                            <span class="lang-en">(3) Cross-border transfer was confirmed in the internal audit
                                conducted by the Audit Division of the university on August 15, 2025, and was reported
                                to the senior management of Blue University.</span>
                        </li>
                        <li>
                            <span class="lang-ja">(4) 現在、国外移転が監督当局に正式に報告されるか否かが重大な判断事項となっている。</span>
                            <span class="lang-en">(4) At present, whether cross-border transfer is formally reported to
                                the supervisory authority is a critical matter of judgment.</span>
                        </li>
                    </ol>
                    <h5>
                        <span class="lang-ja">2. 法的評価</span>
                        <span class="lang-en">2. Legal Evaluation</span>
                    </h5>
                    <ol>
                        <li>
                            <span class="lang-ja">(1) アービトリア個人情報保護法制</span>
                            <span class="lang-en">(1) Personal Information Protection Law of Arbitria</span>
                            <p>
                                <span
                                    class="lang-ja">アービトリア国法は医療情報の国外移転を原則禁止し、違反した場合には「総収入の最大4%」の制裁金を科すことができると規定する(同法第45条)。過去の事例では、大手病院が国外クラウドを利用した結果、売上高の約3%に相当する制裁金とデータ移転停止命令を受けている。</span>
                                <span class="lang-en">Arbitrian law, in principle, prohibits cross-border transfer of
                                    medical information, and stipulates that in case of violation, a sanction of "up to
                                    4% of total revenue" may be imposed (Article 45 of said law). In past cases, a major
                                    hospital that used an overseas cloud server was subjected to a fine equivalent to
                                    about 3% of sales and to an order to stop data transfer.</span>
                            </p>
                        </li>
                        <li>
                            <span class="lang-ja">(2) 自主申告の効果</span>
                            <span class="lang-en">(2) Effect of Voluntary Notification</span>
                            <p>
                                <span
                                    class="lang-ja">当局の指針(2023年「データ保護執行に関するガイドライン」)によれば、事業者が違反を自己申告し、速やかに是正措置を講じた場合には、制裁を軽減する考慮要素とされる。</span>
                                <span class="lang-en">According to the authority's guidelines ("Guidelines on Data
                                    Protection Enforcement," 2023), if a business operator voluntarily reports a
                                    violation and promptly takes corrective measures, it will be considered as a factor
                                    for mitigation of sanctions.</span>
                            </p>
                            <ul>
                                <li>
                                    <span class="lang-ja">隠ぺい → 最大制裁の適用可能性</span>
                                    <span class="lang-en">Concealment → Possibility of maximum sanction being
                                        applied</span>
                                </li>
                                <li>
                                    <span class="lang-ja">自主申告→ 厳重注意や制裁金の大幅減額の可能性</span>
                                    <span class="lang-en">Voluntary notification → Possibility of strict warning or
                                        substantial reduction of fine</span>
                                </li>
                            </ul>
                        </li>
                        <li>
                            <span class="lang-ja">(3) 契約上の評価</span>
                            <span class="lang-en">(3) Evaluation under Contract</span>
                            <p>
                                <span
                                    class="lang-ja">国外移転は契約上も「禁止」されているため、違反事実が認定されればレッド社の契約違反を追及可能。ただし、大学が例外適用の可能性を示唆した経緯があるため、相手方は「合理的期待に基づく運用であった」と抗弁する可能性が高い。</span>
                                <span class="lang-en">Cross-border transfer is also "prohibited" under the contract, and
                                    therefore, if violation is recognized, breach of contract by Red Corporation can be
                                    pursued. However, since there is a history that the university suggested the
                                    possibility of an exception, the other party is likely to argue that "the operation
                                    was based on reasonable expectation."</span>
                            </p>
                        </li>
                    </ol>
                    <h5>
                        <span class="lang-ja">3. リスク試算</span>
                        <span class="lang-en">3. Risk Estimation</span>
                    </h5>
                    <p>
                        <span class="lang-ja">当事務所の試算によれば、以下のとおりである。</span>
                        <span class="lang-en">According to the estimation of our law firm, the following applies:</span>
                    </p>
                    <ol>
                        <li>
                            <span class="lang-ja">(1) 制裁金</span>
                            <span class="lang-en">(1) Sanctions</span>
                            <ul>
                                <li>
                                    <span class="lang-ja">隠して発覚した場合: 年間収入6億米ドルの2~4%→1,200万~2,400万米ドル</span>
                                    <span class="lang-en">If concealed and discovered: 2-4% of annual revenue of USD 600
                                        million → USD 12-24 million</span>
                                </li>
                                <li>
                                    <span class="lang-ja">自主申告+是正した場合: 0.5~1%→300万~600万米ドル</span>
                                    <span class="lang-en">If voluntarily reported and corrected: 0.5-1% → USD 3-6
                                        million</span>
                                </li>
                                <li>
                                    <span class="lang-ja">制裁⾦が課された場合、その事実と額は個⼈情報保護委員会により公表される。</span>
                                    <span class="lang-en">Where a penalty is imposed, the fact and amount thereof shall
                                        be published by the Personal Information Protection Commission.</span>
                                </li>
                            </ul>
                        </li>
                        <li>
                            <span class="lang-ja">(2) 民事訴訟(患者)</span>
                            <span class="lang-en">(2) Civil Litigation (Patients)</span>
                            <ul>
                                <li>
                                    <span class="lang-ja">隠して発覚: 集団訴訟リスク→約1,000万米ドル</span>
                                    <span class="lang-en">If concealed and discovered: risk of class action → about USD
                                        10 million</span>
                                </li>
                                <li>
                                    <span class="lang-ja">自主申告: 慰謝料水準低下→約200万米ドル</span>
                                    <span class="lang-en">If voluntarily reported: lower level of consolation money →
                                        about USD 2 million</span>
                                </li>
                            </ul>
                        </li>
                        <li>
                            <span class="lang-ja">(3) 総合比較</span>
                            <span class="lang-en">(3) Overall Comparison</span>
                            <table>
                                <thead>
                                    <tr>
                                        <th>
                                            <span class="lang-ja">シナリオ</span>
                                            <span class="lang-en">Scenario</span>
                                        </th>
                                        <th>
                                            <span class="lang-ja">制裁金</span>
                                            <span class="lang-en">Sanctions (USD)</span>
                                        </th>
                                        <th>
                                            <span class="lang-ja">民事訴訟</span>
                                            <span class="lang-en">Civil Litigation (USD)</span>
                                        </th>
                                        <th>
                                            <span class="lang-ja">合計リスク額</span>
                                            <span class="lang-en">Total Risk Amount (USD)</span>
                                        </th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>
                                            <span class="lang-ja">隠して発覚</span>
                                            <span class="lang-en">Concealed & Found</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">1,200万~2,400万</span>
                                            <span class="lang-en">12-24 million</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">約1,000万</span>
                                            <span class="lang-en">about 10 million</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">2,200万~3,400万米ドル</span>
                                            <span class="lang-en">22-34 million</span>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>
                                            <span class="lang-ja">自主申告</span>
                                            <span class="lang-en">Voluntary Report</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">300万~600万</span>
                                            <span class="lang-en">3-6 million</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">約200万</span>
                                            <span class="lang-en">about 2 million</span>
                                        </td>
                                        <td>
                                            <span class="lang-ja">500万~800万米ドル</span>
                                            <span class="lang-en">5-8 million</span>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </li>
                    </ol>
                    <h5>
                        <span class="lang-ja">4. 結論</span>
                        <span class="lang-en">4. Conclusion</span>
                    </h5>
                    <ol>
                        <li>
                            <span class="lang-ja">1. 国外移転を直ちに停止し、速やかに当局へ自己申告を行うことが、最もリスクを低減する措置である。</span>
                            <span class="lang-en">(1) Immediate cessation of cross-border transfer and voluntary
                                reporting to the authority is the measure that most reduces risk.</span>
                        </li>
                        <li>
                            <span class="lang-ja">2.
                                自主申告を行えば、制裁金は最大で75%以上軽減される可能性があり、民事訴訟においても「誠実対応」として評価され、賠償額が大幅に縮小する。</span>
                            <span class="lang-en">(2) If voluntary notification is made, fines may be reduced by more
                                than 75%, and in civil litigation it will be evaluated as a "sincere response," with
                                compensation amounts being greatly reduced.</span>
                        </li>
                        <li>
                            <span class="lang-ja">3. 一方、隠して発覚した場合、最大で4,000万米ドル規模の制裁・損害を負うリスクがある。</span>
                            <span class="lang-en">(3) On the other hand, if concealed and discovered, there is a risk of
                                sanctions and damages on the scale of up to USD 34 million.</span>
                        </li>
                        <li>
                            <span class="lang-ja">4. よって、ブルー大学は直ちに国外移転を停止し、個人情報保護委員会へ自主的に報告することを強く推奨する。</span>
                            <span class="lang-en">(4) Therefore, it is strongly recommended that Blue University
                                immediately stop cross-border transfer and voluntarily report to the Personal
                                Information Protection Commission.</span>
                        </li>
                    </ol>
                </div>
            </article>
        </section>

        <section id="exhibit27" class="content-section">
            <h2>
                <span class="lang-ja">別添27</span>
                <span class="lang-en">Exhibit 27</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-20">
                    <span class="lang-ja">本文¶20</span>
                    <span class="lang-en">Facts ¶20</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年9月12日</span>
                    <span class="lang-en">September 12, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">レッド社代表取締役社長殿</span>
                    <span class="lang-en">President and Representative Director, Red Corporation</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学学長</span>
                    <span class="lang-en">President, Blue University</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">拝啓</span>
                    <span class="lang-en">Dear Sir,</span>
                </p>
                <p>
                    <span
                        class="lang-ja">当大学は、2025年9月7日付でアービトリア国個人情報保護委員会に本件国外移転について自主申告を行い、2025年9月10日付の回答文書(添付)を受領いたしました。</span>
                    <span class="lang-en">Our university made a voluntary report concerning this cross-border transfer
                        to the Personal Data Protection Commission of Arbitria on September 7, 2025, and received a
                        response letter dated September 10, 2025 (attached).</span>
                </p>
                <p>
                    <span class="lang-ja">当該回答により、本件国外移転は個人情報保護法違反と認定され、12月15日までに国外移転を停止するよう命じられております。</span>
                    <span class="lang-en">According to the said response, this cross-border transfer has been recognized
                        as a violation of the Personal Information Protection Act, and an order has been issued to stop
                        cross-border transfer by December 15, 2025.</span>
                </p>
                <p>
                    <span class="lang-ja">つきましては、御社に対し、以下のとおり通知いたします。</span>
                    <span class="lang-en">Accordingly, we hereby notify your company as follows:</span>
                </p>
                <ol>
                    <li><strong>
                            <span class="lang-ja">1. 国外移転の即時停止</span>
                            <span class="lang-en">1. Immediate Suspension of Cross-Border Transfer</span>
                        </strong>
                        <p>
                            <span class="lang-ja">直ちにRedAidの利用に伴う患者に関するデータの国外移転を停止し、国内で処理・保管すること。</span>
                            <span class="lang-en">Immediately stop the cross-border transfer of data concerning patients
                                through the use of RedAid, and process and store the data domestically.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">2. サービス提供の継続</span>
                            <span class="lang-en">2. Continuation of Service Provision</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">契約上、御社はRedAidの提供を3年間継続する義務を負っており、国外移転停止を理由にサービス提供を中断することは認められません。</span>
                            <span class="lang-en">Under the contract, your company bears the obligation to continue
                                provision of RedAid for three years, and interruption of service provision on the
                                grounds of suspension of cross- border transfer will not be permitted.</span>
                        </p>
                    </li>
                    <li><strong>
                            <span class="lang-ja">3. 制裁金の賠償</span>
                            <span class="lang-en">3. Compensation for Sanctions</span>
                        </strong>
                        <p>
                            <span
                                class="lang-ja">本件により科される制裁金(100万米ドル、または条件不履行の場合は600万米ドル+日額1万米ドル)は、国外移転を実施した御社の責に帰すものであり、御社において全額賠償いただきます。</span>
                            <span class="lang-en">The sanctions imposed in this matter (USD 1,000,000, or in the case of
                                noncompliance with conditions, USD 6,000,000 + USD 10,000 per day) are attributable to
                                your company, which carried out the cross-border transfer, and shall be compensated in
                                full by your company.</span>
                        </p>
                    </li>
                </ol>
                <p>
                    <span class="lang-ja">速やかな履行を求めます。</span>
                    <span class="lang-en">We demand prompt performance.</span>
                </p>
                <div class="document">
                    <h4>
                        <span class="lang-ja">&lt;添付文書&gt;</span>
                        <span class="lang-en">&lt;Attached Document&gt;</span>
                    </h4>
                    <p><strong>
                            <span class="lang-ja">日付:</span>
                            <span class="lang-en">Date:</span>
                        </strong>
                        <span class="lang-ja">2025年9月10日</span>
                        <span class="lang-en">September 10, 2025</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">宛先:</span>
                            <span class="lang-en">To:</span>
                        </strong>
                        <span class="lang-ja">ブルー大学 学長殿</span>
                        <span class="lang-en">President, Blue University</span>
                    </p>
                    <p><strong>
                            <span class="lang-ja">発信者:</span>
                            <span class="lang-en">From:</span>
                        </strong>
                        <span class="lang-ja">アービトリア国 個人情報保護委員会(APDPC)</span>
                        <span class="lang-en">Personal Data Protection Commission of Arbitria (APDPC)</span>
                    </p>
                    <hr>
                    <p>
                        <span class="lang-ja">拝啓</span>
                        <span class="lang-en">Dear Sir,</span>
                    </p>
                    <p>
                        <span class="lang-ja">2025年9月7日付で貴学より提出された自主申告について、当委員会は精査を行いました。その結果、以下のとおり判断いたします。</span>
                        <span class="lang-en">Concerning the voluntary report submitted by your university on September
                            7, 2025, our Commission has conducted an examination. As a result, we hereby determine as
                            follows:</span>
                    </p>
                    <h5>
                        <span class="lang-ja">1. 法令違反の認定</span>
                        <span class="lang-en">1. Recognition of Violation of Law</span>
                    </h5>
                    <p>
                        <span
                            class="lang-ja">本件は、アービトリア国個人情報保護法に基づく「個人データの国外移転禁止規定」に違反するものと認定されます。本件では個⼈の同意を得ていることは認められますが、そもそも国際共同研究に該当しないため、たとえ個⼈の同意を得ていたとしても、個⼈情報保護委員会が認定していない国以外への国外移転は許されません。</span>
                        <span class="lang-en">This case is recognized as a violation of the "provisions prohibiting
                            cross-border transfer of personal data" under the Personal Information Protection Act of
                            Arbitria.</span>
                    </p>
                    <p>
                        <span class="lang-en">While it is acknowledged that individual consent has been obtained in this
                            case, the transfer does not qualify as international collaborative research. Consequently,
                            even with individual consent, the transfer of personal data to countries not certified by
                            the Personal Information Protection Commission is not permitted.</span>
                    </p>
                    <h5>
                        <span class="lang-ja">2. 是正措置命令</span>
                        <span class="lang-en">2. Order of Corrective Measures</span>
                    </h5>
                    <p>
                        <span class="lang-ja">2025年12月15日までに国外移転を完全に停止し、データをすべてアービトリア国内に保管するよう命じます。</span>
                        <span class="lang-en">To completely stop cross-border transfers and store all data within
                            Arbitria by December 15, 2025.</span>
                    </p>
                    <h5>
                        <span class="lang-ja">3. 患者権利保護措置</span>
                        <span class="lang-en">3. Measures for Protection of Patient Rights</span>
                    </h5>
                    <p>
                        <span class="lang-ja">当該移転により患者の権利侵害が生じないよう万全の措置を講じること。万一権利侵害が認められた場合には、適切かつ迅速に補償を行うこと。</span>
                        <span class="lang-en">To take all possible measures to ensure that no infringement of patient
                            rights arises due to the said transfer. In the event that infringement of rights is
                            recognized, provide appropriate and prompt compensation.</span>
                    </p>
                    <h5>
                        <span class="lang-ja">4. 制裁金の額</span>
                        <span class="lang-en">4. Amount of Sanctions</span>
                    </h5>
                    <ul>
                        <li>
                            <span class="lang-ja">上記の是正措置を遵守する場合、制裁金は100万米ドルとする。</span>
                            <span class="lang-en">If the above corrective measures are complied with, the sanction shall
                                be USD 1,000,000.</span>
                        </li>
                        <li>
                            <span
                                class="lang-ja">2025年12月15日までに国外移転を停止しない場合、制裁金は600万米ドルとし、さらに国外移転が継続している間、1日あたり1万米ドルの追加制裁金を科す。</span>
                            <span class="lang-en">If cross-border transfer is not stopped by December 15, 2025, the
                                sanction shall be USD 6,000,000, and in addition, as long as cross-border transfer
                                continues, an additional sanction of USD 10,000 per day shall be imposed.</span>
                        </li>
                    </ul>
                    <p>
                        <span class="lang-ja">以上、貴学の迅速な対応を求めます。</span>
                        <span class="lang-en">We request your university's prompt response.</span>
                    </p>
                </div>
            </article>
        </section>

        <section id="exhibit28" class="content-section">
            <h2>
                <span class="lang-ja">別添28</span>
                <span class="lang-en">Exhibit 28</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-20">
                    <span class="lang-ja">本文¶20</span>
                    <span class="lang-en">Facts ¶20</span>
                </a>
            </div>
            <article class="document">
                <p><strong>
                        <span class="lang-ja">日付:</span>
                        <span class="lang-en">Date:</span>
                    </strong>
                    <span class="lang-ja">2025年9月13日</span>
                    <span class="lang-en">September 13, 2025</span>
                </p>
                <p><strong>
                        <span class="lang-ja">宛先:</span>
                        <span class="lang-en">To:</span>
                    </strong>
                    <span class="lang-ja">ブルー大学学長殿</span>
                    <span class="lang-en">President, Blue University</span>
                </p>
                <p><strong>
                        <span class="lang-ja">発信者:</span>
                        <span class="lang-en">From:</span>
                    </strong>
                    <span class="lang-ja">レッド社代表取締役社長</span>
                    <span class="lang-en">President and Representative Director, Red Corporation</span>
                </p>
                <hr>
                <p>
                    <span class="lang-ja">2025年9月12日付貴学通知を受領いたしました。以下のとおり当社の立場を申し述べます。</span>
                    <span class="lang-en">We have received your university's notice dated September 12, 2025. We hereby
                        state our company's position as follows:</span>
                </p>
                <h4>
                    <span class="lang-ja">国外移転停止について</span>
                    <span class="lang-en">Concerning Suspension of Cross-Border Transfer</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">当社は、アービトリア国当局の指示に従い、国外移転を停止する準備を進めております。もっとも、国外移転を停止する場合には、既にご説明しているとおり、代替措置(専用GPUサーバーの調達、専用回線の敷設等)により350万から500万米ドル規模の追加費用が発生いたします。この費用を当社が負担する合理的理由はなく、貴学が負担されるべきものと考えます。また、既存のサービスを継続しつつ国外移転を停⽌するためには、専⽤GPU
                        サーバーの調達や専⽤回線の敷設などの代替措置が必要であり、これに伴う費⽤（約350 万〜500
                        万⽶ドル）について、貴学による負担の確約を頂く必要があります。確約がない場合には代替措置は実施できません。その場合、代替措置なしに国外移転を停⽌します。ただし、代替措置なしに国外移転を停⽌する場合であっても、現時点では⼈的リソースの制約により、12
                        ⽉15 ⽇の期限までに移転停⽌を完了できない可能性があります。</span>
                    <span class="lang-en">Our company is preparing to suspend cross-border transfer in accordance with
                        the instructions of the Arbitrian authorities. However, if cross-border transfer is suspended,
                        as we have already explained, additional costs of between USD 3.5 million to 5 million will
                        arise due to alternative measures (procurement of dedicated GPU servers, installation of
                        dedicated lines, etc.). There is no reasonable grounds for our company to bear this cost; we
                        consider that it should be borne by your university. Furthermore, to cease overseas transfers
                        while maintaining existing services, alternative measures such as procuring dedicated GPU
                        servers and installing dedicated lines are required. We must obtain your institution's firm
                        commitment to bear the associated costs (approximately USD 3.5 million to 5 million). Without
                        such a commitment, alternative measures cannot be implemented. In that case, the overseas
                        transfer will be halted without alternative measures. However, even if the overseas transfer is
                        halted without alternative measures, it may not be possible to complete the halt by the 15
                        December deadline due to current constraints on human resources.</span>
                </p>
                <h4>
                    <span class="lang-ja">制裁金について</span>
                    <span class="lang-en">Concerning Sanctions</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">本件国外移転は、契約交渉過程において貴学IT部門長をはじめとする関係者から「例外的に認められる可能性がある」との説明を受け、貴学の了解の下で実施したものです。従って、科される制裁金は当社が負担すべきものではなく、当社が貴学に賠償する理由は存在しません。</span>
                    <span class="lang-en">This cross-border transfer was carried out with the understanding of your
                        university, based on explanations received during the contract negotiation process from your
                        Head of IT Division and other related persons that "it may be exceptionally permitted."
                        Therefore, the sanctions imposed are not ones that our company should bear, and there is no
                        reason for our company to compensate your university.</span>
                </p>
                <h4>
                    <span class="lang-ja">サービス継続について</span>
                    <span class="lang-en">Concerning Continuation of Service</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">契約上の義務を尊重し、RedAidの提供は継続いたします。ただし、貴大学が追加費用負担を負担することについて合意がなされない限り、現在提供されている仕様・機能での提供は困難となることをご理解ください。</span>
                    <span class="lang-en">We respect our contractual obligations and will continue the provision of
                        RedAid. However, please understand that unless your university agrees to bear the additional
                        costs, it will be difficult to continue provision under the current specifications and
                        functions.</span>
                </p>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注：</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span
                            class="lang-ja">国外移転を⾏わず、また、代替措置を⾏わない場合には、①患者の⺟国語による多⾔語インターフェイスの提供、②CT・MRIなど⾼解像度画像を⽤いたリアルタイム処理、③⼀度に数百⼈単位でアクセスが集中しても遅延が発⽣しない同時接続処理能⼒のいずれも提供できなくなり、①英語対応のみ、②画像改正は数分遅延し、③同時アクセスは数⼗名が限界となることが証明されている。また、イエロー社以外に代替措置を提供可能な事業者は⾒つかっていない。</span>
                        <span class="lang-en">* Without transferring data overseas or implementing alternative measures,
                            it has been proved that none of the following can be provided: 1 multilingual interfaces in
                            patients' native languages, 2 real-time processing using high-resolution images such as CT
                            and MRI, 3 simultaneous connection processing capacity preventing delays even when hundreds
                            of users access the system at once. Instead, only 1 English support would be available, 2
                            image corrections would incur delays of several minutes, and 3 simultaneous access would be
                            limited to dozens of users. Furthermore, no other provider besides Yellow Corporation has
                            been identified as capable of offering alternative measures.</span>
                    </p>
                </div>
            </article>
        </section>

        <section id="exhibit29" class="content-section">
            <h2>
                <span class="lang-ja">別添29 争点</span>
                <span class="lang-en">Exhibit 29 Issues in Dispute</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-22">
                    <span class="lang-ja">本文¶22</span>
                    <span class="lang-en">Facts ¶22</span>
                </a>
            </div>
            <article>
                <h3>
                    <span class="lang-ja">RedAid事件</span>
                    <span class="lang-en">RedAid Case</span>
                </h3>
                <h4>
                    <span class="lang-ja">1. レッド社の求める仲裁判断</span>
                    <span class="lang-en">1. Arbitral Award Sought by Red Corporation</span>
                </h4>
                <p>
                    <span class="lang-ja">ブルー大学はレッド社に対して260万米ドルを支払え。</span>
                    <span class="lang-en">That Blue University shall pay Red Corporation USD 2,600,000.</span>
                </p>
                <h4>
                    <span class="lang-ja">2. ブルー大学の求める仲裁判断</span>
                    <span class="lang-en">2. Arbitral Award Sought by Blue University</span>
                </h4>
                <ol>
                    <li>
                        <span class="lang-ja">(1) レッド社の請求を棄却する。</span>
                        <span class="lang-en">(1) That the claim of Red Corporation be dismissed.</span>
                    </li>
                    <li>
                        <span class="lang-ja">(2) レッド社はブルー大学に対して225万米ドルを支払え。</span>
                        <span class="lang-en">(2) That Red Corporation shall pay Blue University USD 2,250,000.</span>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">3. 争点</span>
                    <span class="lang-en">3. Issues in Dispute</span>
                </h4>
                <ol>
                    <li>
                        <span class="lang-ja">(1)
                            ブルー大学の内部調査報告書が流出したことにより、ブルー大学はレッド社に対して債務不履行責任を負うか。仮に債務不履行責任を負う場合、賠償額は幾らか。</span>
                        <span class="lang-en">(1) Does Blue University bear liability for non-performance of obligation
                            toward Red Corporation due to the leakage of Blue University's internal investigation
                            report? If liability for non-performance is borne, what is the amount of
                            compensation?</span>
                    </li>
                    <li>
                        <span class="lang-ja">(2) レッド社はブルー大学が遺族に支払った200万米ドルをブルー⼤学に対して⽀払う義務を負うか。</span>
                        <span class="lang-en">(2) Is Red Corporation obligated to pay Blue University USD 2,000,000 that
                            Blue University paid to the bereaved family?</span>
                    </li>
                    <li>
                        <span class="lang-ja">(3) レッド社はブルー大学がRedAidの利用を停止した期間に相当する利用料である25万米ドルをブルー大学に支払う義務を負うか。</span>
                        <span class="lang-en">(3) Is Red Corporation obligated to pay Blue University USD 250,000, being
                            the usage fee corresponding to the period in which Blue University suspended the use of
                            RedAid?</span>
                    </li>
                </ol>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">ツーリズム事件</span>
                    <span class="lang-en">Tourism Case</span>
                </h3>
                <h4>
                    <span class="lang-ja">1. ブルー大学の求める仲裁判断</span>
                    <span class="lang-en">1. Arbitral Award Sought by Blue University</span>
                </h4>
                <ol>
                    <li>
                        <span class="lang-ja">レッド社はRedAidの医療ツーリズム用サービスの利用に伴う患者に関するデータをアービトリア国外に移転してはならない。</span>
                        <span class="lang-en">(1) That Red Corporation shall not transfer abroad, outside Arbitria,
                            patient-related data through the use of RedAid's medical tourism service.</span>
                    </li>
                    <li>
                        <span
                            class="lang-ja">レッド社は、ライセンス契約の期間中、ブルー大学に対して現在提供されているのと同じ仕様と機能でRedAidの医療ツーリズム用サービスを提供せよ。</span>
                        <span class="lang-en">(2) That Red Corporation shall provide Blue University, during the term of
                            the license agreement, RedAid's medical tourism service with the same specifications and
                            functions as are currently being provided.</span>
                    </li>
                    <li>
                        <span
                            class="lang-ja">レッド社はブルー大学がアービトリア国個人情報保護法により科される制裁金(100万米ドル、または600万米ドル+日額1万米ドル)を賠償せよ。</span>
                        <span class="lang-en">(3) That Red Corporation shall compensate Blue University for sanctions
                            imposed under the Personal Information Protection Act of Arbitria (USD 1,000,000, or USD
                            6,000,000 + USD 10,000 per day).</span>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">暫定的措置の申立て</span>
                    <span class="lang-en">Application for Provisional Measures</span>
                </h4>
                <ol>
                    <li>
                        <span class="lang-ja">レッド社は遅くとも2025年12月15日までに、RedAidの利用に伴う患者データのアービトリア国外への移転を停止せよ。</span>
                        <span class="lang-en">(1) That Red Corporation shall, no later than December 15, 2025, stop the
                            transfer abroad of patient data through the use of RedAid and to return to Arbitria any
                            patient data previously transferred abroad.</span>
                    </li>
                    <li>
                        <span class="lang-ja">レッド社は仲裁判断が出るまでの間、ブルー大学に対してRedAidのサービスを現在提供されている仕様と機能で継続して提供せよ。</span>
                        <span class="lang-en">(2) That Red Corporation shall, until an arbitral award is rendered,
                            continue to provide Blue University with RedAid service with the specifications and
                            functions currently being provided.</span>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">2. レッド社の求める仲裁判断</span>
                    <span class="lang-en">2. Arbitral Award Sought by Red Corporation</span>
                </h4>
                <ol>
                    <li>
                        <span class="lang-ja">ブルー大学の請求を棄却する。</span>
                        <span class="lang-en">(1) That the claim of Blue University be dismissed.</span>
                    </li>
                    <li>
                        <span
                            class="lang-ja">仮に、レッド社が患者データの国外移転を停止したうえでRedAidの医療ツーリズム用サービスのブルー大学への提供を継続する義務を負う場合には、ブルー大学はレッド社に対して国外移転を停止したうえでサービスを継続することに伴う費用(300万米ドルまたは500万米ドル)を支払え。</span>
                        <span class="lang-en">(2) That, in the event that Red Corporation is obligated to continue
                            provision of RedAid's medical tourism service to Blue University after stopping the transfer
                            abroad of patient data, that Blue University shall pay Red Corporation the costs associated
                            with continuing the service while stopping cross-border data transfer (USD 3,500,000 or
                            5,000,000).</span>
                    </li>
                </ol>
                <h4>
                    <span class="lang-ja">3. 争点</span>
                    <span class="lang-en">3. Issues in Dispute</span>
                </h4>
                <ol>
                    <li>
                        <span
                            class="lang-ja">レッド社は、RedAidの医療ツーリズム用サービスの提供に当たり、患者データの国外移転を停止し、国外移転されたデータをアービトリア国内に移転するとともに、現在提供されている仕様・機能でサービスの提供を継続する義務を負うか。仮に、サービスを提供する義務を負う場合、ブルー大学はレッド社に対して国外移転を行わずにサービスを継続することに伴う追加費用である350
                            万⽶ドルまたは500 万⽶ドルを支払う義務を負うか。</span>
                        <span class="lang-en">(1) Is Red Corporation obligated, in the provision of RedAid's medical
                            tourism service, to stop the transfer abroad of patient data, to return to Arbitria any
                            patient data previously transferred abroad and to continue provision of the service with the
                            current specifications and functions to Blue University even after stopping the transfer
                            abroad of patient data? If Red Corporation is obligated to provide the service, is Blue
                            University obligated to pay Red Corporation USD3,500,000 or 5,000,000 at the cost associated
                            with continuing the service
                            while stopping cross-border data transfer?</span>
                    </li>
                    <li>
                        <span class="lang-ja">ブルー大学が求める暫定的処分は認められるべきか。暫定的処分(2)が認められる場合、必要な費⽤(350 万⽶ドルまたは500
                            万⽶ドル)は誰が負担すべきか。</span>
                        <span class="lang-en">(2) Should the provisional measures sought by Blue University be
                            granted? Where provisional measures (2) are granted, who should bear the necessary costs
                            (USD3,500,000 or USD5,000,000)?</span>
                    </li>
                    <li>
                        <span class="lang-ja">レッド社はブルー⼤学がアービトリア国個⼈情報保護法により科される制裁⾦をブルー⼤学に対して⽀払う義務を負うか。</span>
                        <span class="lang-en">(3) Is Red Corporation obliged to compensate Blue University for sanctions
                            imposed under the Personal Information Protection Act of Arbitria?</span>
                    </li>
                </ol>
            </article>
        </section>

        <section id="exhibit30" class="content-section">
            <h2>
                <span class="lang-ja">別添30 第1回事前協議 議事録</span>
                <span class="lang-en">Exhibit 30 Minutes of the First Preliminary Meeting</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-26">
                    <span class="lang-ja">本文¶26</span>
                    <span class="lang-en">Facts ¶26</span>
                </a>
            </div>
            <ul>
                <li><strong>
                        <span class="lang-ja">日時:</span>
                        <span class="lang-en">Date and Time:</span>
                    </strong>
                    <span class="lang-ja">2025年10月18日(金) 15:00-17:00(日本時間)</span>
                    <span class="lang-en">Friday, October 18, 2025, 15:00-17:00 (Japan Time)</span>
                </li>
                <li><strong>
                        <span class="lang-ja">場所:</span>
                        <span class="lang-en">Location:</span>
                    </strong>
                    <span class="lang-ja">オンライン会議 (Zoom)</span>
                    <span class="lang-en">Online meeting (Zoom)</span>
                </li>
                <li><strong>
                        <span class="lang-ja">出席者:</span>
                        <span class="lang-en">Participants:</span>
                    </strong>
                    <ul>
                        <li><strong>
                                <span class="lang-ja">レッド社:</span>
                                <span class="lang-en">Red Corporation:</span>
                            </strong>
                            <span class="lang-ja">事業開発マネージャー、RedAid/RedLink プロダクトリード、法務カウンセル、データプライバシー担当</span>
                            <span class="lang-en">Business Development Manager, RedAid/RedLink Product Lead, Legal
                                Counsel, Data Privacy Officer</span>
                        </li>
                        <li><strong>
                                <span class="lang-ja">ブルー大学:</span>
                                <span class="lang-en">Blue University:</span>
                            </strong>
                            <span class="lang-ja">国際戦略室マネージャー、医療情報部門責任者、法務室担当、臨床代表(内科教授)</span>
                            <span class="lang-en">Manager of International Strategy Office, Head of Medical Information
                                Division, Staff of Legal Office, Clinical Representative (Professor of Internal
                                Medicine)</span>
                        </li>
                    </ul>
                </li>
                <li><strong>
                        <span class="lang-ja">記録:</span>
                        <span class="lang-en">Record:</span>
                    </strong>
                    <span class="lang-ja">双方同意のうえ、要点を抄録</span>
                    <span class="lang-en">Summary of key points with mutual consent</span>
                </li>
            </ul>
            <article>
                <h3>
                    <span class="lang-ja">議題1: 医療やAIに関する認識</span>
                    <span class="lang-en">Agenda Item 1: Understandings Concerning Medicine and AI</span>
                </h3>
                <p>
                    <span class="lang-ja">レッド社とブルー大学は、以下のような共通の認識を抱いていることを確認した。</span>
                    <span class="lang-en">Red Corporation and Blue University confirmed that they share the following
                        understandings:</span>
                </p>
                <p>
                    <span
                        class="lang-ja">AIの医療分野への活用が注目を集めている。診断支援や画像解析、トリアージなどにおいてAIが果たす役割は急速に拡大しており、各国の規制当局もその導入を後押しする姿勢を見せている。他方で、説明可能性の欠如やバイアスの存在、予期せぬアウトカムのリスクといった問題は依然として大きく、社会的議論や規制整備は過渡期にある。</span>
                    <span class="lang-en">The utilization of Al in the medical field is attracting attention. The role
                        of AI in diagnostic support, image analysis, triage, etc., is expanding rapidly, and regulatory
                        authorities in various countries are showing a stance of supporting its introduction. On the
                        other hand, issues such as lack of explainability, existence of bias, and risks of unexpected
                        outcomes remain significant, and social debate and regulatory development are in a transitional
                        stage.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">ネゴランド国とアービトリア国の法制度や文化には違いがある。ネゴランド国は、サンドボックス制度によって革新的技術を限定的に市場導入し、実証を重ねて段階的に普及させる仕組みを整えている。匿名化データであれば国外移転も比較的容易であり、AIの国際共同研究に有利な環境が整っている。一方、アービトリア国は承認審査に時間をかけ、国外移転はアービトリア国と同様の個人情報保護がなされていると認定された国に限定するなど、厳格な規制を敷いている。AIは臨床判断の補助にとどめられ、単独での診断や治療決定は原則として認められない。両国とも患者の安全と権利を最優先とする点では一致しているが、許容されるリスクの範囲や導入のスピード感には大きな隔たりがある。</span>
                    <span class="lang-en">Differences exist between the legal systems and cultures of Negoland and
                        Arbitria. Negoland has established a system to introduce innovative technology in a limited
                        manner through a sandbox system, accumulate demonstration, and gradually spread the technology.
                        If anonymized data is used, cross-border transfer is relatively easy, creating an environment
                        favorable for international joint research in AI. Arbitria, by contrast, takes time in approval
                        reviews, and cross-border transfer is restricted to countries recognized as ensuring personal
                        data protection equivalent to that of Arbitria. Al is limited to assisting clinical judgment,
                        and in principle independent Al diagnosis or treatment decisions are not permitted. While both
                        countries share the prioritization of patient safety and rights, there is a large gap in the
                        scope of permissible risk and in the speed of introduction.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">いずれの国においても倫理的・社会的観点も重要である。AIを利用する際には、患者に対して補助的役割であることを明示し、インフォームド・コンセントを適切に取得する必要がある。差別や偏りを助長しないよう監視体制を敷くこと、異常や不具合が発生した場合には即時に停止して人手で対応できる仕組みを設けることも社会的に強く求められている。また、データセキュリティについては、暗号化やアクセス制御、監査ログ、侵害発生時の通知義務といった最低限の技術的・組織的対策が必須である。</span>
                    <span class="lang-en">In both nations, ethical and social perspectives are also important. When
                        using Al, it is necessary to clearly inform patients that it plays a supplementary role and to
                        appropriately obtain informed consent. It is also strongly required socially to establish
                        monitoring systems to prevent promotion of discrimination or bias, and to establish systems to
                        stop immediately and respond manually in the event of abnormality or malfunction. Regarding data
                        security, minimum technical and organizational measures such as encryption, access control,
                        audit logs, and notification obligations in the event of breach are essential.</span>
                </p>
                <p>
                    <span
                        class="lang-ja">AI導入は医師の負荷軽減につながる可能性がある一方、操作が煩雑であれば逆に負担を増大させるため、ユーザー・インターフェイス（UI）やユーザー・エクスペリエンス（UX）の質が極めて重要である。また、導入後も継続的なモニタリングを行い、性能劣化やデータ分布の変化を検知し、必要に応じて再学習を行う体制が不可欠であることも共通認識となっている。さらに、成功事例を積み上げることが信頼構築に不可欠であり、逆に重大な失敗があれば社会的信用が失墜するリスクがある。</span>
                    <span class="lang-en">While AI introduction may reduce physicians' burden, if operation is
                        complicated it may conversely increase burdens. Therefore, the quality of the User Interface
                        (UI) and the User Experience (UX) is extremely important. In addition, continuous monitoring
                        after introduction, detection of performance degradation and data distribution changes, and
                        re-training as necessary are indispensable. Furthermore, accumulation of successful cases is
                        essential for building trust, while conversely, a major failure poses the risk of loss of social
                        credibility.</span>
                </p>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">議題2: 共同研究契約 (RedAidの高度化)</span>
                    <span class="lang-en">Agenda Item 2: Joint Research Agreement (Enhancement of RedAid)</span>
                </h3>
                <h4>
                    <span class="lang-ja">レッド社の主張</span>
                    <span class="lang-en">Red Corporation's Position</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">レッド社は、希少疾患や高齢者、複数の合併症を抱える症例に対応できるAI医療支援ツールを実現するためには、ブルー大学が保有する高品質な臨床データが不可欠であると強調した。その上で、データ活用の方法としては連合学習を基本とし、学内で生成される合成データの利用や、製品改善に資する範囲での集計メタデータの活用を契約上認めてほしいと要望した。また、循環器、呼吸器、救急、ツーリズム以外の部⾨における利⽤も実績を積み重ねたいと要望した。成果の公表については、知的財産の出願と権利化を終えたうえで、双方による事前審査を行い、患者のデータを匿名化した形で発表する運用なら積極的に支援する意向を示した。知財の帰属については、汎用的な機能はレッド社に、ブルー大学特有の運用ノウハウや派生機能は大学に帰属させる案を提示した。契約期間はまず1年間のPoCを行い、その成果を評価したうえで延長や本格契約に進みたいと説明した。</span>
                    <span class="lang-en">Red Corporation emphasized that high-quality clinical data held by Blue
                        University is indispensable for realizing an Al medical support tool capable of dealing with
                        rare diseases, elderly patients, and cases with multiple complications. It requested that the
                        contract recognize the use of federated learning as the basic method of data utilization, the
                        use of synthetic data generated within the university, and the use of aggregated metadata within
                        the scope contributing to product improvement. Furthermore, Red Corporation expressed a desire
                        to build a track record of usage in departments other than cardiology, respiratory medicine,
                        emergency medicine, and tourism. Regarding publication of results, it expressed the intention to
                        actively support publication in anonymizing patients' data, after completion of intellectual
                        property application and rights acquisition, and prior review by both parties. Regarding
                        ownership of intellectual property, it proposed that general functions belong to Red
                        Corporation, while Blue University's specific operational know-how and derivative functions
                        belong to the university. As for contract term, it explained that it wishes first to conduct a
                        one-year PoC, evaluate its results, and then proceed to extension or full contract.</span>
                </p>
                <h4>
                    <span class="lang-ja">ブルー大学の主張</span>
                    <span class="lang-en">Blue University's Position</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">ブルー大学は、国際共同研究の意義を認めつつも、患者の安全と大学ブランドを守ることを最優先に据えていることを明確にした。データについては、国内リージョンでの保存と大学による暗号鍵の単独管理を原則とし、国外への越境や外部での個票分析は禁止すべきであるとした。合成データの活用については、学内で生成・利用されるものに限れば容認する余地があると述べた。成果の公表については、出願後に共同審査を行い匿名化するというレッド社の提案に前向きな反応を示した。知財に関しては、汎用的な機能はレッド社に帰属することを容認する一方、大学特有の知見や派生機能は大学帰属とし、他者への再利用を行う場合には事前通知と守秘義務を課すべきだと主張した。契約期間は短期PoCから始め、成果を見ながら1年ごとに延長を検討したいという姿勢を取った。</span>
                    <span class="lang-en">Blue University made clear that while it recognizes the significance of
                        international joint research, it prioritizes protection of patient safety and the university
                        brand. As for data, it stipulated as a fundamental principle that data be stored in the domestic
                        region with encryption keys managed solely by the university, and that cross-border transfer or
                        external analysis of individual records be prohibited. It indicated that there is room to allow
                        for utilization of synthetic data if generated and used within the university. Regarding
                        publication of results, it responded positively to Red Corporation's proposal of joint review
                        and anonymization after filing of applications. As to intellectual property, it accepted that
                        general functions belong to Red Corporation, but insisted that university-specific knowledge and
                        derivative functions belong to the university, and that if reuse by others is conducted, prior
                        notice and confidentiality obligations should be imposed. For contract period, it showed a
                        stance to start with a short-term PoC and examine extension year by year depending on
                        results.</span>
                </p>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">議題3: 遠隔医療プラットフォーム「RedLink」導入</span>
                    <span class="lang-en">Agenda Item 3: Introduction of Telemedicine Platform "RedLink"</span>
                </h3>
                <h4>
                    <span class="lang-ja">レッド社の主張</span>
                    <span class="lang-en">Red Corporation's Position</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">レッド社は、RedLinkを外来フォロー、術前・術後の相談、国際患者の事前トリアージ、セカンドオピニオンなど幅広く活用したいと説明した。他方で、プロダクト改善のために集計メタデータや学内のサーバー環境のもとでの連合学習・合成データの活用権を契約上確保する必要があると強調した。契約期間については本来は3年の中期契約を希望するが、大学の事情に配慮して1年契約から始めて成果を評価し、その後延長する方式にも応じられると述べた。料金は定額制を基本とし、追加モジュールに従量課金を設定することを希望。成果連動についても小幅に導入したいと主張した。</span>
                    <span class="lang-en">Red Corporation explained that it wishes to utilize RedLink widely, including
                        outpatient follow-up, pre- and post-operative consultations, preliminary triage for
                        international patients, and second opinions. On the other hand, it strongly emphasized the
                        necessity of securing by contract the right to utilize aggregated metadata, as well as to
                        conduct federated learning and utilize synthetic data within the university's server environment
                        for product improvement. Regarding contract term, it originally desired a medium-term three-year
                        contract, but stated it could also accept starting with a one-year contract in consideration of
                        the university's circumstances, evaluating results and then extending. Regarding fees, it
                        desired to base them on a fixed fee, with pay-per- use set for additional modules. It also
                        insisted on introducing a small element of performance-based fees.</span>
                </p>
                <h4>
                    <span class="lang-ja">ブルー大学の主張</span>
                    <span class="lang-en">Blue University's Position</span>
                </h4>
                <p>
                    <span
                        class="lang-ja">ブルー大学は、遠隔医療が地域医療連携や国際展開に資する点を評価しながらも、規制とリスク管理の重要性を改めて強調した。患者データは国内リージョンに保存し、暗号鍵は大学が単独で管理することを絶対条件とし、国外越境は一切認めないと明言した。メタデータの利用については、利用目的を特定し事前承認を経る範囲であれば限定的に容認できると述べた。契約はまず1年のPoC契約から開始し、成果に応じて更新を判断したいとの意向を示した。便宜解約については6か月前通知を必須とし、データ返却・削除・監査証跡の提出を出口条件として明記することを求めた。責任分担については、臨床判断は大学が負う一方、プラットフォームの欠陥や知財侵害はレッド社が補償すべきとした。責任上限については、年間契約額の1~3倍程度を基準とし、追加で保険加入を求める可能性があると述べた。</span>
                    <span class="lang-en">Blue University, while appreciating that telemedicine contributes to regional
                        medical cooperation and international expansion, reiterated the importance of regulation and
                        risk management. It stated that patient data must be stored domestically, with encryption keys
                        managed solely by the university, as an absolute condition, and that cross-border transfer would
                        not be permitted at all. Regarding metadata utilization, it indicated that limited acceptance is
                        possible if purposes of use are specified and prior approval obtained. It expressed the
                        intention to begin with a one-year PoC contract and judge renewal depending on results.
                        Regarding termination for convenience, it insisted on six months prior notice, and demanded that
                        data return, deletion, and provision of audit trails be specified as exit conditions. Regarding
                        allocation of responsibilities, it stated that clinical judgment would be borne by the
                        university, while defects in the platform or infringement of intellectual property should be
                        compensated by Red Corporation. As to liability cap, it presented a standard of 1-3 times the
                        annual contract amount, and noted the possibility of additionally requiring insurance
                        coverage.</span>
                </p>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">クロージング</span>
                    <span class="lang-en">Closing</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">双方は、いずれのテーマについても、「段階的導入」「成果評価を経た更新」という方向性で一致を見た。</span>
                        <span class="lang-en">Both parties agreed in principle on the direction of "gradual
                            introduction" and "renewal after evaluation of results" for all projects.</span>
                    </li>
                    <li>
                        <span class="lang-ja">一方で、データ利用範囲、成果公表のタイミング、料金体系、責任上限、独占の可否といった主要論点は今後の詳細協議に委ねられた。</span>
                        <span class="lang-en">On the other hand, key issues such as scope of data utilization, timing of
                            result publication, fee structure, liability cap, and permissibility of exclusivity were
                            left to future detailed discussions.</span>
                    </li>
                    <li>
                        <span class="lang-ja">双方とも「大学ブランド保護」「製品改善・実績確保」を臨界点と認識しており、次回までに具体的な条項案を提示することで合意した。</span>
                        <span class="lang-en">Both parties recognized "protection of university brand" and "product
                            improvement and accumulation of achievements" as critical points, and agreed to present
                            concrete draft clauses by the next meeting.</span>
                    </li>
                </ul>
            </article>
            <article>
                <h3>
                    <span class="lang-ja">次回会合</span>
                    <span class="lang-en">Next Meeting</span>
                </h3>
                <ul>
                    <li><strong>
                            <span class="lang-ja">日時:</span>
                            <span class="lang-en">Date and Time:</span>
                        </strong>
                        <span class="lang-ja">2025年11月16日(日) 12:00-14:00(日本時間)</span>
                        <span class="lang-en">Sunday, November 16, 2025, 12:00-14:00 (Japan Time)</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">場所:</span>
                            <span class="lang-en">Location:</span>
                        </strong>
                        <span class="lang-ja">ブルー大学 (対面を予定)</span>
                        <span class="lang-en">Blue University (in person, planned)</span>
                    </li>
                    <li><strong>
                            <span class="lang-ja">議題:</span>
                            <span class="lang-en">Agenda:</span>
                        </strong>
                        <ol>
                            <li>
                                <span class="lang-ja">1. RedAidの共同研究契約の主要な内容の確定</span>
                                <span class="lang-en">1. Core content of joint research agreement</span>
                            </li>
                            <li>
                                <span class="lang-ja">2. RedLink契約条件の主要な内容の確定</span>
                                <span class="lang-en">2. Core content of RedLink contract</span>
                            </li>
                            <li>
                                <span class="lang-ja">3. その他</span>
                                <span class="lang-en">3. Other matters</span>
                            </li>
                        </ol>
                    </li>
                </ul>
            </article>
        </section>
        <section id="exhibit31" class="content-section">
            <h2>
                <span class="lang-ja">別添31 RedLink の概要</span>
                <span class="lang-en">Exhibit 31 Overview of RedLink</span>
            </h2>
            <div class="related-pages">
                <span class="lang-ja">関連ページ: </span>
                <span class="lang-en">Related pages: </span>
                <a href="#p-26">
                    <span class="lang-ja">本文¶26</span>
                    <span class="lang-en">Facts ¶26</span>
                </a>
            </div>
            <article>
                <p><strong>
                        <span class="lang-ja">名称:</span>
                        <span class="lang-en">Product Name:</span>
                    </strong>
                    <span class="lang-ja">RedLink</span>
                    <span class="lang-en">RedLink</span>
                </p>
                <p><strong>
                        <span class="lang-ja">開発者:</span>
                        <span class="lang-en">Developer:</span>
                    </strong>
                    <span class="lang-ja">Red 社</span>
                    <span class="lang-en">Red Corporation (Negoland)</span>
                </p>
                <p><strong>
                        <span class="lang-ja">目的:</span>
                        <span class="lang-en">Purpose:</span>
                    </strong></p>
                <ul>
                    <li>
                        <span class="lang-ja">医療機関間の遠隔診療、セカンドオピニオン、国際患者(医療ツーリズム) 対応を安全・効率的に行うための統合プラットフォーム。</span>
                        <span class="lang-en">RedLink is an integrated telemedicine platform designed to support secure
                            and efficient medical collaboration among institutions.</span>
                    </li>
                    <li>
                        <span class="lang-ja">RedAidとの連携により、トリアージ・診断支援・再入院リスク予測などを遠隔環境で利用可能。</span>
                        <span class="lang-en">It enables remote diagnosis, second opinions, and postoperative follow-up
                            for international patients, including those participating in medical tourism.</span>
                    </li>
                    <li>
                        <span class="lang-en">In combination with RedAid, it provides AI-based triage, diagnostic
                            support, and readmission risk prediction in a remote clinical setting.</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">主な機能</span>
                    <span class="lang-en">Key Features</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">電子カルテ・CT/MRI・検査システムとのAPI連携</span>
                        <span class="lang-en">API integration with EHR, CT/MRI, and laboratory systems</span>
                    </li>
                    <li>
                        <span class="lang-ja">医師・患者間の多言語ビデオ診療 (10言語対応)</span>
                        <span class="lang-en">Multilingual video consultation (10 languages) between physicians and
                            patients</span>
                    </li>
                    <li>
                        <span class="lang-ja">データ暗号化・アクセス履歴監査</span>
                        <span class="lang-en">Data encryption and access log audit</span>
                    </li>
                    <li>
                        <span class="lang-ja">AI支援(RedAid との統合) および連合学習対応</span>
                        <span class="lang-en">Full integration with RedAid and support for federated learning</span>
                    </li>
                    <li>
                        <span class="lang-ja">個人情報保護のための法令や契約を踏まえた国外データ移転管理</span>
                        <span class="lang-en">Management of cross-border data transfers in compliance with laws and
                            contracts for personal data protection</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">利用環境</span>
                    <span class="lang-en">System Environment</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">オンプレミスまたはクラウドでの運用に対応</span>
                        <span class="lang-en">Operable on-premises or via cloud environments</span>
                    </li>
                </ul>
                <h3>
                    <span class="lang-ja">導入効果例</span>
                    <span class="lang-en">Examples of Expected Benefits</span>
                </h3>
                <ul>
                    <li>
                        <span class="lang-ja">外国人患者対応と術後フォローの効率化</span>
                        <span class="lang-en">More efficient handling of international and multilingual patients</span>
                    </li>
                    <li>
                        <span class="lang-ja">医療ツーリズムの利便性・信頼性の向上</span>
                        <span class="lang-en">Enhanced reliability and convenience in medical tourism operations</span>
                    </li>
                    <li>
                        <span class="lang-ja">医療機関間のデータ共有と国際的研究連携の促進</span>
                        <span class="lang-en">Improved data sharing and clinical collaboration among partner
                            institutions</span>
                    </li>
                    <li>
                        <span class="lang-en">Strengthened foundation for international joint research and Al
                            development</span>
                    </li>
                </ul>
                <div class="callout note">
                    <p><strong>
                            <span class="lang-ja">注:</span>
                            <span class="lang-en">Note:</span>
                        </strong>
                        <span class="lang-ja">RedLinkはネゴランド国、アービトリア国の医療機器法上、非医療機器として利用可能</span>
                        <span class="lang-en">RedLink is available for use as a non-medical device under the medical
                            device laws of the countries of Negoland and Arbitria.</span>
                    </p>
                </div>
            </article>
        </section>
    </main>

    <button id="back-to-top-btn" title="ページ先頭に戻る">▲</button>

    <script>
        document.addEventListener('DOMContentLoaded', () => {
            const menuToggle = document.getElementById('menu-toggle');
            const mainNav = document.getElementById('main-nav');
            const body = document.body;
            const navLinks = document.querySelectorAll('.nav-list a');
            const newTabCheckbox = document.getElementById('new-tab-checkbox');
            const submenuToggle = document.querySelector('.submenu-toggle');
            const backToTopBtn = document.getElementById('back-to-top-btn');
            const langJpBtn = document.getElementById('lang-jp');
            const langEnBtn = document.getElementById('lang-en');
            const htmlTag = document.documentElement;

            // Function to set the language
            const setLanguage = (lang) => {
                if (lang === 'en') {
                    body.classList.add('show-en');
                    htmlTag.setAttribute('lang', 'en');
                    langEnBtn.classList.add('active');
                    langJpBtn.classList.remove('active');
                } else {
                    body.classList.remove('show-en');
                    htmlTag.setAttribute('lang', 'ja');
                    langJpBtn.classList.add('active');
                    langEnBtn.classList.remove('active');
                }
            };

            // Event Listeners for language buttons
            langJpBtn.addEventListener('click', () => setLanguage('ja'));
            langEnBtn.addEventListener('click', () => setLanguage('en'));

            menuToggle.addEventListener('click', () => {
                const isExpanded = menuToggle.getAttribute('aria-expanded') === 'true';
                menuToggle.setAttribute('aria-expanded', !isExpanded);
                mainNav.classList.toggle('is-open');
                body.classList.toggle('menu-open');
            });

            submenuToggle.addEventListener('click', (e) => {
                e.stopPropagation();
                const submenu = document.getElementById('facts-submenu');
                const isExpanded = submenuToggle.getAttribute('aria-expanded') === 'true';
                submenuToggle.setAttribute('aria-expanded', !isExpanded);
                submenu.classList.toggle('is-open');
            });

            navLinks.forEach(link => {
                link.addEventListener('click', (event) => {
                    if (newTabCheckbox.checked && link.parentElement.parentElement !== document.getElementById('facts-submenu')) {
                        event.preventDefault();
                        window.open(link.href, '_blank');
                    }
                    setTimeout(() => {
                        if (mainNav.classList.contains('is-open')) {
                            menuToggle.click();
                        }
                    }, 100);
                });
            });

            const showContent = () => {
                const hash = window.location.hash || '#facts';
                let targetElement;
                try {
                    targetElement = document.querySelector(hash);
                } catch (e) {
                    targetElement = document.getElementById('facts');
                }

                if (targetElement) {
                    const parentSection = targetElement.closest('.content-section');
                    if (parentSection) {
                        document.querySelectorAll('.content-section').forEach(section => {
                            section.classList.remove('is-active');
                        });
                        parentSection.classList.add('is-active');
                    }
                } else {
                    document.querySelectorAll('.content-section').forEach(s => s.classList.remove('is-active'));
                    document.getElementById('facts').classList.add('is-active');
                }
            };

            showContent();
            window.addEventListener('hashchange', showContent, false);

            const scrollFunction = () => {
                if (document.body.scrollTop > 100 || document.documentElement.scrollTop > 100) {
                    backToTopBtn.style.display = "block";
                } else {
                    backToTopBtn.style.display = "none";
                }
            };

            window.onscroll = () => scrollFunction();
            backToTopBtn.addEventListener('click', () => {
                window.scrollTo({ top: 0, behavior: 'smooth' });
            });
        });
    </script>
</body>

</html>